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 Near-infrared (NIR) Raman spectroscopy is a vibrational spectroscopic 
technique capable of non-destructively probing endogenous biomolecules and their 
changes associated with tissue disease transformation. In this dissertation, we develop 
a real-time, portable, cost-effective, integrated fingerprint (FP) and high wavenumber 
(HW) confocal Raman spectroscopy for simultaneous acquisition of FP and HW 
Raman spectra predominantly from the epithelial layer of cervix to enhance cervical 
precancer diagnosis in vivo. We further established the Raman diagnostic framework 
integrated with the developed system, enabling the colposcopists’ to perform routine 
point-wise scanning for targeted biopsies of high-risk tissue sites in sub-seconds. 
Firstly, we realized the in vitro Raman spectroscopic diagnosis of cervical cancer at 
the cellular level and further characterized different stages of cervical tissue precancer 
(i.e., low-grade and high-grade) with promising results. We actualized that the 
diagnosis achieved using in vivo confocal Raman diagnostic modality was superior to 
NIR autofluorescence (AF) spectroscopy, but marginally higher than the 
co-contributions of NIR AF and confocal Raman spectroscopy. The confocal Raman 
spectroscopy in conjunction with feature selection algorithm (e.g., genetic algorithm 
(GA)) identifies the diagnostically important Raman features to further improve the 
diagnosis of cervical precancer in vivo. We also demonstrate for the first time the 
promising potential of HW confocal Raman spectroscopy in conjunction with 
biomolecular modeling for identifying hormone/menopause-related variations in 
native squamous epithelium of normal cervix, as well as for assessing the effect of 
Vagifem treatment on postmenopausal atrophic cervix in vivo during clinical 
colposcopic inspections. We also evidenced the diagnostic utility of FP and HW 
confocal Raman spectroscopy alone and in combination for identifying compositional 
IX 
 
changes in cervix associated with precancer transformation. The study disclosed that 
the complementary information obtained from FP and HW confocal Raman 
spectroscopy can enhance the in vivo diagnosis of cervical precancer. It is expected 
that the integrated FP/HW confocal Raman spectroscopy coupled with the on-line 
spectroscopic diagnostic framework has the potential to become a promising clinical 
diagnostic tool in adjunct to colposcopy for realizing real-time in vivo diagnosis of 
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Chapter 1. Introduction 
1.1 Cervical cancer 
Cancer is a major health burden and leading cause of death in humans among 
other diseases world-wide. Cancers of epithelial origin approximately constitutes of 
90% of all cancers, characterized by a marked proliferation of epithelium with 
infiltration into the surrounding tissues. Although cancer can devastate many organs 
of the body, the incidences of breast, endometrial, ovarian, and cervical malignancies 
play a prominent role in overall female cancers. Cervical cancer is the second most 
common cancer and the fifth leading cause of cancer deaths among women worldwide 
and generally more common in developing countries.1, 2  In 2002, there were about 
493,243 new cases and 273,505 deaths attributed to cervical cancer worldwide.3 Early 
identification and eradication are the critical measures to decrease the cervical cancer-
related mortality. For instance, the 5-year survival rate for women after diagnosis and 
treatment with stage I cervical cancer is 80 to 90%, 60 to 75% for stage II, 30 to 40% 
for stage III cancer and 15% or fewer for stage IV.4 However, identification of 
cervical cancer at early stage is difficult because it has no signs or symptoms. As the 
cancer progresses to the advanced stages, symptoms begin to appear. Pelvic pain, 
abnormal vaginal bleeding between the periods, after intercourse or menopause, 
heavier or longer periods or continuous vaginal discharge are some of the major 
symptoms attributed to cervical cancer. Hence, it is very important to develop 
advanced diagnostic techniques for improving both diagnostic sensitivity and 
specificity of early cervical cancer detection in vivo in real-time. The biology of 
cervical cancer including anatomy, histology and pathogenesis, current screening 
methods and its challenges that motivated us to develop new diagnostic techniques are 
discussed in remaining part of this chapter. 
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1.1.1 Anatomy  
Cervix is a small, cylindrical organ that makes up the lower part and neck of 
the uterus. The cervix measures 3 to 4 cm in length and 2.5 cm wide.5 However, the 
size and shape differs according to age, parity and menstrual status of women. The 
cervix is mainly composed of fibrous tissue and smooth muscle. The internal os is the 
upper boundary of the cervix that opens between the cervix and corpus of the uterine 
cavity. The external os is the opening between the cervix and vagina. The cervix has 
no perimetrium covering (serosal covering). The upper two-third of the cervix 
(endocervix) is lined by columnar glandular epithelium. The lower third of the cervix 
(ectocervix) is covered by non-keratinizing stratified squamous epithelium. The 
passage way between the external os and uterine cavity is called cervical canal or 
endocervical canal. The squamocolumnar junction (SCJ) or transformation zone (TZ), 
where the squamous epithelium of ectocervix meets the columnar epithelium of 
endocervix is the seat of most of the epithelial diseases that occur in the cervix. In the 
TZ, the columnar epithelium is being replaced by squamous epithelium and extremely 
susceptible to carcinogenesis. The pockets in the lining of the cervix are known as 
cervical crypts that produce the cervical fluid.  
 






The cervix is made up of epithelium and underlying stroma. The squamous 
epithelium lining the ectocervix is about 0.5 mm thick and composed of multiple 
layers divided into basal, parabasal, intermediate and superficial. The superficial layer 
varies in thickness and composition, depending on the degree of estrogen stimulation. 
The parabasal and intermediate layers together constitute the prickle-cell layer. The 
basal layer consists of a single row of cells resting on a thin basement membrane and 
mitosis occurs exclusively at this layer. The basal membrane is made up of type IV 
collagen and forms a stabile layer between the epithelium and connective tissue 
(stroma).7 The collagenous connective tissue comprises of 15% of smooth muscle, a 
small amount of elastic tissue and ground substance of mucopolysaccharides. In 
premenopausal stage, during the menstrual cycle, the cervix becomes softer and more 
elastic under the influence of increased estrogen. After the ovulation, it loses some 
elasticity. The layer of epithelial cells become thin, the vascularity and cellular 
contents are erratic at the perimenopausal stage. In the postmenopausal women, 
dryness and atrophy of cervix occurs due to lack of estrogen and progesterone. The 
endocervix is covered by a single layer of mucin-secreting simple columnar 
epithelium, which lines the surface and underlying glands. These glands are not true 
glands but deep, cleft-like infoldings of the surface epithelium with numerous blind, 
tunnel-like collaterals. The squamous epithelium shows progressive differentiation or 
maturation, but columnar epithelium does not undergo any maturation.  
1.1.3 Pathogenesis         
  Cancer mostly arises from single cell origin,8 and starts to proliferate to 
become precancer and cancer. Dysplasia is confined to epithelial layer, and is 
characterized by cellular proliferation, abnormal appearance of cell nuclei and 
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changes in tissue micro-architecture. During the development of dysplasia, the nuclei 
become enlarged occupying almost entire cell volume, crowded, and hyper chromatic 
as well as altered in its structure and organization. Cellular metabolism increases as a 
consequence of fast proliferation of cells. Although the macroscopic appearance of 
dysplastic lesions in different organs (i.e., different types of epithelium) can vary 
significantly, these cytological changes are common to all types of epithelial 
precancer. In many cases, the dysplastic tissue is flat and indistinguishable from 
surrounding non-dysplastic tissue and the diagnosis is based on random biopsy. These 
precancerous lesions invade through basement membrane to progress into cancer. 
Cervical cancer is mainly caused by human papilloma virus (HPV) infections. Most 
HPV infections are transient with no significant clinical manifestation and can regress 
back to normal. However, persistence infection with high-risk HPV (e.g., type 16, 18) 
can lead to cervical precancer and cancer. In the early stage of cancer, the presence of 
HPV strains can be noticed. These viruses infect the skin and mucous membranes of 
cervix, produce proliferation in the epithelium and can be transformed to malignant.9  
In cervix, about 80% of cervical cancers are of squamous cell carcinoma and 
adenocarcinoma accounts for majority of the remainders.10 Precancerous changes in 
the squamous epithelium of cervix are termed as cervical intraepithelial neoplasia 
(CIN) categorized into CIN 1 (LSIL - low-grade squamous intraepithelial lesion) and 
CIN 2/3 (HSIL - high-grade squamous intraepithelial lesion) depending upon the 
proportion of the thickness of epithelium showing matured and differentiated cells 
(Figure 1.2). In CIN 1 (mild dysplasia), the abnormal cells are limited to outer one-
third of epithelium. CIN 2 (moderate dysplasia) is confined to two-third of epithelium 
and CIN 3 (severe dysplasia) involves full thickness of epithelium and known as 




Figure 1.2 Stages of cervical precancer.11 
As the lesion progresses from CIN 1 to CIN 3, the epithelial differentiation 
diminishes drastically.12 The important characterization of cervical precancer is 
thickening of epithelium and the biochemical changes include replacement of high 
molecular weight keratins by low molecular weight keratins,8 depleted glycogen, 
decrease of hydrogen bonds within protein structure and increase of nucleic acids.13  
 
1.2 Conventional screening procedures 
Papanicolaou (Pap) smear followed by colposcopy and colposcopy-directed 
biopsy is the common protocol for cervical precancer diagnosis. Pap smear is the 
cytology-based screening test for cervical cancer to detect premalignant/malignant 
cells, the potential precursors of cervical cancer. In Pap smear, a speculum is placed in 
the vagina and the live-cells from SCJ of cervix are gently scraped using a spatula or 
brush for microscopic viewing. The cells are smeared as a thin layer on a glass slide 
and stained with Pap stain for examination by the cytologist to diagnose the presence 
of precancerous changes. However, this routine cytology tests (i.e., Pap smear) have 
high diagnostic specificity but with a relatively low sensitivity for the diagnosis of 
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precancerous lesions in the cervix.14 HPV-DNA testing is an adjunct to Pap smear test 
in which the cells from the cervix are collected similar to Pap test. However, this test 
checks the cervix for the genetic material (deoxyribonucleic acid (DNA)) of HPV that 
causes the abnormal cells and lead to cancer. The white-light colposcopy is the 
common gynecology follow-up procedure for abnormal Pap smears in which the 
surface of the cervix is closely examined through a special low-powered microscope 
called colposcope. In colposcopy, the speculum is used to hold the vaginal walls 
slightly apart for visualization of cervix, similar to Pap smear. A mild solution of 3 to 
5% acetic acid is swabbed onto the cervix with a long cotton-tipped brush. Abnormal 
areas stain white in color with the topical acetic acid application. Visual inspection of 
cervix after the application of Lugol’s iodine is also a proposed method for cervical 
cancer screening. Evaluation of colposcopy-directed punch biopsies of the cervix 
(histopathology) still serves as the gold standard diagnostic approach for cervical 
precancer diagnosis. However, the colposcopy-directed punch biopsy and cone biopsy 
for histological evaluation is impractical for mass screening patients. Moreover, 
cutting and processing that likely alters the biochemical state of the tissue. 
Histopathology does not consider the biochemical changes that all tissues undergo 
during active mitosis and is merely based on visual inspection of gross morphological 
changes in biopsies. This limits the diagnostic efficacy due to its subjectivity and 
hence suffers from low inter- and intra-observer reproducibility.15 Recently, HPV 
vaccines have been developed for preventing cervical cancer, however, the HPV 
vaccines can only target some high-risk types of HPV. For instance, Gardasil can 
target the HPV types 6, 11, 16 and 18. Hence, regular Pap smear is still recommended 




1.3 Overview of Raman spectroscopy  
1.3.1 The Raman effect  
Raman spectroscopy is a non-destructive inelastic light scattering technique 
and capable of probing vibrational modes of molecules without labeling, revealing the 
speciﬁc vibrational ﬁngerprinting of molecular compositions and structures of tissues. 
In 1928, the Indian physicist Sir Chandrasekhara Venkata Raman (1888-1970) 
discovered the Raman effect, and won the 1930 Nobel Prize in Physics “as the first 
Asian for his work on the scattering of light and for the discovery of the effect named 
after him”.16 When the light photon encounters the molecule, the energy is exchanged 
between the incident photons and the molecules that get interrogated. The electrons 
are perturbed periodically relative to the nuclei with the frequency of incident wave 
electric field. This perturbation causes periodic separation of charges within the 
molecule (polarized molecule) and results in induced dipole moment. The induced 
dipole moment (P) is proportional to the electric field of the incident wave (E) and the 
polarizability (α- property of the molecule).  
 
P =  E    (1.1) 
 
Expanding  this  and  using  harmonic  vibrations  i.e.,  3N-6  normal  vibrations  (or  
3N-5 for linear molecules), we get  
P= oEocos2  ot+
2
1
(  / q)o qoEo[cos{2 ( o+ m)t}+cos{2 ( o- m) t}] (1.2) 
 
Where  o is the inherent polarizability of the molecule, Eo and  o are the vibrational 
amplitude and frequency of incident light, qo and  m are the vibrational amplitude and 
frequency of the molecule, respectively. The first term represents the Rayleigh 
scattering and the second term represents anti-Stokes and Stokes scattering, 
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respectively. This classical electromagnetic theory explains the basics of Raman 
scattering, however, a more comprehensive theory requires quantum mechanical 
description to provide more complete understanding of Raman scattering process in 
terms of discrete vibrational energy states of each molecular vibrational mode. 
 
Figure 1.3 Energy transition diagram showing Stokes and anti-Stokes Raman scattering. 
 
According to quantum theory, when the energy of the incident photon is not sufficient 
to excite the molecule to higher energy electronic level, the molecule is excited to 
virtual energy level within the electronic level.17 If the energy of the incident photon 
is unaltered after the collision with the molecule, the scattering phenomenon is called 
Rayleigh scattering (elastic scattering). However, a very small proportion of incident 
photons (~1 in 1010) are scattered with a change in frequency,18 called an inelastic 
light scattering or Raman scattering technique that resolves the fundamental 
vibrational frequencies of molecules. The energy transferred from (giving rise to anti-
Stokes lines) or to the molecule (Stokes) brings the vibrational motion (e.g., bending 
or stretching motion of the molecular bond etc.) in the molecule (Figure 1.3). The 
intensity of the Raman signal depends on the concentration of scattered molecules and 
inversely proportional to the fourth power of laser wavelength.  
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1.3.2 Raman instrumentation 
1.3.2.1 Confocal Raman microscopy 
 
Figure 1.4 Confocal Raman microscopy principle and instrumentation set-up. BPF, band-pass 
filter; LPF, long-pass filter; DM, dichroic mirror. Dotted line represents out-of-focus light rays and 
the shaded area represents in-focus light rays. 
 
Confocal Raman microscopy couples a Raman spectrometer with the standard 
microscope to permit the collection of Raman spectra as well as detailed chemical 
images of samples with sub-micrometer spatial resolution. The modern system 
(Figure 1.4) includes laser light to illuminate the sample, illumination and confocal 
pinholes, excitation filter (i.e., a narrow band-pass filter) for suppressing laser noise, 
emission filter (i.e., an edge long-pass filter) for suppressing the Rayleigh light while 
allowing the scattered Raman signals to pass towards the Raman spectrograph, an 
imaging spectrograph and a charge coupled device (CCD) camera. The illumination 
pinhole virtually produces a single point source and it is refocused onto the sample by 
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the objective to examine each point on the sample. The confocal pinhole acts as a 
spatial filter and provides good depth resolution by allowing only the in-focus light 
and effectively eliminating the out-of-focus light from the specimen. In principle, the 
object and images are confocal when the image point on the detector has the same 
focus of the illumination light spot on the object plane (i.e., the object point and the 
image point lie on the optically conjugated planes). The diameter of the confocal 
pinhole is set to the size of the Airy disc or slightly smaller than the Airy disc to 
achieve maximum axial resolution. The depth-resolved micro-Raman spectra can be 
acquired from different depths of tissue and cells when z-scanning the sample stage or 
microscope objective, and hence, the biochemical distributions inside the tissue and 
cells can be uncovered noninvasively using the confocal Raman microscopy 
technique.  
1.3.2.2 Fiber-optic Raman spectroscopy 
The basic fiber-optic Raman instrumentation that can access and measure in 
vivo tissue Raman signals non-invasively from internal organs is shown in Figure 1.5. 
For the development of in vivo Raman diagnostic system, a laser light source to 
illuminate the sample especially red lasers (600 - 800 nm) for reduced tissue 
autofluorescence (AF), a narrow band-pass filter for suppressing laser noise, and to 
reduce most of the fused-silica noise generated in the excitation fiber of the Raman 
probe before the excitation beam hits the tissue, an edge long-pass filter for further 
reduction of scattered laser light while permitting the scattered-tissue Raman signals 
to pass towards the Raman spectrograph, fiber-optic light delivery and collection 
system for remote sampling, high-throughput imaging spectrographs and low-noise 
CCD detectors are essential. Generally, the fiber optic probe composed of excitation 
fiber to shine the light onto the sample, surrounded by a bundle of collection fibers 
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and they are aligned along a parabolic line when connected to the spectrograph to 
correct the image aberration and to improve the spectral resolution and signal-to-noise 
ratio (SNR).19 
 
Figure 1.5 Basic fiber-optic Raman instrument set-up. 
 
1.3.3 Excitation system 
The excitation source should be strong enough to produce sufficient Raman 
signals and it should be monochromatized to have little power and to produce 
uncomplicated spectra.20 Hence, the lasers have been used as an excitation source 
which produces coherent beam of monochromatic light. At early stages, gas lasers 
(e.g., Ar+ ion - 488 and 514.5 nm, Kr+ ion - 530.9 and 647.1 nm, He-Ne laser - 
632.8 nm) were used to extract Raman spectra from the molecules in the visible 
range. The fluorescent nature of the sample with visible excitation and the 
instrumentation limitation reduces the usefulness of this technique in tissue diagnosis. 
The main difficulty for the implementation of in vivo tissue Raman diagnosis system 
is the interference of tissue AF, which is typically of several orders of magnitude 
stronger than the inherently weak tissue Raman signals, and the interference of silica 
fluorescence and Raman signals.21 To avoid the strong AF interference, the samples 
were subsequently excited with ultraviolet (UV) or near-infrared (NIR) radiation.  
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With UV excitation, the higher electronic states are excited which induces 
quenching and non-radiative relaxation to eliminate the fluorescence or make it to 
occur at longer wavelengths. The UV light penetrates shallower tissue depth, so that it 
can effectively target biomolecules on the superficial tissue surface layer. However, 
the clinical use of UV light is limited due to its photomutagenicity. On the other hand, 
NIR excitation does not induce electronic absorption, so there is little or no 
fluorescence interference from the biological tissue.
22
 For biomedical Raman 
spectroscopy, the AF is accordingly reduced with larger excitation wavelength while 
the tissue optical window exists in the NIR region. NIR wavelength requires less 
sample preparation and can interrogate deeper part of the tissue due to less water 
absorption. For these reasons, in vivo biomedical Raman spectroscopic diagnosis is 
preferably performed in the NIR region with typical excitation wavelengths ranging 
from 785, 830 and 1064 nm. Hence, Nd: YAG lasers (wavelength of 1064 nm) were 
used in the Fourier transform (FT) Raman spectroscopy in which the AF is almost 
suppressed. However, InGaAs detector produces substantial noise
23
 and requires long 
collection times (typically 30 min) to measure high-quality tissue Raman spectra.
24
 
For the wavelength above 850 nm range, the AF is further reduced, but the CCD 
detector efficiency drops off and the statistical noise increases with increasing 
wavelength.
23
 Nowadays the NIR diode lasers replaced the gas and ND: YAG lasers 
because of its low cost, compact size and high reliability.
20
 Diode laser provides good 





The development of high-throughput imaging spectrographs based on a 
volume phase holographic transmission or reflective type grating with low f/# 
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(e.g., f/1.8), low stray light background (10
-11
), NIR optimized refractive optics, 
optimum system throughput covering the desired spectral range (e.g., fingerprint (FP) 
region (-50 - 2000 cm
-1
) and high wavenumber (HW) region (2800 - 4000 cm
-1
)) 
becomes mandatory to reject the Rayleigh line. In single stage monochromator, 
Rayleigh light intensity can be eight orders of magnitude stronger than the Raman 
intensity and this stray light level is too high to be used in Raman spectroscopy. The 
use of double or triple monochromators becomes essential to suppress the stray light 
level. However, these multi-stage monochromators transmission efficiency is lower 
(1-5%) due to reflection losses and grating efficiencies and they are expensive, bulky 
and need prefiltering stage.
25, 26
 The use of a single-stage monochromator combined 
with an efficient filter with high optical density at the laser frequency and sharp onset 
of absorption can replace the prefilter stage by effectively suppressing the stray light, 
thereby making the instrument compact with large optical throughput.
25, 26
 The 
cardinal factor determining the sensitivity of Raman system is the usable detection 
area [usable silt width X height].
27
 The spectrometer resolution is determined by the 
entrance slit width (i.e., convolution of the entrance slit width with the CCD pixel). 
Increasing the slit width enhances the throughput (i.e., increases the collection of 
scattered Raman signal due to larger sampling area), however, reduces the spectral 
resolution. Therefore, the spectral resolution restricts the usable slit size. Extending 
the slit height using the straight slit results in a curved image (usually parabolic) on 
the detector, caused by out-of-plane diffraction by the grating (i.e., the rays from 
different positions along the length of the slit are incident on the grating at varying 
degrees of obliqueness).
28
 If this curvature is not corrected, the curved slit image will 
degrade the peak shape and spectral resolution. This image distortion or curvature can 
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be corrected by using the curved entrance slit with reverse orientation of the 
horizontal displacement in the spectrograph image aberration. 
1.3.5 Detection system 
In early stages, photomultiplier tube (PMT) (single-channel detector) is used 
to detect the Raman signals because of its sufficient sensitivity to detect a single 
photon and low dark noise. But the work function of the photocathode surface is low 
in the red and NIR region. Moreover, it is very difficult to prevent the dark electron 
generation and the detector can be damaged permanently if exposed to light (room 
light/laser) with the PMT active.
18
 Avalanche photodiodes (APD) are subsequently 
used for detection because of its smaller size and less expensive than PMT. However, 
the dark signal from thermally generated/amplified electrons are still higher than 
PMT.
18
 Intensified photodiode array (IPDA) detector are successively emerged for 
multichannel detection, but the dark signal is relatively high compared to CCD. The 
intensifier is also expensive and can be easily damaged due to over exposure of light 
(room light/laser). Furthermore, the quantum efficiency is comparatively lower than 
the CCD detectors.
18
 Recently, the CCD (multi-channel array detector) detection 
system replaced the single-channel detector (e.g., PMT, APD, etc.) due to its reduced 
integration time, spectrum multiplexing capability, enhanced quantum efficiency and 
reduced etaloning effect over a large wavelength range (e.g., from 400 to 1100nm).
20
 




1.3.6 Fiber-optic probes 
The development of miniaturized flexible bifurcated fiber-optic Raman probe 
designs for remote delivery and collection of tissue Raman spectra with high 
collection efficiency and reduced fused-silica Raman and fluorescence interference is 
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essential and yet challenging in the field of biomedicine. Because, many medical 
diagnostic and therapeutic applications need remote sampling by the use of optical 
fiber bundles to access the desired internal organs. There are several critical design 
considerations for fiber-optic Raman probes:29-31 (i) The probe must have high 
collection efficiency to acquire tissue Raman signal in very short acquisition time 
(<0.5 sec) with high SNR and low laser excitation power. (ii) Integration of filters to 
reduce laser noise, Rayleigh scattered light as well as fused-silica Raman and 
fluorescence interference. (iii) Constrained geometry for flexible clinical use to fit 
into the instrument channel of the desired medical equipment (e.g., endoscope, 
bronchoscope, colonoscope etc.). (iv) Bio-compatible and capable to withstand 
medical sterilization. Furthermore, the fiber length should be kept as small as possible 
for the specific application, as these induced fused-silica fiber background is to a good 
approximation linearly related to the length of the fiber. Hence, significant research 
efforts have been undertaken on the optimization of optical fiber probe designs for 
developing fiber-optic Raman spectroscopy compatible for in vivo disease diagnosis 
in internal organs.  
For instance, in 1995, Frank et al. developed a fiber-optic needle probe with 
one laser fiber and 6 surrounding collection fibers (200 µm diameter of each), 
embedded within a 1 mm internal diameter core biopsy needle for in vitro diagnosis 
of malignant lesions in breast tissue.32 Richards-Kortum and colleagues have 
constructed a fiber optic probe33 (diameter of 12 mm) and pioneered the use of Raman 
spectroscopy for clinical diagnosis of cervical dysplasia.34 The probe was configured 
with a single delivery fiber (200 µm diameter) at the outer edge of the probe, 50 
closely-packed collection fibers where the diameter of each collection fiber is 
100 µm.33 One of the collection fibers was coupled to 632.8 nm laser to provide an 
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aiming beam. The group reported that silica-silica fiber probes interferes less with the 
weak tissue Raman signal compared to sapphire and liquid guide fibers, despite of the 
intense fluorescence and Raman signals generated from the silica. First in vivo 
cervical tissue Raman spectra were subsequently acquired in 90 sec using 789 nm 
laser excitation.  
Zhang et al. tested different designs of endoscopic fiber-optic probes of 
diameter <3 mm (single fiber, simple bifurcated probe and bifurcated probe with 
narrow band (NB) coating at the excitation fiber tip) on chicken fat tissue.30 Typically, 
the collection efficiency of the single fiber probe configurations were high due to 
complete overlap between the illumination and collection light cones.35 However, the 
bifurcated multi-fiber probe bundle with separate illumination and collection fibers 
were subsequently developed to diminish the intrinsic fiber signal.36 The group 
eventually concluded that the miniaturized bifurcated multi-fiber probe with NB filter 
in front of the excitation fiber and long-pass/band rejection filter at the tip of the 
collection fibers could preferably maximize the collection of tissue Raman signals 
while reducing the interference of fiber silica fluorescence and Raman signals.30 
However, controlling the probing depth and sampling volume is of clinical 
importance because carcinogenesis typically initiates in the epithelial layer. Several 
design strategies such as beveled collection fibers, graded-index (GRIN) lens or distal 
ball lens have been proposed to maximize shallower tissue Raman measurements in 
the epithelial tissue. For instance, in 1999, Shim et al. has developed a beveled 
endoscopic fiber probe35 and performed the pioneering work on in vivo Raman 
endoscopic spectral measurements from the gastrointestinal tract.37 The 1.5 m long 
endoscopic compatible probe comprised of a single 400 µm diameter central delivery 
fiber, surrounded by seven 300 µm diameter beveled collection fibers in order to 
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enhance the collection efficiency particularly from the region in front of the excitation 
fiber at a specified sampling depth. The novel design of “in-the-tip” filters for 
suppressing fluorescence and silica Raman signals were incorporated onto the core of 
the fibers about 2.5 cm from the probe tip. Wilson and co-workers have utilized a 
reusable probe with non-traumatic 2 mm outer diameter tip and successfully 
differentiated the dysplastic lesions in Barrett's esophagus in vivo.38 The reusable 
probe consisted of a central delivery fiber of 400 µm diameter and a set of six 300 µm 
diameter beveled collection fibers that can maximize the signal collection efficiency 
from the sampling depth of ~ 500 µm. Apart from the beveled collection fibers, GRIN 
lens as well as distal ball lens based Raman probes were also developed as alternative 
methods, facilitating improved performance and collection efficiency. In 2004, 
Motz et al. presented a 2 mm diameter sapphire ball lens based fiber-optic probe29 
equipped with a novel sapphire/fused silica filter module consisting of a rod that 
carrying a short-pass filter on one plane face, fitted into the tube carrying a long-pass 
dielectric coating on one plane face. The distal ball lens was utilized to improve the 
performance and collection efficiency of the probe. The diagnostic utility of the probe 
that comprises a central excitation fiber, 15 collection fibers (200 µm diameter each) 
and distal tip ball lens was tested through simulations, tissue model experiments and 
in vitro tissues such as artery and breast tissue samples. Short et al. developed a 
technically challenging endoscopic fiber-optic catheter Raman probe featuring a 
200 µm central excitation fiber with the surrounding 27 collection fibers (100 µm 
diameter each) to characterize the highly autofluorescent lung tissue in vivo in real-
time.39 Day et al. has specially designed a miniaturized confocal endoscopic Raman 
probe consisting of a single illumination fiber and a single collection fiber and further 
utilized a GRIN lens for optimizing the depth of focus ~150 µm to especially study 
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early (premalignant) changes in esophageal malignancy.31 In 2009, our group (Huang 
and co-workers) has developed a special bifurcated internally filtered fiber-optic 
volume Raman probe of outer diameter 1.8 mm, consisting of a bundle of 200 µm 
fibers in a 32-around-1 configuration on the distal end for endoscopic applications.40 
High-quality Raman spectra from upper gastrointestinal tract were accordingly 
acquired in sub-seconds (1 sec). Our group has subsequently reported on the design of 
a fiber-optic distal ball lens Raman probe with a single excitation and a single 
collection fiber of 200 µm diameter to realize the depth-resolved Raman 
spectroscopy.41 The study results demonstrated that the ball lens probe with larger 
refractive index and smaller diameter could improve the depth-selective Raman 
measurements of epithelial tissue. Our group has also recently established a beveled 
fiber-optic confocal endoscopic Raman probe42 (1.8 mm outer diameter) with distal 
ball lens that can pick up ~85% of the total Raman signals originating from the 
epithelial tissue layer for tissue Raman measurements at endoscopy. This internally 
filtered confocal endoscopic Raman probe comprises one central flat fiber for laser 
light delivery, surrounded by a ring of nine beveled collection fibers (20° beveled 
angle of 9 x 200 m collection fibers; zero fiber-ball lens gap), coupled with a high-
index miniaturized ball lens for selective interrogation and scattered tissue Raman 
photons collecion from the epithelial layer (< 300 m). The performance of the 
developed probe favoring for epithlial malignancy diagnosis was tested through 
Monte Carlo simulations, two-layer tissue phantom and esophageal tissue in vivo at 
endoscopy. 
Few reports have also focused on the design of fiber-optic probes for 
intravascular Raman spectroscopy. Buschman et al. developed a forward and side 
viewing intravascular fiber-optic Raman probe (diameter of 2.5 mm) to determine the 
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chemical composition of blood vessel wall in vivo in lambs and sheep.43 Komachi 
et al. has presented the narrowest intravascular micro-Raman probe with the diameter 
of 600 µm and evidenced the excellent performance of the probe for discerning 
coronary atherosclerosis in vitro in rabbit44 and in vivo in living rat’s esophagus and 
stomach45. Very recently, Krafft et al. has reported on the novel miniaturized 
(~0.375 mm diameter) fiber-optic probe based on multi-core single-mode fibers 
(MCSMF) with inscribed in-line fiber Bragg gratings (FBGs) as collection fibers for 
improving the collection efficiency of the probe, reducing the fiber background and 
distance dependence of the probe.46 The applicability of the developed probe for 
clinically relevant samples was tested on porcine brain tissue. Thus, the contemporary 
rapid Raman instrumentation and recent advances in fiber-optic probe designs such as 
minimally invasive access to desired internal organs, controlled sampling depth and 
volume, and the use of NIR wavelength make Raman technique readily accessible and 
promising for routine in vivo clinical applications. 
1.4 In vitro Raman spectroscopy for cancer diagnosis 
In early 1990s, interpretable NIR Raman spectra were obtained from various 
tissues such as breast,32, 47, 48 gynecology tissues,49 brain,50, 51 artery,52, 53 and skin54, 55 
etc. by employing FT spectrometers at 1064 nm laser excitation. For instance, in 
1992, Liu et al. performed the pioneering work by acquiring the first interpretable 
Raman spectra from gynaecological tract (i.e., cervix, endometrium, ovarian tissue) 
using FT-Raman spectroscopy and observed the differences between normal, benign 
and cancerous tissues using relative intensities of important Raman peaks.49 The 
major advances such as continuous wave NIR diode lasers, fiber-optic sampling 
combined with single-stage imaging spectrographs, and CCD detectors, high-
sensitivity NIR Raman spectroscopy with low-fluorescence interference has emerged 
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as an alternative to FT-Raman. Further developments of deep-depletion CCDs with 
significantly better quantum efficiency in the NIR region facilitated the development 
of hospital-compatible, clinical based rapid NIR Raman spectroscopy (in 1992) that 
can measure the Raman spectra from intact human aorta in vitro under 1 sec.56-58 The 
technique has further been studied with promising results for in vitro tissue diagnosis 
in a number of organs such as skin,59-62 breast,63-66 oral,67, 68 larynx/nasopharynx,69, 70 
esophagus and gastric,15, 71, 72 colon,15, 65, 73 lung,74-76 bladder,65, 77-79 prostate,15, 80 
cervix,2, 24, 81, 82  brain79, 83-87 and bone88, 89 and consequently has now been recognized 
as an effective diagnostic tool for tissue diagnosis.  
For instance, the peer group of Feld extensively studied the histochemical 
analysis of breast and artery tissues using NIR Raman spectroscopy.56, 63-66, 90, 91 Feld 
et al. also evaluated the potential of Raman spectroscopy to quantify the 
histochemistry of frozen colonic and bladder tissue specimen under 830 nm excitation 
with the acquisition time of 60 sec.65 Mahadevan-Jansen et al. acquired Raman 
spectra from 36 cervical tissue biopsies from 18 patients using 789 nm Raman 
spectroscopy and distinguished precancer from benign tissue with a sensitivity of 82% 
and a specificity of 92% using principle component analysis (PCA) combined with 
Fisher discriminant analysis.24 Lyng et al. also obtained Raman spectra from formalin-
fixed paraffin preserved histological samples of normal, CIN and invasive cervical 
carcinoma tissue from 40 patients as well as from pure biochemicals such as proteins, 
nucleic acids, lipids and carbohydrates in order to gain an insight into the biochemical 
changes accompanying cervical cancer progression and discriminated the pathologies 
with promising results using confocal micro-Raman spectroscopy.2 Several other 
group have also explored the in vitro Raman spectral properties of cervical cells (Jess 
et al92) and tissues (Krishna et al81, 82).  
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Stone et al. demonstrated the potential of micro-Raman spectroscopy using 
830 nm laser for molecular level identification of epithelial cancers and precancers in 
variety of organs including esophagus, colon, and prostate with sensitivities and 
specificities ranging from ~91-96%.15, 93 Crow et al also performed a similar study on 
the bladder and prostate tissue using micro-Raman spectroscopy at 830 nm laser 
excitation and classified with an overall accuracy of >90%.77, 80 The Raman 
spectroscopic properties of nasopharyngeal tissue (Lau et al.70) and brain tissues 
(Krafft and colleagues84, 85, 94) have also been demonstrated successfully. The research 
carried out by the team headed by Puppels et al. focused on the Raman spectral 
histopathology of skin,61, 62 brain,79, 87 and bladder tissue78, 79. Huang and co-workers 
explored the potential of rapid NIR Raman spectroscopy for the diagnosis of cancers 
in lung ,74, 76 larynx,69 colon,73 and extensively studied different gastric tissue 
pathologies71, 72, 95, 96 such as intestinal metaplasia, helicobacter pylori infection, 
dysplasia, and adenocarcinoma in vitro with diagnostic sensitivities ranging from ~85-
95% and speciﬁcities ranging from ~90-98%. In a study by Bensalah et al. Raman 
spectra collected from the surgical renal specimens from 36 patients using 785 nm 
Raman spectroscopy coupled with fiber-optic magnetic resonance probe classified the 
benign tissue with an accuracy of 84% from the malignant tumors.97 Overall, the in 
vitro studies performed on a variety of tissue types have indicated that NIR Raman 
spectroscopy could have a very promising role in clinical medicine as a non-invasive 
tool for detection of early cancer.  
1.5 In vivo Raman spectroscopy for cancer diagnosis 
Ground-breaking research attempts on cancer diagnosis by shedding the light 
and tremendous advancements across the field of Raman spectroscopy over the past 
two decades have opened a new frontier of very high resolution real-time in vivo 
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Raman spectroscopy promising for clinical cancer management and screening of early 
cancer. Consequently, numerous in vivo studies have been performed for assessing the 
potential of Raman spectroscopy for in vivo diagnosis of cancers and precancers in a 
number of organs such as skin,21, 28, 98 oral,21, 99, 100 breast,101 larynx,102, 103 esophagus 
and gastric,37, 104-110 bladder,111 lung,39, 112 colon,37, 113 and cervix9, 114-117.  
For instance, Richards-Kortum and colleagues have developed a compact 
fiber-optic probe (in 1998) and played a key role in opening up new line of approach 
for cervical cancer and precancer management by means of Raman spectroscopy 
during clinical colposcopy (integration time: 90 sec).33 In 2001, the group published 
the first in vivo clinical trial results, demonstrating the use of Raman spectroscopy for 
in vivo cervical precancer diagnosis during colposcopy based on 13 patients 
recruited.34 The in vivo Raman spectra were measured from normal, inflammation, 
squamous metaplasia, low-grade and high-grade precancer cervical tissue sites with 
the integration time ranged from 60 to 180 sec and successfully differentiated the 
high-grade precancer using intensity ratio algorithms. Mahadevan-Jansen et al.9, 114, 
115, 118 and our group117, 119, 120 have comprehensively investigated the diagnostic 
capability of Raman spectroscopy for differentiating dysplastic cervix in vivo. Our 
group also illustrated the feasibility of HW Raman spectroscopy for in vivo 
identification of cervical precancer with a diagnostic sensitivity of 93.5% and a 
speciﬁcity of 97.8% based on recruited 46 patients. We concluded that the precancer 
cervical tissue showed signiﬁcantly lower lipids and proteins, however, increased 
water content compared to normal tissue. The Raman spectral pathology of cervix 
tissue has been further described in detail in the chapters 2-7. 
Besides the cervix tissue, the diagnostic potential of Raman spectroscopy for 
disease diagnosis in other organs such as skin, esophagus, gastric, etc. have been 
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comprehensively investigated. For instance, Shim et al. described the fiber-optic 
based in vivo NIR Raman system to measure Raman spectra from human skin, buccal 
cheek epithelium, fingernail and tooth within 30 sec.21 Caspers et al. have 
comprehensively characterized the skin tissue in vivo61 and monitored the changes in 
stratum corneum water concentration profiles due to hydration121 using confocal 
Raman micro-spectrometer. In 2001, Huang et al. have first developed an image-
aberration-corrected rapid Raman spectroscopy and a special skin Raman probe for in 
vivo skin Raman measurements within sub-seconds (<1 sec).28 First time 
demonstration of real-time (1 sec) spectral-based in vivo breast tissue characterization 
and diagnosis has also been presented (Haka et al.101) based on recruited 9 patients 
with an accuracy of 93%. Shim et al. has performed the first in vivo endoscopic 
Raman measurements (in 2000) on human gastrointestinal tissues (i.e., esophagus, 
stomach, and colon) in 5 sec during routine clinical endoscopy.37 Later the same 
group first reported the in vivo trial results for differentiating the colon adenomatous 
polyps from hyperplastic polyps113 and also identified the dysplastic lesions in 
Barrett’s esophagus in vivo with promising results.38 Short et al. for the first time 
collected real-time, in vivo lung tissue Raman spectra in both FP and HW region 
within 1-2 sec, despite of the high AF generated from lung tissue39 and concluded that 
HW region is more reliable in case of lung tissue due to its strong AF in FP region. In 
2009, our group (Huang and colleagues) has successfully developed a trimodal wide-
field image-guided fiber-optic Raman endoscopy40 and extensively investigated in 
vivo Raman diagnosis of laryngeal,102, 103 esophageal109 and gastric105, 106, 108, 122, 123 
cancer and precancer within 0.1 - 0.5 sec during routine clinical endoscopic 
inspections, approaching real-time clinical application. Utilizing the developed fiber-
optic Raman system, our group conducted a preliminary study on 30 gastric and 27 
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esophageal patients and reported sensitivities and specificities of ~94-97% for 
identifying the biomolecular changes associated with cancer and precancer 
transformation in vivo.109, 122 Our group also first critically evaluated the molecular 
level discrimination of benign and malignant ulcers in the stomach107 and inter-organ, 
inter-anatomical variability of tissues in the upper gastrointestinal tract as well.104 
Very recently, our group has reported the first implementation of transnasal, white-
light reflectance (WLR) / narrow band imaging (NBI) - guided Raman endoscopy to 
measure the Raman spectral properties of different anatomic locations of 
nasopharyngeal and laryngeal tissue from 23 normal subjects in real-time, in vivo, 
within 0.5 sec during transnasal clinical endoscopy.102 We further assessed the 
performance of transnasal image-guided HW Raman spectroscopy which could 
measure the Raman spectra within 1 sec and provided a diagnostic sensitivity of 
90.3% and a speciﬁcity of 90.9% based on enrolled 39 laryngeal cancer patients.103 
Draga et al. investigated the normal and bladder cancer in vivo using 785 nm high-
volume (Raman probe which measures up to a depth of 2 mm) Raman spectroscopy to 
determine the biochemical differences during the procedure of transurethral resection 
of bladder tumors with Raman signal collection time of 1-5 sec.111 Overall, the 
biochemical designation of different tissue Raman peaks remains uncertain. However, 
the biochemical changes associated with malignant transformation including increase 
of nucleic acids, protein conformation changes, and reduction in glycogen and lipids 
are common in most of the tissues. These reported in vivo Raman studies successfully 
translate the Raman spectroscopy from the current laboratory-based bench-top 
technique to clinical bedside applications for real-time, in vivo diagnosis of 




1.6 Data preprocessing 
The spectra acquired using the developed Raman system never be the true 
sample spectra. Each of the components in the instrument has its own spectral 
response and therefore the sample response is modified by the instrumental response. 
Etaloning in the CCD, modal interference in optical ﬁlters, variation in the CCD pixel 
sensitivity and particularly, gradual change in quantum eﬃciency of the detector 
across the spectral range can cause a signiﬁcant change in instrument sensitivity that 
varies slowly with wavelength, results in rapid oscillation in the sensitivity of a 
Raman instrument with changing wavelength.15 Therefore, the wavelength calibrated 
spectra have to be corrected for the wavelength dependence of the system. The 
intensity corrected spectra represented a combination of prominent tissue AF 
background, weak tissue Raman scattered signals, and noise. Hence, the intensity 
corrected spectra were further smoothed (e.g., Savitzky-Golay) to reduce the 
uncorrelated noise.124, 125 Since, the AF is typically several orders of magnitude more 
intense than the Raman signal, accurate subtraction of this AF signal to obtain the 
pure Raman signal is still a challenge.126  
A number of methodologies including instrumental-based (e.g., time gating, 
frequency shifted excitation, and shifted subtraction Raman spectroscopy (SSRS)) and 
computational-based (e.g., frequency-domain filtering, first- and second-order 
differentiation, wavelet transformation, Fourier transformation method, and 
polynomial fitting) have been proposed for effectively removing the tissue AF 
background.127-130 However, polynomial fitting is one of the most commonly used 
methods and found to be the simplest and accurate to describe the broad AF line shape 
and retain the Raman spectral features.128 In wavelet transformation method, the 
signal is decomposed into different frequency components and the varying low 
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frequency background signal is removed. Y.Hu et al131 showed that this technique 
could deal the measured signals with different kinds of background or low signal to 
background ratio without requiring prior knowledge about the sample composition, no 
selection of suitable background correction points and no mathematical assumption of 
background distribution. The derivative method can distort the Raman line shapes and 
requires a complex mathematical fitting algorithm to reconstruct the Raman 
spectra.132 The Fourier transform method can produce severe artifacts when the 
frequency components of the Raman spectra and noise features are not separated 
well.132 Simple least square fitting method minimizes the differences between the 
fitted and measured spectra. The polynomial fitting method is one of the most 
commonly used methods and can retain the spectral features of Raman signal. The 
modified polyfit (polynomial fitting and reassignment of the original input pixel 
intensity when the value of the polynomial exceeds the input pixel intensity) process 
is repeated (25 to 200 iterations) till the Raman contour is eliminated.128, 133 Then the 
AF background (polynomial) is subtracted from the smoothed spectrum which yields 
the high frequency Raman spectrum alone. The background subtracted Raman spectra 
were further normalized to an integrated area under the curve for standardizing the 
absolute tissue Raman spectral intensities, so that the relative peak intensities among 
different samples can be compared. Following the preprocessing, Raman spectra can 
be fed to the outlier detection algorithm based on PCA statistics (i.e., Hotelling’s T2 
and Q-residuals) for tissue Raman spectra verification (e.g., noncontact 
measurements, spectral interference from confounding factors such as blood, white 





1.7 Multivariate statistical analysis 
Subsequent to verification of tissue Raman spectrum quality, empirical 
approaches like comparing intensity of Raman peaks or intensity ratio of Raman 
peaks are used to classify those qualified Raman spectra according to tissue pathology 
types. In early approaches, these empirical methods are broadly used to classify 
normal and abnormal samples because there is a consistent variation in the number of 
peaks or peak locations. The intensity ratio algorithms provide tissue diagnosis which 
is independent of Raman spectroscopic measurement conditions.71 However, with the 
recent developments in the sophisticated statistical methods, such as PCA - linear 
discriminant analysis (LDA),105 partial least squares - discriminant analysis (PLS-
DA),107, 134 the samples can be classified more accurately.   
1.7.1 Principal component analysis 
After the spectral preprocessing, PCA can be employed to reduce the spectral 
space through the identification of a reduced number of orthogonal principal 
components (PCs) and the PCs are arranged in descending order of variance 
explained. The PCA model of the data matrix X is defined by135: 
 TX TP E       (1.3) 
where T and P represent scores and loadings, and E contains the residuals. The 
loadings correspond to the new rotated axis, whereas scores represent the data 
projection values. The PCs preserve most of the total variance in the spectral dataset 
for effective tissue classification, whilst eliminating the redundant information.105 It 
transforms the number of possibly correlated variables into a smaller number of 
uncorrelated variables called PCs. The first PC corresponds to the maximum 
variability in the data set, and the variability goes on decreasing for successive 
components. These low variance components are arranged at lost which can be 
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removed further without losing the significant details. Briefly, PCA reduces the 
dimension of the Raman spectra by decomposing them into linear combinations of 
PCs, such that the spectral variations in the dataset are maximized. The PCs can be 
fed to clustering algorithm (e.g., LDA classifier) for further classification.  
1.7.2 Classification algorithms 
Several multivariate supervised classification methods (e.g., LDA, PLS-DA) 
have recently been used for spectroscopic data classification. LDA finds the linear 
combinations of the original variables that provide the best possible separation 
between the groups in the data set. LDA determines the discriminant function that 
maximizing the ratio of between-class variance to the within-class variance, 
warranting maximum separability. In this dissertation, we mainly utilized PLS-DA for 
classifying the tissue spectral data. PLS is a two-block regression method, 
establishing a relationship between one or more dependent variables and a group of 
descriptors. It extracts the latent variables (LVs) in a decreasing order of their 
respective singular values from the input dataset.136-138 PLS-DA follows the principle 
of PCA, but further rotates the components (LVs) to achieve maximum group 
separation.107 PCA retains as much as possible variations present in the dataset 
without considering the response variable. Unlike PCA, PLS-DA correlates the 
variations in the dataset with the response variable.134 Thus, it could explain the 
diagnostic relevant variations rather than the significant differences in the dataset. The 
latent scores, loadings and weights are extracted for the corresponding number of 
components selected. In PLS-DA, the complexity of the model is controlled by the 
number of components selected and the number of optimal components is determined 
from cross validation (CV) error values. By selecting the optimum number of 
components it is possible to avoid over fitting and under fitting. Other clustering 
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methods including support vector machines (SVM),73 classification and regression 
trees (CART)139 can also be utilized for spectral classification. Feature selection 
algorithms such as ant colony optimization (ACO)123 iterative variable selection 
(IVS), uninformative variable elimination (UVE) and iterative predictor weighting 
(IPW) or genetic algorithm (GA)140, 141 can be advantageously combined with 
multivariate analysis for improving the predictive performance and reduce the model 
complexity.123 The feature selection algorithm (e.g., GA) has been comprehensively 
investigated in chapter 5. 
1.8 Biomolecular modeling 
The measured macroscopic tissue spectra were fit to a linear combination of 
major pure tissue biochemical constituents based on prior biochemical knowledge 
using linear least-squares method with non-negative constraints (non-negativity-
constrained least squares minimization (NNCLSM) fitting).109, 142-145 
The developed NNCLSM modeling can be expressed as,  
 Min E(c) = ||c. S – d||2, where c ≥ 0, 
 
(1.4) 
where c is the matrix of concentrations or contribution coefﬁcients to be predicted, 
S is the matrix of spectral components of biochemicals, and d is the measured tissue 
spectrum of different types. The best fit can be obtained by minimizing the 
residuals (E). The developed biochemical model determines the relative concentration 
profiles of major tissue biochemical constituents responsible for prominent tissue 
Raman spectral features and its changes associated with disease progression. The 
developed semi-quantitative biochemical diagnostic model fits the measured tissue 
spectra with the basis spectra obtained from the selected biochemicals with very small 
ﬁt-residuals. Consequently, the fitting coefficients yield the concentration of each 
biochemical component making up the lesions, providing an insight into 
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chemical/morphological changes in the tissue associated with disease development 
and progression. The NNCLSM model presumes that the Raman spectra measured 
from the tissue is a linear combination of its biochemical components spectra and the 
signal intensity scales linearly with the concentration of biochemical components in 
the tissue.143 It should be noted that the Raman spectral biomolecular modeling and 
characterization using NNCLSM modeling can provide only gross semi-quantitative 
estimate of biochemical compositions of tissue and the in vitro biomolecular 
confirmations may not fully reflect its true in vivo conditions. Furthermore, the 
spectral reconstruction does not take effect of optical properties (e.g., absorption and 
scattering coefficients, anisotropy, refractive index, tissue layer thickness) of the 
tissue into consideration, thus the penetration depth may affect the estimated 
distribution of molecules in different tissue types.109  
Thus, the above discussed topics provided us the background of technological 
advancements in Raman instrumentation including fiber-optics probes development, 
real-time data processing and multivariate methods, and the use of conventional 
Raman spectroscopy for in vitro and in vivo disease diagnosis in various organs. 
However, development of confocal Raman spectroscopy that can maximize the 
collection of epithelial tissue Raman measurements containing dysplasia-associated 
molecular changes is highly required for early cervical cancer diagnosis. Because, the 
conventional Raman spectroscopy with volume Raman probe largely contains the 
signal from deeper tissue layer (i.e., stroma) and dilutes the epithelial tissue Raman 
signals. Moreover, most of the reported studies were limited to post processing of 
Raman spectra and off-line algorithm development for disease classification. 
Therefore, in this dissertation, we develop a confocal Raman spectroscopy that 
simultaneously measures both the FP and HW tissue Raman signals coupled with the 
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on-line biomedical Raman spectroscopic framework that has the potential to become a 
clinically useful tool for real-time, in vivo diagnosis of cervical precancer during 
colposcopy. Next chapter explains Raman spectroscopic diagnosis of cervical cancer 
and precancer at the cellular and tissue level. Chapter 3 details the development of 
real-time FP/HW confocal Raman spectroscopy system that can achieve the Raman 
spectral acquisition, optical diagnosis and processing time of ~1 sec. The remaining 
chapters demonstrates the implications of removing AF from Raman and the 
feasibility of FP, HW and integrated FP/HW Raman spectroscopy in conjunction with 
PCA-LDA, PLS-DA and novel application of GA for further improving the predictive 
accuracy of FP Raman spectroscopy for cervical precancer diagnosis. 
1.9 Thesis motivation and organization  
1.9.1 Motivation 
Identification of cancer at very early stages is an important critical measure to 
decrease the cervical cancer-related mortality. However, there are profound challenges 
in the definitive diagnosis of precancers in cervix using the standard Pap smear 
followed by colposcopy and directed biopsies. Because, these procedures rely on 
visual assessment of structural details and provides little or no biomolecular 
information. The routine exfoliative cervicovaginal cytology tests (i.e., Pap smear) 
have high diagnostic specificity of 93% (95% confidence interval (CI): 89% - 97%) 
but with a relatively low sensitivity of 57% (95% CI: 38% - 76%) for the diagnosis of 
precancerous lesions in the cervix.14 The white-light colposcopy has a good sensitivity 
of ~96%, but this is tempered by a mediocre detection specificity of ~48% for 
identifying preneoplastic changes in the cervix.14, 146 The current conventional 
screening and diagnostic procedures could not achieve high detection sensitivity and 
specificity concurrently, leading to missed or overcalled lesions.14, 146, 147 Additionally, 
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histopathological diagnosis depends on whether the colposcopist took the biopsies 
from the premalignant lesion (acetowhite areas) or not.2, 14, 148 The current routine is 
however invasive and impractical for high-risk patients who may have multiple 
suspicious lesions and highly prone to subjective interpretation due to inter-observer 
variability both at biopsy sampling as well as histopathological characterization. For 
these reasons, the development of minimal to non-invasive technologies that can 
reduce or eliminate the subjectivity of diagnostics has received increased attention in 
the last two decades. With the recent developments in the state-of-the-art lasers, 
spectrometers and CCDs, technologies such as optical spectroscopic methods have 
become a promising candidate for biomedical diagnostics based on endogenous 
biomolecules.  
The various optical spectroscopic diagnosing techniques based on light-tissue 
interactions such as reflectance spectroscopy, fluorescence and Raman spectroscopy 
have been comprehensively investigated for precancer and cancer diagnosis in various 
organs.24, 71, 74, 93, 109, 119, 145, 149-157 Among the diversified optical spectroscopic 
techniques, NIR Raman spectroscopy has been comprehensively investigated in the 
past two decades to detect precancer and cancerous lesions non-invasively in different 
tissues due to its high biomolecular specificity.24, 74, 93, 109, 119, 157 NIR Raman 
spectroscopy is a vibrational spectroscopic technique for optically probing the 
vibrations of biomolecules, revealing the highly specific biochemical surface and 
subsurface inter/intra-cellular structures and conformations. For biological 
applications, the most commonly used excitation wavelengths are in the NIR range 
(e.g., 785, 830 or 1064 nm), because NIR light penetrates deeper due to less water 
absorption and generates less tissue AF interference in the working wavelength range. 
Therefore, we initially demonstrated the diagnostic potential of NIR Raman 
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spectroscopy for identifying cervical cancer cells and tissues ex vivo. The encouraging 
ex vivo results further enabled us to move our study to in vivo clinical settings for 
precancer diagnosis. Precancerous lesions are usually confined to epithelium and 
therefore the development of in vivo Raman spectroscopy with confocal capability in 
favor of probing the biochemical changes of superficial epithelial layer is of great 
importance compared to conventional Raman spectroscopy with volume Raman probe 
(i.e., predominantly probes the deeper tissue layer) for early cancer diagnosis. 
Furthermore, most of the Raman spectroscopic studies are limited to either FP or HW 
region with off-line post processing and algorithm development for cancer diagnosis. 
Herein, we develop an integrated FP/HW Raman spectroscopy with targeted confocal 
illumination and collection of signals from the epithelial layer of cervix. We further 
develop a fully automated on-line Raman spectral diagnostics framework integrated 
with a colposcopy-guided confocal Raman technique for real-time, on-line in vivo 
cervical precancer detection. 
Since Raman spectral patterns among different tissue types are very similar, 
powerful chemometrics methods were comprehensively investigated to translate the 
molecular differences in the Raman spectra into clinically valuable diagnostic 
information. We assessed the diagnostic performance of different multivariate 
methods such as PCA-LDA and PLS-DA together with CV. Such statistical methods 
improved the precision of quantitative spectral analysis enormously by including 
multiple spectral intensities simultaneously.158 However, these methods are still 
considered as full spectrum analysis and often contain redundant and noisy 
variables.159 Hence, feature selection algorithm (e.g., GA) has been utilized to provide 
a simplified model with improved predictive accuracy for detecting early cancer by 
eliminating non-informative variables from the spectral dataset.  
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Besides the early cancer identification, it is also essential to identify the 
hormone/menopause-related variations in normal cervix to further improve the 
disease diagnosis. Hence, we utilized HW confocal Raman spectroscopy for 
non-invasive assessment of subtle variations in the Raman spectra due to normal 
physiological changes in women such as changes in cervix related to menopausal 
status of women as well as Vagifem (estradiol vaginal tablets) treatment on 
postmenopausal women with atrophic cervix together with biomolecular modeling. 
With the promising results achieved using FP or HW Raman spectroscopy, we 
further evaluated the diagnostic utility of integrated FP/HW confocal Raman 
spectroscopy in conjunction with multivariate techniques for further improving in vivo 
cervical dysplasia detection. We found that the integrated FP and HW Raman 
spectroscopy can enhance tissue diagnosis and characterization by providing 
complementary biochemical information. With the immediate diagnostic feedback 
from the developed real-time confocal Raman spectroscopy integrated with the 
on-line spectroscopic diagnostic framework, the colposcopists can now perform a 
routine point-wise scanning for targeted biopsies of the high-risk tissue sites. 
Biomedical spectroscopic modalities can thus now function in free-running mode, 
opening the possibility of true prospective spectroscopic screening. 
1.9.2 Thesis organization 
The main purpose of the dissertation is to develop a real-time confocal Raman 
spectroscopy that can measure the tissue Raman signals simultaneously from both the 
FP (800 - 1800 cm-1) and HW (2800 - 3800 cm-1) region in conjunction with the 
spectroscopic diagnostic framework implementing on-line preprocessing, outlier 
detection for tissue Raman spectrum verification, as well as organ-specific 
probabilistic diagnostics using different robust chemometric algorithms such as PCA-
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LDA and PLS-DA for the diagnosis of cervical precancer within spectral acquisition, 
optical diagnosis and processing time of ~1 sec. To achieve the goals outlined above, 
the specific aims are formulated as follows: 
1. To explore the diagnostic utility of NIR-FP Raman spectroscopy for in vitro 
cell / tissue characterization and diagnosis in cervix (chapter 2). 
2. To develop a portable, cost-effective, real-time confocal Raman spectroscopy 
that acquires both the FP and HW cervical tissue Raman signals 
simultaneously within the Raman signal acquisition, optical diagnosis and 
processing time of ~1 sec (chapter 3). 
3. To investigate the implications of eliminating tissue AF for improving in vivo 
confocal FP Raman spectroscopic diagnosis of cervical precancer (chapter 4).  
4. To study the feature-based multivariate diagnostic algorithm (GA-PLS-DA) 
and double cross-validation (dCV) for effective in vivo diagnosis and detection 
of cervical precancer using confocal FP Raman spectroscopy (chapter 5). 
5. To characterize the spectral variations in normal cervix associated with 
hormonal/menopausal status of women and evaluate the effect of Vagifem 
treatment on the atrophic cervical epithelium of postmenopausal women using 
in vivo HW Raman spectroscopy (chapter 6). 
6. Combining the FP and HW Raman spectroscopy to further enhance the in vivo 
diagnosis of cervical precancer (chapter 7).  
The final chapter (chapter 8) recapitulates the thesis work and gives some future 
directions for further exploration in Raman diagnosis of cervical precancer.  
36 
 
Chapter 2. Raman spectroscopic characterization of cervical 
cells and tissue samples  
Raman spectroscopy is a vibrational spectroscopic technique that can measure 
the endogenous biomolecular properties of cells and tissues, and its changes 
associated with disease progression, providing a unique way for discriminating 
different cell/tissue pathologies. In this study, we first evaluate the potential of Raman 
micro-spectroscopy for studying the biochemical changes associated with cervical 
cancer transformation at the cellular level. Raman maps revealing the distribution of 
key biochemical components such as nucleic acids, proteins were reconstructed using 
univariate imaging of characteristic bands. Encouraged by the promising preliminary 
results obtained at cellular level, we further developed a rapid-acquisition fiber-optic 
based NIR Raman diagnostic system for tissue Raman spectral measurements. A total 
of 68 Raman spectra (23 benign, 29 LSIL and 16 HSIL) were measured from 25 
cervical tissue biopsy specimens. The measured macroscopic tissue Raman spectra 
were fit to a linear combination of basis spectral signatures in order to quantify the 
chemical composition of benign cervix, LSIL and HSIL. The tissue spectra were 
classified with the diagnostic sensitivities of 95.7%, 82.8% and 81.3%; specificities of 
100%, 92.3% and 88.5%, respectively, for discriminating benign cervix, LSIL and 
HSIL, using PLS-DA algorithm, indicating the potential of Raman spectral markers 
for identifying cervical precancer. 
2.1 Introduction 
Visualization of cells and subcellular organelles are currently carried out using 
available microscopy methods such as cryoelectron microscopy and fluorescence 
microscopy. These methods require external labeling using fluorescent dyes and 
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extensive sample preparations to access the subcellular structures. However, Raman 
micro-spectroscopy provides non-invasive, label-free method for imaging cells with 
high chemical specificity at sub-micrometer spatial resolution. For the past few 
decades, the development of advanced optical modalities, especially NIR Raman 
micro-spectroscopy/spectroscopy is a topic of continuous research for cancer and 
precancer diagnosis.
24, 28, 74, 92, 93, 108, 160
 Raman micro-spectroscopy is an upcoming 
non-destructive analytical technique for cancer detection at cellular level, and requires 
little or no sample preparations to obtain detailed information about cell morphology 
and biochemistry. Therefore, this technique can overcome the limitations of electron 
microscopy and fluorescence microscopy such as applying vacuum, fixatives, 
markers, and labels. In this chapter, we first evaluate the potential of Raman micro-
spectroscopy for studying the biochemical changes associated with cervical cancer at 
cellular level. We performed a preliminary study to characterize the normal (HaCaT) 
and cancer (HeLa) cervical cells with sub-cellular level spatial resolution using 
785 nm Raman micro-spectroscopy. Multivariate analysis including PLS-DA was 
employed to convert the subtle Raman differences observed between different cell 
types into valuable diagnostic information. The univariate hyperspectral images 
revealing the biochemical distribution in the normal and cancer cells were also 
reconstructed from the Raman mapping dataset. To further bring Raman 
spectroscopic technique for in vivo cancer diagnosis in the clinic, fiber-optic based 
Raman spectroscopy system was developed.
40
 We initially utilized the developed 
fiber-optic Raman spectroscopy system for ex vivo cervix tissue characterization. We 
also developed the biochemical diagnostic models for understanding the 
chemical/morphological makeup of benign cervical tissue and its changes associated 
with progressive cervical precarcinogenic lesions (i.e., LSIL, HSIL). We further 
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employed PLS-DA together with leave-one patient-out, CV to generate multi-class 
diagnostic algorithms
106, 107
 for evaluating the diagnostic utility of Raman 
spectroscopy to differentiate different stages of cervical precancer, translating the 
Raman spectroscopy towards in vivo cancer diagnosis at colposcopy. 
2.2 Raman spectroscopy characterization of cells 
2.2.1 Materials and methods 
2.2.1.1 Cervix cell preparation 
HaCaT cell lines derived from neonatal keratinocytes was considered as normal 
cells and HeLa cell lines was used as cervical cancer cells. HeLa and HaCaT cell lines 
were cultured in DMEM supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin. The culture was maintained at 37°C in a humidified 
atmosphere with 5% (v/v) CO2 and the cells were passaged using 0.05% trypsin - 
0.53 nM EDTA. The cells were grown on 35 mm coverslip (MgF2) bottom dishes at 
37°C and harvested at ~50% confluence (cell density of ~0.7X106 per dish). The 
harvested cells were then fixed with 4% paraformaldehyde for 10-20 minutes for 
Raman spectral measurements.  
2.2.1.2 Micro-Raman instrumentation  
The micro-Raman spectrometer system (InVia, Renishaw, UK) coupled with a 
microscope (DMI 5000M, Leica, Germany) in a backscattering geometry was utilized 
to acquire Raman spectra from normal and cancer cervical cell lines and the system 
has been described in detail elsewhere.161 Briefly, the system consists of a 785-nm 
diode laser (maximum output of 300mW, Renishaw, UK), a Czerny - Turner type 
spectrograph (f = 250 mm) equipped with a holographic grating (1800 g/mm) and an 
NIR-enhanced CCD detector (Peltier-cooled at −70 °C, Renishaw, UK). The laser was 
focused onto the fixed cell lines that were grown on MgF2 substrates with a power of 
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~25 mW through the water immersion microscope objective (63×, N.A. 1.2, Olympus, 
USA). The wavelength-dependence of the system was corrected using a 
tungsten-halogen calibration lamp. Each micro-Raman spectrum was collected with a 
signal integration time of 10 sec and spectral resolution of ~2 cm-1. Automatic raster 
scanning of cell lines for creating Raman spectral maps was enabled by an xyz-
motorized, computer controlled sample stage. For each Raman map, the area to be 
mapped on the cell line and the scanning step size were selected.  The micro-Raman 
spectral map was collected at a 1µm grid with a dwell time of 10 sec, using extended 
scanning. The spectral acquisition and microscope stage movement was controlled by 
Wire 2 software package. 
2.2.1.3 Data preprocessing  
Spectral preprocessing and analysis was performed using in-house written 
Matlab scripts (Mathworks Inc., Natick, MA). The constant spectral background was 
calculated by taking the mean of spectra acquired around the cell and subtracted from 
the cell Raman spectra to correct the contributions from MgF2 substrate, buffer and 
optical elements in the beam path. Intensity correction was done on the cell Raman 
spectra in order to reduce the influence of instrument response and optical elements in 
the beam path.  The micro-Raman spectra were further smoothed by a first-order, 
sequential 9-point, Savitzky-Golay filter to reduce the noise.124 The fifth order 
polynomial was utilized to fit the tissue AF background over the working wavelength 
range of 800-1800 cm-1. This AF background was subtracted from the smoothed 
spectra to yield pure cell Raman spectra. The spectra were further normalized to the 
integrated area under the intense Raman peak (1450 cm-1).  
2.2.1.4 Univariate and multivariate analysis 
Univariate images based on the integrated intensity at a certain characteristic 
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Raman peak/band were created to study the biomolecular distribution as well as its 
changes associated with cancer transformation. Chemometric techniques including 
PLS-DA were utilized to extract the subtle spectral differences between different 
pathological cell types. The PLS-DA multivariate method has been described in detail 
in Multivariate statistical analysis section in chapter 1. By correlating the variations 
in the dataset with the response variable, PLS-DA method can identify diagnostically 
important variations for effective classification. The performance of the developed 
PLS-DA diagnostic model was further validated using leave-one cell-out, CV 
methodology. In this validation procedure, one cell was left out and the PLS-DA 
modeling was redeveloped using the remaining spectra. The redeveloped PLS-DA 
diagnostic algorithm was then used to classify the withheld spectra. This process was 
repeated iteratively until all withheld spectra were classiﬁed. 
2.2.2 Results  
Multiple Raman spectra (~3-4) were acquired from the nucleus of each HeLa 
and HaCaT cell lines and the average spectrum of repeated Raman measurements on 
the nucleus of each cell was used for the classification. Figure 2.1 shows the mean 
Raman spectra acquired from the nucleus of normal (n=10) and cancer (n=20) cells. 
The mean Raman spectra of normal and cancer cells showed significant differences 
associated with carcinogenesis transformation. The changes in the relative percentage 
of distinctive biomolecules with cancer is particularly enlightened in the spectral 
ranges around 1004 cm-1, 1095 cm-1, 1265 cm-1, 1335 cm-1, and 1655 cm-1 related to 
phenylalanine, nucleic acid, amide III of proteins, CH3CH2 twisting of proteins and 
nucleic acids, and amide I of proteins, respectively. The spectral changes of 
aforementioned tissue Raman peaks with the development of cancer such as increase 
of nucleic acids, proteins are consistent with the literature.24, 92, 160 The cancer cells 
show reduced intensities at 1004 and 1265 cm-1, but exhibited much increased Raman 
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signals at the following positions 1095, 1335 and 1665 cm-1 compared to normal cells, 
indicating that there is a signiﬁcant increase or decrease in the percentage of 
distinctive biomolecules relative to the total Raman-active constituents in different 
cell types. For instance, increase of DNA associated with malignant transformation 
can be reflected in the DNA backbone signal at 1095 cm-1, which is higher for 
cervical cancer cells compared to normal cells. The increased Raman signal at 
1335 cm-1 is also likely related to higher nucleic acid content in cancer cells. The 
proteins and amino acids are usually higher for cancer cells due to increased 
metabolic activity, however, the change in proteins remains unclear. The changes 
noticed in some of the Raman spectral features may also account for the biological 
differences between HeLa and HaCaT cell types. The substantial differences noticed 
between normal and cervical cancer cells demonstrate the diagnostic potential of 
Raman micro-spectroscopy for the identification of cancer cells from normal cells. 
 
Figure 2.1 Comparison of mean Raman spectra acquired from HeLa (n=20) and HaCaT 
(n=10) cell lines. 
 
PLS-DA multivariate method was further utilized to determine the 
diagnostically significant Raman features. The normalized cell Raman spectra were 
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mean-centered to eliminate the common variance in the dataset. The leave-one cell-
out, cross-validated PLS-DA diagnostic model was subsequently developed to 
differentiate normal and cervical cancer cells using optimum number of components 
(1LV). The optimum number of components was determined (1LV) based on the local 
minimum of CV classification error values, accounting for 52.4% and 98.2% of total 
Raman spectral variations in X and Y direction, respectively. The LVs typically 
represented the features, such as peaks, troughs, and spectral shapes similar to those 
cell Raman spectra (i.e., the Raman spectral variations around the prominent Raman 
peaks (1004, 1095, 1265, 1335 and 1665 cm-1)). The diagnostic algorithm developed 
based on PLS-DA together with leave-one cell-out, CV provided a diagnostic 
accuracy of 100% (sensitivity of 100% (20/20) and specificity of 100.0% (10/10)) 
(Figure 2.2) for discriminating the two cell lines, demonstrating the potential of 
micro-Raman spectroscopy for diagnosing cervical cancer at the cellular level. 
 
Figure 2.2 Scatter plot of the posterior probability values for normal and cancer cervical cells using 
PLS-DA together with leave-one cell-out, CV method. The separate line provides a diagnostic 
sensitivity of 100.0% (20/20) and a specificity of 100.0% (10/10) for discriminating cancer cell lines 
(HeLa , n=20) from normal cervical cell lines (HaCaT, n=10).  
 
Following the Raman spectral acquisition and classification of normal and cervical 
cancer cells, mapping was done on the HeLa and HaCaT cells by raster-scanning the 
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laser beam over the cell with 1 μm step size to observe cancer-related biomolecular 
changes in the cells. For instance, the univariate hyperspectral images (the spectral 
contrast at different pixels of the cell due to variations in the biochemical distribution) 
were reconstructed for entire Raman spectral intensities as well as to illustrate nucleic 
acids (1095 cm
-1
) and proteins (amide I - 1665 cm
-1
) content in normal and cancer 
cell lines. Figure 2.3 apparently shows the increase of nucleic acids and amide I of 
proteins in cancer cell, similar to the variations observed in the acquired spectra 
(Figure 2.1), evidencing the diagnostic ability of Raman micro-spectroscopy for 
identifying cervical cancer at cellular level. 
 
Figure 2.3 White light reflection image of (a) HeLa cell and (b) HaCaT cell. Univariate images 
reconstructed from the entire Raman spectral intensities for (c) HeLa and (d) HaCaT. Univariate 
images reconstructed from the Raman peak 1095 cm
-1
 over the band 1095 ± 10 cm
-1
 for (e) HeLa and 
(f) HaCaT. Univariate images reconstructed from the Raman peak of 1665 cm
-1
 over the band 1665 ± 
20 cm
-1
 for (g) HeLa and (h) HaCaT cell lines. 
 
Besides tumorigenicity, Raman micro-spectroscopy can also provide information on 
cell viability, differentiation status, biomolecular composition in different organelles, 
etc. The utilization of Raman micro-spectroscopy / spectroscopy to obtain information 
about major extracellular matrix components of tissue, their secondary structures and 
changes associated with disease transformation is fundamental for more practical 
diagnostic applications in clinics. However, the use of Raman micro-spectroscopy is 
limited to in vitro cell or tissue diagnosis. The development of fiber-optic Raman 
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spectroscopy that can access and measure tissue Raman signals non-invasively from 
internal organs in sub-seconds is essential to realize in vivo tissue diagnosis at the 
clinic. Hence, we developed a fiber-optic based Raman spectroscopy that can acquire 
high-quality tissue Raman spectra within 1 sec, and tested on in vitro cervix tissue 
samples, opens new pathway for real-time, biopsy-free, in vivo cervical precancer 
diagnosis at colposcopy. 
2.3 Raman spectroscopy characterization of tissues 
2.3.1 Materials and methods 
2.3.1.1 Raman instrumentation  
A rapid NIR Raman spectroscopy system (Figure 2.4) developed for cervix 
tissue Raman spectral measurements has been described in detail elsewhere.40 Briefly, 
the developed Raman spectroscopy system consists of an external cavity spectrum 
stabilized 785 nm diode laser (maximum output: 300 mW, B&W TEK Inc., Newark, 
DE), a transmissive imaging spectrograph (Holospec f/2.2, Kaiser Optical Systems, 
Ann Arbor, MI) equipped with a liquid nitrogen-cooled (-120°C), NIR-optimized, 
back-illuminated, deep depletion CCD camera (1340400 pixels at 2020 μm/pixel; 
Spec-10: 400BR/LN, Princeton Instruments, Trenton, NJ), and a specially designed 
bifurcated fiber-optic Raman probe that transfers the laser light to the tissue and 
collects the scattered tissue Raman signal. The flexible fiber-optic Raman probe 
(1.8 mm in outer diameter and 2.5 m in length) consisting of a central 200 μm fiber 
(NA=0.22) for laser light delivery, surrounded by 32 collection fibers (core diameter 
of 200 μm, NA=0.22) with two stages of optical filtering incorporated at the proximal 
and distal ends of the probe for maximizing the collection of tissue Raman signals, 
while reducing the interference of Rayleigh scattered light, fiber fluorescence and 
silica Raman signals. The 785 nm laser light with the tissue spot size of 0.2 mm and 
45 
 
irradiance of 1.5 W/cm2 was utilized for tissue Raman spectral measurements. The 
tissue Raman spectra were acquired in the molecular FP region (800-1800 cm-1) 
within an integration time of 1 sec, and the spectral resolution of 9 cm-1. The first-
order and second-order atomic spectral emission lines (HG-1 and AR-1, Ocean Optics 
Inc., Dunedin, FL) produced by mercury-argon spectral calibration lamps are used for 
wavelength calibration. All the wavelength-calibrated Raman spectra are also 
corrected for the wavelength-dependence of the system using a tungsten-halogen 
calibration lamp (RS-10, EG&G Gamma Scientific, San Diego, CA). The entire 
system can be controlled by a personal computer using a Matlab software 
environment (Mathworks Inc., Natick, MA, USA). 
 
Figure 2.4 Schematic of the NIR Raman spectroscopy 
2.3.1.2 Cervix tissue samples 
A total of 25 cervical tissue biopsies were obtained from the patients between 
18 to 70 years of age who were not pregnant and diagnosed with an abnormal Pap 
smear recruited in the colposcopy clinic at the National University Hospital (NUH), 
Singapore. The study protocol was approved by the Institutional Review Board (IRB) 
of the National Healthcare Group (NHG) of Singapore. An informed consent form 
was signed by each patient undergoing colposcopy, permitting the investigative use of 
cervical tissue biopsy specimens. After the biopsy, the tissue specimens were 
immediately stored in physiologic saline solution (pH=7.4) and subjected to Raman 
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spectroscopic measurements with no pretreatment, typically within 30 min of biopsy. 
The tissue specimens were kept moist with saline solution during the Raman spectral 
measurements. Multiple Raman spectral measurements were taken from the same 
tissue site of each biopsy specimen and they were averaged out to one spectrum to 
include inter- and/or intra-tissue variability for data analysis. As a result, a total of 23 
benign, 29 LSIL and 16 HSIL Raman spectra were measured from 25 cervix biopsy 
samples. After the spectral acquisition, the biopsy samples were fixed in 10% 
formalin solution and then submitted for histopathology confirmation. The 
colposcopy-guided histopathology results serve as the gold standard for evaluation of 
the performance of Raman spectroscopy for cervix tissue diagnosis and 
characterization. The results confirmed that out of 25 cervix tissue specimens, 8 were 
benign, 10 were LSIL and 7 were HSIL. The benign tissue samples include chronic 
cervicitis and squamous metaplasia. 
2.3.1.3 Data preprocessing  
The raw spectrum measured from the cervix tissue is composed of intense 
tissue AF and weak tissue Raman signals. The intensity corrected composite NIR 
AF/Raman spectra were gently smoothed without distorting the spectral shape using a 
first-order, sequential five-point smoothing filter (moving average, Savitzky-Golay) to 
reduce the noise.124 Unlike AF, which usually exhibits a featureless broad line shape, 
Raman spectra are typically characterized by sharp and narrow peaks. A fifth-order 
modified polynomial was found to be optimum to fit the lower bound of the smoothed 
spectra.74 This polynomial was then subtracted from the measured tissue spectra to 
extract the pure tissue Raman spectrum. The background subtracted Raman spectra 
were finally normalized to the integrated area under the curve from 800 to 1800 cm-1, 
for standardizing the absolute tissue Raman spectral intensities to enable a better 
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comparison of spectral shapes and relative Raman band intensities among different 
tissue pathologies.  
2.3.1.4 Spectral modeling 
The measured macroscopic tissue spectra were fit to a linear combination of 
major pure tissue biochemical constituents (DNA, proteins (histone, collagen), lipid 
(triolein) and carbohydrates (glycogen) (Sigma-Aldrich, St. Louis, MO, USA)) that 
best represented the cervical tissue Raman features using linear least-squares method 
with non-negative constraints (NNCLSM fitting).109, 142-144, 162 The detailed 
information about NNCLSM fitting has been provided in detail in Biomolecular 
modeling section in chapter 1. The developed biochemical model determines the 
relative concentration of selected biochemical constituents that grossly approximates 
the chemical composition of cervix tissue and its changes associated with disease 
progression. The developed semi-quantitative biochemical diagnostic model fits the 
measured tissue spectra with the basis spectra obtained from selected biochemicals 
with very small ﬁt-residuals. Consequently, the fitting coefficients yield the 
concentration of each biochemical component making up the lesions, providing an 
insight into chemical/morphological changes in the tissue associated with disease 
development and progression. The fitting coefﬁcients for each pathology rendered 
using NNCLSM model were further constrained to a coefficients sum of 100% to 
estimate the relative contribution of each basis spectrum to the measured tissue 
Raman measurements.   
2.3.1.5 Multivariate statistical analysis  
Multivariate technique including PLS-DA was employed to the preprocessed 
Raman spectra for developing multi-class diagnostic algorithms for tissue pathology 
detection and characterization.106, 107 PLS-DA follows the principle of PCA, but 
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further rotates the components to achieve maximum group separation.107 PCA retains 
as much as possible variations present in the dataset without considering the response 
variable. Unlike PCA, PLS-DA correlates the variations in the dataset with the 
response variable.134 Thus, it could explain the diagnostic relevant variations rather 
than the significant differences in the dataset. The performance of the multi-class 
probabilistic PLS-DA model was validated in an unbiased manner using leave-one 
patient-out, CV for differentiating benign cervix, LSIL and HSIL. All the above 
mentioned spectral analysis was conducted using the PLS toolbox (Eigenvector 
Research, Wenatchee, WA) in the Matlab (Mathworks Inc., Natick, MA) scripting 
environment. The PLS-DA analysis has been explained in detail in Multivariate 
statistical analysis section in chapter 1. 
2.3.2 Results 
Figure 2.5a shows the mean Raman spectra ± 1 standard deviations (SD) 
acquired from benign cervix (n=23), LSIL (n=29) and HSIL (n=16) within an 
integration time of 1 sec. The measured tissue spectra contains information on the 
fundamental vibrational modes of tissue and found at the following peak positions 
with tentative biomolecular assignments: 849 cm-1 (ring breathing mode of tyrosine 
and glycogen CCH aromatic deformation), 933 cm-1 (glycogen CCH deformation and 
proline, hydroxyproline, and C-C skeletal stretching of structural proteins and 
collagen), 1004 cm-1 (symmetric breathing of phenylalanine), 1085 cm-1 (C-C 
stretching of phospholipids), 1125 cm-1 (C-C skeletal stretch in lipids), 1255 cm-1 and 
1285 cm-1 (amide III – βsheet), 1339 cm-1 (CH3CH2 wagging mode of collagen 
/nucleic acid polynucleotide chain), 1450 cm-1 (CH2 deformation in lipids), 1578 cm
-1 
(nucleic acids), 1658 cm-1 (amide I (α-helix)) and 1738 cm-1 (C=O stretching of 
lipids).2, 74, 160, 163 The difference spectra ± 1 SD (Figure 2.5b) clearly shows 
progressive increase or decrease of distinctive molecular markers in cervical tissue 
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associated with precancer progression (i.e., from benign to LSIL and to HSIL). For 
instance, the dysplastic tissue (LSIL and HSIL) showed increased Raman signals at 
1004, 1339, 1578 and 1738 cm-1, but exhibited much lower signal at 849, 933, 1085, 
1255, 1285, and 1658 cm-1 (p < 0.05) as compared to benign tissue. Raman spectra 
measured from the tissue contains complex spectral signatures of biochemical 
components mixture that are overlapped significantly.  
  
Figure 2.5 (a) Comparison of mean tissue Raman spectra ±1 standard deviations (SD) acquired 
from benign (n=23), LSIL (n=29) and HSIL (n=16) cervix tissue. (b) The mean difference spectra 
± 1SD comparing different tissue pathologies (benign, LSIL and HSIL). Note that the mean tissue 
Raman spectra are shifted vertically for better visualization. The shaded area represents the 
respective SD.  
 
 
Figure 2.6 The basis Raman spectra (i.e., DNA, proteins (histones, collagen), lipids (triolein) and 
carbohydrates (glycogen)) used for biochemical modeling of precarinogenesis process in cervix. 
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Therefore, we developed a semi-quantitative NNCLSM Raman spectroscopic model 
of cervix tissue to quantify relative fractions of prominent tissue biochemicals such as 
proteins, lipids, DNA and carbohydrates (Figure 2.6) and its variations associated with 
pathogenesis using a linear combination of measured pure biochemical spectra. The 
selected basis biochemical spectral set provided the best fit to the measured tissue 
spectra, resulting in optimum fitting coefficients with minimum residuals, 
representing the relative spectral contribution of these biochemicals underpinning 
different precarcinogenic lesions of cervix.  
 
Figure 2.7 Comparison of Raman spectra measured from benign, LSIL and HSIL cervix with the 
corresponding reconstructed Raman spectra using a linear combination of basis spectral set: 
(a) benign, (b) LSIL, and (c) HSIL. Residuals (measured spectrum minus ﬁt spectrum) are also 
shown in each plot. 
 
Figure 2.7 shows the mean measured Raman spectra obtained from benign cervix, 
LSIL and HSIL together with their corresponding reconstructed Raman spectra and 
residual (measured – reconstructed) spectra. From Figure 2.7, it is obvious that very 
small (residual variations for 2.7(a)-2.7(c): ±5E−4) ﬁt-residuals (of <10%) were 
obtained for all tissue pathology categories, demonstrating that the contribution of 
selected biochemicals loosely representing the original biochemical composition of 
tissue. Figure 2.8 displays the mean fit coefficients corresponding to the concentration 
of distinctive biochemical components and its relative changes across different 
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cervical tissue pathologies together with their corresponding p-value. These changes 
in the concentration of selected biochemical components in accordance with tissue 
pathology results in the spectral intensity variations among benign cervix, LSIL and 
HSIL. The results described above demonstrate that Raman spectroscopy is able to 
provide a deep understanding about a biochemical basis of tissue and the relationship 
between the Raman spectral variability and tissue disease state. 
 
Figure 2.8 Histograms displaying the relative biochemical concentration profile of benign, LSIL, 
and HSIL cervix tissues. The one standard deviation (SD) conﬁdence intervals are shown for each 
model component. Note: (*) indicates a signiﬁcant differences (p < 0.05) for discriminating 
benign cervix from HSIL and (x) indicates a signiﬁcant differences (p < 0.05) for discriminating 
benign cervix from LSIL. 
 
The chemical differences observed in the Raman spectra of benign cervix, LSIL and 
HSIL were further explored in detail using PLS-DA multi-class diagnostic algorithm 
to improve tissue disease diagnosis.106, 107 The measured tissue Raman spectral 
datasets were mean-centered to eliminate common variance in the dataset.107 Raman 
spectral dataset was cleaned using PCA coupled with Hotelling’s T2 and Q-residual 
statistics to remove outliers.108 After the spectral quality verification, the leave-one 
patient-out, cross-validated PLS-DA multi-class diagnostic model was developed for 
the dataset using optimum number of components (1LV) (Figure 2.9). The optimum 
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number of components was determined to be 1LV based on the local minimum of CV 
classification error values, accounting for 19.0% and 22.1% of total Raman spectral 
variations in X and Y direction, respectively. The selected diagnostically significant 
LV typically represented the spectral variations around the prominent Raman peak 
positions (849, 933, 1003, 1098, 1182, 1248, 1276, 1313, 1465, 1635 and 1667 cm-1).  
 
Figure 2.9 The diagnostically signiﬁcant latent variable (LV) accounting for 19.0% and 22.1% of 
the total variation in the Raman spectral dataset in X and Y direction, respectively, revealing the 
diagnostically signiﬁcant (p < 0.05) Raman spectral features for tissue classiﬁcation. 
 
 
Figure 2.10 Two-dimensional ternary plot of the posterior probabilities belonging to benign 
cervix, LSIL and HSIL achieved by PLS-DA multi-class model, together with leave-one patient-
out, CV method. 
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The developed PLS-DA multi-class diagnostic model was utilized to estimate the 
posterior probability values (2-D ternary scatter plot (Figure 2.10)). The diagnostic 
results for Raman spectra acquired from benign cervix, LSIL and HSIL using PLS-DA 
together with leave-one patient-out, CV method were summarized in Table 2.1. The 
multi-class model provided sensitivities of 95.7%, 82.8%, 81.3%, and speciﬁcities of 
100.0%, 92.3%, 88.5%, for the diagnosis of benign, LSIL and HSIL cervix, 
respectively.  
Table 2.1 Classiﬁcation results obtained from NIR Raman spectra prediction of benign cervix, 
LSIL and HSIL using PLS-DA algorithms, together with leave-one patient-out, CV method. 
 
Raman prediction 
Tissue type Benign LSIL HSIL 
Benign 22 0 1 
LSIL 0 24 5 
HSIL 0 3 13 
Sensitivity (%) 95.7 82.8 81.3 
Specificity (%) 100 92.3 88.5 
 
 
Figure 2.11 Receiver operating characteristic (ROC) curves of discrimination results for 
classification of benign, low-grade (LSIL) and high-grade (HSIL) lesions of cervix using Raman 
spectroscopy and PLS-DA together with leave-one-patient-out, CV method.  
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The receiver operating characteristic (ROC) curves (Figure 2.11) were further 
generated to determine correct and incorrect classifications for all tissue categories. 
The areas under the ROC curves (AUC) are 0.97, 0.87 and 0.89 for classifying 
benign, LSIL and HSIL cervix, respectively, using PLS-DA algorithm, confirming the 
diagnostic efficacy of Raman spectroscopy for differentiating different stages of 
cervical precancer. 
2.3.3 Discussion 
Histopathologic correlation of cervical cytology for precancer diagnosis relies 
on cytological and morphological alterations within the cells and tissues. Furthermore, 
the recommended clinical diagnostic techniques colposcopy and histology 
(colposcopy-directed biopsies) are visual inspection methods and prone to 
considerable intra- and inter-observer disagreements. Moreover, the acceptable level 
of agreements among pathologists is especially poor for precancer prediction 
(e.g., low-grade precancer). Hence, optical diagnosis of cancer and precancerous 
biomarkers has been a hot research area over the past few decades and extensive 
research efforts have been made towards Raman-based medical diagnosis of 
precancerous lesions due to its ability to provide good spectral markers for probing 
changes in intrinsic biochemicals associated with precancer progression.24, 28, 73, 74, 93, 
108, 117, 122 In this study, we utilized Raman spectroscopy for determining the average 
biochemical makeup of benign cervix and different grades of precancerous lesions. 
We further developed a multi-class PLS-DA discrimination model to classify them.  
The distinctive and reproducible changes observed in the Raman spectral 
shapes and intensities (e.g., 849, 933, 1004, 1085, 1125, 1255, 1285, 1339, 1450, 
1578, 1658 and 1738 cm-1) (Figure 2.5b) among benign, LSIL and HSIL can be 
instantly correlated to the change of tissue biochemical composition associated with 
progressive dysplastic transformation. For instance, the collagen (structural proteins) 
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content is higher in benign tissue due to periodic inflammation in cervix associated 
with fibrotic changes.2, 117, 119, 160 The reduced Raman spectral intensity from 800 to 
1000 cm-1 indicated the loss of structural proteins especially collagen (849, 936, and 
1085 cm-1) in dysplastic tissue. Research studies also reported that the decreased 
Raman bands at 849, 933, and 1085 cm-1 for dysplasia is associated with glycogen 
depletion, indicating the retardation of cellular maturation.2, 160 The consistent 
increase in the Raman bands around 1339 and 1578 cm-1 with progressive dysplasia 
indicated the pronounced nuclear content in dysplastic lesions due to increased 
epithelial cell proliferation.117, 119 The reduction in amide I (1658 cm-1) and amide III 
(1255 and 1285 cm-1) band, and increment in phospholipids and mixture of 
lipid/protein bands (1339, 1450 and 1738 cm-1) were noticed with dysplastic 
transformation.164, 165 Overall, diminishment in Raman intensity for the peaks 
associated with collagen, amide I and amide III bands, and enhanced Raman peaks 
attributed to nucleic acids and phospholipids were observed with multi-step process of 
cervical preoncogenesis. 
These biochemical changes described above produce distinctive spectral 
makers and relative contribution of these major biochemicals among benign cervix, 
LSIL and HSIL was estimated by developing Raman spectroscopic biochemical 
model of cervix based on NNCLSM fitting. The biochemical model was generated 
using the linear combination of basis spectral dataset derived from the representative 
Raman-active biomolecules (i.e., proteins, lipids, nucleic acids and carbohydrates) 
(Figure 2.6) in the cervical tissue to understand the chemical variations in tissue 
associated with dysplastic progression. We have initially measured over 20 major 
biochemicals associated with cervical tissue such as glycogen, phosphatidylcholine, 
triolein, cholesterol, actin, histones, collagen type I, albumin, DNA, RNA, etc. 
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Exhaustive NNCLSM modeling with all possible combinations of biochemicals based 
on priori insight of inter-/intra-cellular constituents of cervix tissue were carried out to 
determine the biomolecules best representing the measured cervical tissue Raman 
spectra. As a result, our NNCLSM models directed that the biomolecules such as 
DNA, proteins (histone, collagen), lipid (triolein) and carbohydrates (glycogen) make 
up the basic building blocks of normal and progressive precancer cervix tissue 
(Figure 2.6) with minimum residuals (Figure 2.7). For instance, abundant amount of 
glycogen is traced in the stratum spinosum zones of normal cervical squamous 
epithelium.166 Histones represent the DNA-binding proteins found in the chromatin of 
cell nuclei that aid in DNA’s packaging. It has been reported that DNA methylation 
and histone modification profiles can be effectively used for screening, early 
detection, or prognostic markers in cervical cancer.167 Triolein indicates the lipid 
droplets168 and collagen is the main structural proteins in the extracellular matrix of 
normal cervical epithelium.160, 169 The biomolecular modeling and the measured tissue 
spectra across different tissue pathology essentially showed consistent molecular 
changes in the tissue, such as increased DNA, proteins (histones) and lipids as well as 
decreased collagen and carbohydrates. Figures 2.8 shows the diagnostically 
signiﬁcant ﬁt coefﬁcients for the selected biochemicals, revealing the grossly 
quantified biochemical composition of benign cervix and their relative concentration 
changes with progressive cervical dysplasia.  
Following the assessment of chemical composition across different tissue 
pathology, we also utilized PLS-DA diagnostic algorithms to evaluate the diagnostic 
efficacy of Raman spectroscopy for disease classification. The multi-class PLS-DA 
model was developed using the diagnostically significant LVs (1LV), representing the 
highly specific Raman spectral markers of various biomolecules (e.g., 849, 933, 1003, 
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1098, 1182, 1248, 1276, 1313, 1465, 1635 and 1667 cm-1). The developed diagnostic 
model provided diagnostic sensitivities of 95.7%, 82.8% and 81.3%; specificities of 
100%, 92.3% and 88.5% for molecular discrimination of benign, low-grade and high-
grade precancerous cervix, respectively (Figure 2.10). In the ternary plot 
(Figure 2.10), it can be noticed that the posterior probability values of benign lesions 
lie closer to LSIL. However, Raman spectroscopy in conjunction with multi-class 
model can still be able to distinctly separate benign lesions from LSIL. The same 
diagnostic difficulty of separating benign lesions from LSIL notably appears among 
pathologists. This could be due to the following reason: The benign lesions 
(e.g., inflammation, squamous metaplasia) have the features such as mild nuclear 
enlargement, multinucleation, even chromatin coarsening, cellular disorganization, 
and maturation disturbances; These mild changes occurring in a background of benign 
lesions lack true nuclear atypia compared to LSIL, but can be overdiagnosed as 
LSIL.170 The another highly challenging difficulty faced in histopathologic/ 
colposcopic evaluation of cervical precancerous lesions is identification of HSIL from 
benign (e.g., squamous metaplasia) and LSIL,170, 171 and prone to subjective diagnosis 
among cloposcopist/pathologists. For instance, squamous metaplasia is the cytologic 
mimics of HSIL, but the nuclear atypical changes hardly rise to the level of atypia 
found in HSIL.171 Similarly, LSIL and HSIL lesions also have same atypical nuclear 
features mainly comprising hyperchromasia, irregular chromatin distribution, 
membrane contour irregularity, but the severity is more in HSIL.171, 172 Nevertheless, 
Raman spectroscopy coupled with biomolecular modeling (Figure 2.8) and multi-
class diagnostics (Figure 2.10) established significant molecular changes and notable 
diagnostic results for classifying benign cervix from precancerous lesions (LSIL and 
HSIL) and for identifying different grades of cervical precancer. Therefore, Raman 
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spectroscopy coupled with PLS-DA multi-class diagnostic modeling can be 
advantageously utilized as a powerful and versatile clinical diagnostic tool for 
identifying progressive precancer in cervix. 
2.4 Conclusion 
The study first realizes the potential of micro-Raman spectroscopy for 
studying the biomolecular distribution and its changes in cervical cells associated with 
cancer transformation. The developed point-wise fiber-optic Raman diagnostic system 
rendered successful discrimination among benign, LSIL and HSIL cervix tissue. The 
development of Raman spectroscopic biochemical model of cervix tissue associated 
with increasing grades of dysplasia provides insight into molecular origin responsible 
for prominent Raman spectral features and its variability with progressing dysplasia. 
The PLS-DA based multi-class diagnostic model provides good discrimination for 
non-neoplastic as well as preneoplastic (i.e., LSIL, HSIL) lesions. This study 
demonstrates the promising potential of Raman micro-spectroscopy/spectroscopy for 
characterizing cancer and precancer in cervix cells and tissues, pushing the Raman 




Chapter 3. Development of simultaneous fingerprint and 
high wavenumber confocal Raman spectroscopy for real-
time in vivo tissue Raman measurements at colposcopy  
Most of the tissue Raman spectroscopic studies, till date, limited to either FP 
or HW region with post-processing and off-line algorithm development for disease 
diagnosis. The main objective of this chapter is to develop an integrated FP and HW 
confocal Raman spectroscopy using a single laser and grating together with a ball lens 
Raman probe that simultaneously acquires real-time in vivo FP/HW tissue Raman 
spectra from the epithelial layer of cervix (~160 µm) at colposcopy. We further 
develop a fully automated on-line Raman spectral diagnostics framework integrated 
with a colposcopy-guided FP/HW confocal Raman technique for real-time in vivo 
cervical precancer detection. The novel diagnostic scheme developed implements on-
line preprocessing, outlier detection based on PCA statistics (i.e., Hotelling’s T2 and 
Q-residuals) for tissue Raman spectrum verification, as well as organ-specific 
probabilistic diagnostics using different diagnostic algorithms. Free-running spectral 
acquisition, optical diagnosis and processing time of ~1 sec can be achieved. This 
work demonstrates for the first time that the simultaneous FP/HW confocal Raman 
spectroscopy has the potential to be a clinically powerful tool for improving early 
diagnosis and detection of cervical precancer in vivo during clinical colposcopic 
examinations and moves biomedical Raman spectroscopic technique into real-time, 
on-line clinical precancer and cancer diagnosis at colposcopy. 
3.1 Introduction 
Optical spectroscopic techniques such as reflectance, fluorescence, and Raman 
spectroscopy have been comprehensively investigated for precancer and cancer 
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diagnosis in various organs including cervix.24, 72, 74, 119, 152, 173-176 Recent researches 
based on optical diagnostics of diseases have been directed towards Raman spectral 
diagnostics because Raman spectroscopy can provide extensive information about the 
changes of biochemical/biomolecular structures and conformations in tissue for 
molecular discrimination of precancer and cancer.24, 72, 74, 109, 119 However, the 
conventional Raman spectroscopy (i.e., with volume Raman probe) is not favorable 
for identifying epithelial cancers (i.e., dysplasia) because it largely detects changes in 
deeper tissue (e.g., collagen in stromal tissue, vascular information). In this 
dissertation, we aimed to design a confocal Raman spectroscopy that can selectively 
probe the biochemical changes of epithelial layer of cervix, targeting the diagnosis of 
cervical dysplasia confined within the basement membrane. Currently, Raman 
research in diagnosing precancer and cancer tissues are mostly focused on the spectral 
region between 800 and 1800 cm-1 which is the so-called "FP region” containing rich 
tissue biochemical information.34, 71, 72, 74, 75, 109, 119, 160 However, the strong tissue AF 
background and fiber-silica signals severely interfere with the detection of inherently 
weak tissue Raman signal, leading to complex fiber probe filtering design as well as 
signal analysis in the FP region.79, 116, 177 On the other hand, the HW (2800 – 
3700 cm-1) Raman spectroscopy can also provide complementary biochemical 
information for tissue diagnosis and characterization with stronger tissue Raman 
signals and greatly reduced tissue AF and fiber Raman background,79, 116, 176-178 
compared to FP Raman spectroscopy. Most of the previous Raman studies have 
evaluated tissue Raman spectra either in FP24, 71, 72, 74, 109, 119 or HW79, 116, 176, 178, 179 
region. Only a very limited amount of work has been reported on the measurements of 
Raman signals from both the FP and HW regions,160, 178 but the Raman signals are 
measured either by successively switching different excitation laser lines or by 
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rotating the gratings for each individual region.160, 178 These methods are very time-
consuming and not suited for rapid in vivo disease diagnostics in clinical settings. For 
example, Chau et al.178 utilized a 830 nm excitation laser for FP Raman spectral 
acquisition, and then switched to another 740 nm excitation laser for HW Raman 
spectral acquisition. Besides the simultaneous acquisition of FP/HW Raman spectral 
measurements, implementation of real-time Raman spectral processing is essential for 
in vivo tissue disease diagnosis in clinical environment.98, 180 For instance, Motz et al. 
presented a synchronized laser Raman system to study atherosclerosis that could 
acquire and process Raman spectra within 2 sec using spectral modeling of reference 
biochemicals with an aid of least squares regression techniques.180 Lui et al. 
developed a real-time integrated Raman system for evaluating skin that could acquire 
and process the signal within 1.1 sec.98 Nevertheless, most of the current Raman 
spectroscopic analyses have been limited to off-line post processing for the 
classification of spectra with CV procedures, which render practical limitations 
including setting of exposure times, post-verification of spectrum quality, and lack of 
automatic feedback mechanisms to clinicians for implementation of straightforward 
probabilistic diagnostics in clinical settings. Hence, fully automated tissue spectral 
quality verification and real-time tissue cancer diagnostics are vital to translating the 
Raman spectroscopic diagnostic technique into practical clinical colposcopic routine. 
In this work, for the first time, we have developed a fully automated, colposcopy-
guided confocal integrated FP/HW Raman diagnostic system (Figure 3.1) with a 
single diode laser, a spectrometer with a permanently fixed NIR-enhanced grating and 
a confocal Raman probe with ball lens at the tip that simultaneously measures the FP 




3.2 Materials and methods 
3.2.1 Confocal Raman instrumentation 
Figure 3.1 shows the schematic of the simultaneous FP/HW confocal Raman 
spectroscopy system developed for in vivo cervical Raman measurements during 
clinical colposcopy. The system consists of a 785 nm diode laser (100 mW, B&W 
TEK Inc., Newark, DE), a high-throughput spectrometer (QE65000, Ocean Optics 
Inc., Dunedin, FL), an NIR-enhanced back-thinned CCD detector (1024 × 58 with 
pixel sizes of 24.6 µm, QE > 90%, Hamamatsu, Shizuoka, Japan), and a custom 
designed hand-held confocal Raman probe with an NIR-coated sapphire ball lens 
(5 mm in diameter, refractive index n = 1.77) mounted on the probe tip that can 
eﬀectively collect the scattered tissue Raman signals from epithelial layer of cervix. 
The ball-lens bifurcated ﬁber-optic confocal Raman probe consists of two ﬁbers: one 
excitation ﬁber (200 μm, NA = 0.22) coated with a narrow band-pass ﬁlter (centered 
at 785 nm, fwhm = ± 2.5 nm) on the ﬁber tip for laser excitation, and the collection 
ﬁber (200 μm, NA = 0.22) coated with a long pass ﬁlter (cut oﬀ at 800 nm) on the 
ﬁber tip for collecting scattered tissue Raman signal. The coupling of an NIR-coated 
sapphire ball lens (NA = 1.5) with the bifurcated ﬁber Raman probe oﬀers a good 
confocality for selective collection of backscattered tissue Raman photons from the 
epithelial tissue (of ∼160 μm) of cervix based on Monte Carlo simulations.41 All the 
optics of the ball-lens Raman probe is sealed into stainless steel sleeve (outer diameter 
of 8 mm) with a polytetrafluoroethylene jacket. The collected tissue Raman photons 
are fed into the spectrometer equipped with a customized grating and a CCD detector. 
The grating diffracts the incoming light and the CCD produces a digital response by 
converting the wavelength of Raman scattered light into a digital signal. This 
customized grating has the diffraction efficiency of ~80% in the NIR region (800-
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1200 nm) and allows the in-house built integrated confocal Raman system to cover 
both the FP (800 - 1800 cm-1) and HW (2800 - 3700 cm-1) regions simultaneously for 
tissue Raman measurements. After the selection of required starting wavelength for 
spectral acquisition, the grating was permanently fixed to eliminate mechanical drifts. 
The detector can be cooled down to -20 °C with an on-board thermoelectric cooler to 
reduce dark noise. The combination of the spectrometer’s low-noise detector and a 
16-bit A/D converter provides a SNR of 1000:1. The entire control of Raman 
spectroscopy system is implemented by a personal computer. The atomic emission 
lines of mercury-argon spectral calibration lamps (HG-1 and AR-1, Ocean Optics Inc., 
Dunedin, FL) are used for wavelength calibration. All wavelength-calibrated spectra 
were corrected for the wavelength-dependence of the system, using a tungsten-
halogen calibration lamp (RS-10, EG&G Gamma Scientiﬁc, San Diego, CA). The 
developed confocal Raman spectroscopy system can simultaneously acquire FP (800 - 
1800 cm-1) and HW (2800 - 3700 cm-1) tissue Raman spectra within an integration 
time of 1 sec with a spectral resolution of ∼8 cm-1.   
 
Figure 3.1 Schematic of the integrated FP/HW Raman spectroscopy system coupled with a ball-
lens confocal Raman probe for in vivo Raman spectral measurements on the cervix at colposcopy. 
BP, band-pass; LP, long-pass. 
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3.2.2 On-line biomedical spectroscopic framework 
The on-line biomedical Raman spectroscopic framework developed has been 
implemented as a graphical user interface (GUI) under the Matlab 2011a (Mathworks 
Inc., Natick, MA) scripting environment in a fast computing workstation (64 bit I7 
quad-core 4GB memory). This framework has been thoroughly optimized for rapid 
data processing for real-time tissue diagnostics. Hardware components of the rapid 
Raman system (e.g., laser power control, spectrometer, CCD shutter and camera 
readout synchronization) have been interfaced to the Matlab software through 
libraries for different spectrometers/cameras (e.g., PVCAM library (Princeton 
Instruments, Roper Scientific Inc., Trenton, NJ) and Omni Driver (Ocean Optics Inc., 
Dunedin, FL, USA), etc.). A schematic of the spectral acquisition and processing flow 
of on-line diagnostic framework is depicted in Figure 3.2. The laser was electronically 
synchronized with the CCD shutter. The automatic adjustment of laser power, 
exposure time and accumulation of spectra were realized by scaling to within 85% of 
the total photon counts (e.g., 55,250 of 65,000 photons) based on preceding tissue 
Raman measurements, whereas an upper limit of 1 sec was set to realize clinically 
acceptable conditions. The accumulation of multiple spectra and automatic adjustment 
of exposure time provides a rapid and straightforward methodology to prevent CCD 
saturation and to obtain high SNR for clinical applications. The Raman-shift axis 
(wavelength) was calibrated using a mercury/argon calibration lamp. The spectral 
response correction for the wavelength-dependence of the system was conducted 
using a standard tungsten lamp. The reproducibility of the platform can be 
continuously monitored with the laser frequency and Raman spectra of cyclohexane 
and acetaminophen as wavenumber standards. All the system performance measures 
including CCD temperature, integration time, laser power are accordingly logged into 
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a central database via SQL server. Due to the inter-anatomical and inter-organ spectral 
variances as we observed earlier,99, 104 the on-line framework we designed implements 
organ-specific diagnostic models and can instantly switch among the spectral 
databases of different organs (e.g., esophagus, gastric, colon, cervix, bladder, lung, 
nasopharynx, larynx, and the oral cavity), making this Raman platform a universal 
diagnostic tool for clinical cancer diagnosis. 
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Figure 3.2 Flow chart of the on-line biomedical Raman spectroscopic diagnostic platform. 
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3.2.3 On-line preprocessing and outlier detection 
The cervical tissue Raman spectra were acquired in the spectral range of 800 - 
4000 cm-1, containing FP (800 - 1800 cm-1) and HW (2800 - 3700cm-1) region. The 
middle region (1800 - 2800cm-1) was eliminated due to the absence of biochemical 
information associated with tissue dysplastic transformation. Real-time preprocessing 
of Raman signals was realized with the rapid detection of cosmic rays using the first 
derivative with a 99% CI over the whole spectral range set as a maximum threshold. 
Data points lying outside of a threshold were interpolated to 2nd order. The spectra 
were further scaled with integration time and laser power. Savitzky-Golay smoothing 
filter was used to remove noise in the intensity corrected spectra, while a fifth and 
first order modified polynomial constrained to the lower bound of smoothed spectra 
was subtracted to resolve the tissue Raman spectrum alone in FP and HW region, 
respectively.74, 116, 133 The Raman spectra were further normalized to an integrated area 
under the curve belonged to their respective spectral range (FP or HW), enabling a 
better comparison of spectral shapes and relative Raman band intensities among 
different tissue pathologies. The spectra were then locally mean-centered according to 
the specific database to remove common variations in the data. Following 
preprocessing, the Raman spectra were fed to a model-specific outlier analysis.  
We incorporate an on-line outlier detection scheme into biomedical 
spectroscopy as a high-level model-specific feedback tool in our on-line framework 
by using PCA coupled with Hotelling’s T2 and Q-residual statistics (Figure 3.2).181, 182 
Briefly, PCA reduces the dimension of Raman spectra by decomposing them into 
linear combinations of orthogonal components (PCs), such that the spectral variations 
in the dataset are maximized. The PCA model of the data matrix X is defined by 135: 
 TX TP E       (3.1) 
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where T and P represent scores and loadings, and E contains the residuals. The 
loadings correspond to the new rotated axis, whereas scores represent the data 
projection values. Accordingly, Hotelling’s T2 statistics is a measure of variance 
captured by the PCA model (sample to model distance) and is defined by 181:   
 
2 1( ) Tik ik k ikT t t
      (3.2) 
 
where tik is PC scores for i
th sample spectrum using component k, and 1k
  is the 
diagonal matrix of normalized eigenvalues of the covariance matrix for component k. 
Therefore, Hotelling’s T2 gives an indication of extreme values within the PCA model. 
On the other hand, Q-residuals is a measure of variance which is not captured by the 
PCA model (lack of model fit statistics) and is defined by 181:  
 
2( )Tik i ik kQ x t P       (3.3) 
 
where xi is the sample spectrum, Qik is the sum of squared reconstruction error for i
th 
sample spectrum using component k and Pk is the PC loadings. For both Hotelling’s 
T2 and Q-residuals, the normalized 99% CI was utilized as upper thresholds to 
intercept anomalous Raman spectra (e.g., non-contact measurements, spectra from 
blood, etc.) Accordingly, the Hotelling’s T2 and Q-residuals are the two independent 
parameters providing quantitative information about the model fit. Using these 
parameters as indicators of spectra quality (i.e., probe contact mode, confounding 
factors, white light interference, etc.), auditory feedback has been integrated into the 
on-line Raman diagnostic system, facilitating real-time probe handling advice and 
spectroscopic screening for clinicians during clinical colposcopy procedures. 
3.2.4 On-line probabilistic diagnostics 
Subsequent to verification of tissue Raman spectrum quality, those qualified 
Raman spectra were immediately fed to probabilistic models for on-line in vivo 
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diagnostics and pathology prediction. The GUI can instantly switch among different 
models such as PLS-DA,36, 107 PCA-LDA,71, 105 ACO-LDA,123 CART,139 SVM,73 etc. 
for prospective cervical tissue spectral classification at colposcopy. The most 
commonly used chemometric methods for spectral classification and tissue diagnosis 
has been described in detail in Multivariate statistical analysis section in chapter 1. 
The models can be switched to either two class (low-risk (normal, CIN 1), high-risk 
(CIN 2/3)) or three-class (normal, low-risk (CIN 1) and high-risk (CIN 2/3)).  
3.3 Real-time diagnosis 
 
Figure 3.3 On-line biomedical Raman spectroscopic diagnostic platform for cervical precancer 
detection.  
 
The developed novel GUI for on-line biomedical spectroscopic processing and 
diagnostics is shown in Figure 3.3. The measured tissue Raman spectra were 
displayed on the GUI with diagnostic results. The probabilistic diagnostic outcomes 
were presented in real-time to the colposcopist with the total processing time of 
0.13 sec (Table 3.1). As an example, we display the in vivo integrated FP/HW Raman 
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spectrum acquired from high-grade precancer tissue site of cervix within 1 sec using 
the developed integrated FP/HW confocal Raman spectroscopy together with real-
time probabilistic diagnostics (high-risk) based on PLS-DA model developed from the 
stored spectral database (100 patients). 
Table 3.1 Average processing time for on-line biomedical Raman spectroscopic framework on a 
personal computer with a 64 bit I7 quad-core 4GB memory. 
 
Analyses Computational time (milliseconds) 
Cosmic ray rejection 0.5 
Laser response time 10 
Preprocessing 40 
Outlier detection 10 
Probabilistic PLS-DA prediction 70 
Total computation time 100 to 130 
 
Figure 3.4 shows the representative Raman spectra acquired from normal and 
precancer cervix within 1 sec using the developed integrated FP/HW Raman 
spectroscopy. The normal and precancerous cervix tissue spectra showed prominent 
Raman vibrational bands at 854 (glycogen ((CCH) deformation - aromatic) and (C-C) 
stretching of structural protein and collagen), 937 ((C-C) peak of proline, valine, and 
glycogen), 1001 ((C–C) ring breathing of phenylalanine), 1095 (phospholipids and 
nucleic acids), 1253 (amide III), 1313 (CH3CH2 twisting mode of lipid/protein 
(collagen)), 1445 (CH2 bending mode of proteins and lipids), 1654 (amide I band - 
(C=O) stretching mode of proteins), 2946 (proteins – CH3 stretching), and 3400 cm
-1 
(water - (OH) stretching), respectively.24, 71, 74, 116, 118, 160 Good-quality Raman spectra 
can be simultaneously measured from both the FP and HW region together with real-
time disease diagnosis from in vivo cervix within 1 sec with the laser power of 10 mW 
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at the sample, moving the biomedical Raman spectroscopy into real-time, on-line 
cancer detection and diagnosis during routine clinical colposcopic examination.  
 
Figure 3.4 Representative of in vivo integrated FP/HW Raman spectra acquired from normal and 
precancer cervix at colposcopy. Note that the tissue Raman spectra are shifted vertically for better 
visualization. 
 
We find that this processing time is clinically acceptable, and with the immediate 
auditory diagnostic feedback from the developed GUI, the colposcopists can now 
perform routine point-wise scanning for targeted biopsies of the high-risk tissue sites, 
opening the possibility of real-time tissue diagnosis.  
3.4 Conclusion 
 We report for the first time (to the best of our knowledge) the development 
of simultaneous FP/HW confocal Raman spectroscopy integrated with biomedical 
Raman diagnostic framework for successful acquisition of in vivo cervical tissue 
Raman spectra together with real-time tissue diagnosis in sub-seconds. The developed 
on-line biomedical Raman spectroscopic framework can decipher the cumbersome 
processing and multivariate analysis into an easy-to-use GUI interface for real-time in 
vivo diagnosis of malignancies in cervix.  
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Chapter 4. Near-infrared confocal Raman spectroscopy 
advances in vivo diagnosis of cervical precancer 
In this chapter, we evaluate the clinical utility of confocal Raman spectroscopy 
over NIR AF spectroscopy and the composite NIR AF/Raman spectroscopy for 
improving early diagnosis of cervical precancer in vivo at colposcopy. A rapid NIR 
Raman system coupled with a ball-lens fiber-optic confocal Raman probe developed 
was utilized for in vivo NIR AF/Raman spectral measurements on the cervix. A total 
of 1240 in vivo Raman spectra (normal (n=993), dysplasia (n=247)) were acquired 
from 84 cervical patients recruited. PCA-LDA together with leave-one patient-out, 
CV method was used to extract the diagnostic information associated with distinctive 
spectroscopic modalities. The diagnostic ability of confocal Raman spectroscopy was 
evaluated using the PCA-LDA model developed from the significant PCs (i.e., PC4, 
0.0023%; PC5, 0.00095%; PC8, 0.00022%, (p < 0.05)), representing the primary 
tissue Raman features (e.g., 854, 937, 1095, 1253, 1311, 1445 and 1654 cm-1). 
Confocal Raman spectroscopy coupled with PCA-LDA modeling yielded a diagnostic 
accuracy of 84.1% (sensitivity of 81.0% and specificity of 87.1%) for in vivo 
discrimination of dysplastic cervix. The ROC curves further confirmed that the best 
classification was achieved using confocal Raman spectroscopy compared to the 
composite NIR AF/Raman spectroscopy or NIR AF spectroscopy alone. This study 
illustrates that confocal Raman spectroscopy has great potential to improve early 
diagnosis of cervical precancer in vivo during clinical colposcopy.  
4.1 Introduction  
NIR Raman spectroscopy is a molecule-specific technique for optically 
probing the biomolecular changes associated with disease transformation. However, 
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Raman signal emanating from the tissue is inherently weak, and occurs concurrently 
with the intense tissue AF background. The tissue NIR AF background typically 
represents the light re-emission from the excited endogenous fluorophores. NIR AF 
has shown promise in differentiating cancer from normal tissues, probably due to the 
neoplasia-associated changes in tissue absorption, scattering or endogenous 
fluorophore content and distribution in tissue.105, 157 NIR-excited spectroscopy holds 
potential benefits for safe tissue diagnosis, such as non-carcinogenic and relatively 
insensitive to tissue water content, compared to the UV-visible-excited spectroscopy. 
The diagnostic capability of the composite NIR AF/Raman spectroscopy together with 
PCA-LDA for enhancing the assessment of in vivo skin tumors was demonstrated 
using mice tumor models.157 We have also documented the complementary nature of 
NIR AF and Raman spectroscopy techniques using volume-type Raman endoscopic 
probe,40 and found that combining NIR AF and Raman modalities improved the 
gastric cancer diagnosis in vivo during gastroscopic inspections.105 The diagnostic 
potential of in vitro NIR AF imaging, as well as in vivo NIR AF spectroscopy for 
colonic cancer and precancer detection have also been reported very recently.145, 183, 
184 However, to date, no systematic studies have been conducted to investigate the 
diagnostic utility of confocal Raman, NIR AF and the composite NIR AF/Raman 
spectroscopy for cervical precancer detection. In this work, we use a ball-lens 
confocal Raman probe developed to acquire spectroscopic information about cervical 
tissue in vivo. We compare the diagnostic performance of the three spectroscopic 
modalities (i.e., confocal Raman, NIR AF, and the composite NIR AF/Raman 
spectroscopy) using PCA-LDA-based diagnostic algorithms, and confirm that 
confocal Raman spectroscopy is the most robust means for improving in vivo 
diagnosis of cervical precancer at colposcopy.  
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4.2 Materials and methods 
4.2.1 Raman instrumentation  
The confocal Raman spectroscopy system used for in vivo tissue NIR AF and 
Raman measurements has been reported in detail in Confocal Raman 
instrumentation section in chapter 3.  
4.2.2 Patients  
This study protocol was approved by the IRB of the NHG of Singapore. A 
total of 84 non-pregnant female patients (between 18 to 70 years of age) who 
underwent a colposcopy procedure due to an abnormal Pap smear were recruited for 
Raman studies. A written informed consent form was signed by each patient before 
the spectroscopic measurements. Prior to the in vivo tissue Raman spectral 
measurements, a 5% acetic acid solution was applied topically on the cervix for two 
minutes for evaluation of the color whitening changes in the tissue (the degree of 
white discoloration in the cervix is related to the grade of precancer).185 The 
application of acetic acid reduces transparency of the epithelium due to the 
dehydration of cells and surface coagulation in cellular proteins, and develops a 
distinct demarcation between normal and abnormal epithelium by inducing the 
acetowhitening changes of cervical epithelium.186, 187 High nuclear density in the 
abnormal epithelium promoted maximal coagulation, such that the light passing 
through the epithelium was prevented, which caused the tissue to become visibly 
acetowhite.185 The fiber-optic confocal Raman probe was eventually advanced 
through the speculum and placed in gentle contact with the cervix. The Raman 
spectral measurements were subsequently taken from abnormal (i.e., acetowhite 
epithelium) sites of the cervix as well as from the surrounding normal ectocervical 
squamous epithelial sites identified by the experienced colposcopists (i.e., the normal 
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tissue does not exhibit color patterned changes that only accompany dysplastic 
epithelium).119 Hereafter, these colposcopically normal looking tissue sites were 
referred to as normal and no biopsies were taken from these cervical tissue sites. To 
include the intra/inter-subject variations for data analysis, multiple Raman spectra 
(~5-8 spectra) were collected from each tissue site. As a result, a total of 1240 in vivo 
composite NIR AF/Raman spectra were measured on the cervix from the recruited 84 
patients (20 high-grade and 64 normal), in which 993 spectra were collected from 115 
normal sites, whereas 247 spectra were from 20 high-grade precancerous lesions. 
After the Raman spectral acquisition, tissue biopsies were taken from the abnormal 
tissue sites measured and sent for histopathology conﬁrmation. The histopathology 
results served as the gold standard for the assessment of diagnostic sensitivity and 
specificity of confocal Raman spectroscopy for dysplasia classiﬁcation in the cervix.  
4.2.3 Data preprocessing  
The in vivo composite NIR AF/Raman spectra acquired from cervix in the 
800-1800 cm-1 range represented a combination of prominent tissue AF background, 
weak tissue Raman scattered signals, and noise. Subsequent spectral preprocessing 
such as CCD dark-noise subtraction, system spectral response calibration, tissue AF 
background subtraction (5th order polynomial provided the best fit), and laser power 
normalization were performed on the measured spectra. The spectral preprocessing 
and diagnostic algorithms were completed in on-line and displayed in a real-time, 
interactive GUI together with the diagnostic outcomes. 
4.2.4 Multivariate statistical analysis  
After the spectral preprocessing, direct implementation of conventional 
statistical analysis and clustering algorithms (e.g., LDA, etc.) to these high-
dimensional composite NIR AF/Raman spectral dataset may lead to inefficient disease 
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classification.105 Hence, PCA can be initially employed to reduce the spectral space 
through the identification of a reduced number of orthogonal (independent) PCs and 
the PCs are arranged in descending order of variance explained. The PCs preserve 
most of the total variance in the spectral dataset for effective tissue classification, 
whilst eliminating the redundant information.105 In this study, the diagnostic 
information contained in the PCs can be perceived in the context of identifying the 
discriminating features in the underlying spectroscopic data associated with distinct 
spectroscopic modalities.105 The identified significant PCs (p < 0.05) were further fed 
to the LDA classifier for effective disease classification. LDA determines the 
discriminant function line that maximizing the variance between the groups, while 
minimizing the variance within a group. The performance of the diagnostic algorithms 
rendered by the PCA-LDA models for predicting different tissue pathologies was 
validated in an unbiased manner using leave-one patient-out, CV method. The ROC 
curves were further generated to determine correct and incorrect classifications. The 
spectral analysis was performed using in-house written Matlab scripts (Mathworks 
Inc., Natick, MA). The PCA-LDA method has been described in detail in 
Multivariate statistical analysis section in chapter 1. 
4.3 Results 
Figure 4.1, 4.2, 4.3 show the in vivo mean composite NIR AF/Raman, NIR AF 
and NIR Raman spectra together with the corresponding difference spectra, 
respectively, collected from normal (n=993) and precancerous (n=247) cervical 
tissues under the guidance of white-light colposcopy. The composite NIR AF/Raman 
spectra (Figure 4.1) exhibit an intense, broad, but overall decreasing AF intensity 
curves (5th order polynomial fit, Figure 4.2) with the superimposed prominent tissue 
Raman peaks (Figure 4.3). The major Raman peaks are found in the cervix tissues at 
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the following positions with their tentative biochemical assignments: 854 cm-1 
(glycogen ((CCH) deformation - aromatic) and (C-C) stretching of structural proteins 
and collagen), 937 cm-1 (stretching of proline, valine, and glycogen), 1001 cm-1 ((C–
C) ring breathing of phenylalanine), 1095 cm-1 (DNA phospholipids backbone), 
1253 cm-1 (amide III), 1313 cm-1 (CH3CH2 twisting mode of lipids/proteins), 
1445 cm-1 (CH2 bending mode of proteins and lipids) and 1654 cm
-1 (amide I band - 
(C=O) stretching mode of proteins).15, 24, 74, 160, 163  
 
Figure 4.1 (a) The mean in vivo composite NIR AF and Raman spectra ± 1 standard errors (SE) 
and (b) the mean difference spectrum ± 1 SE from normal (n=993) and precancer (n=247) cervical 
tissue. The mean in vivo spectrum of precancer cervical tissue is shifted vertically for better 
visualization. The shaded area represents the respective SE. 
 
 
Figure 4.2 (a) The mean in vivo composite NIR AF spectra ± 1 standard errors (SE) and (b) the 
mean difference spectrum ± 1 SE from normal (n=993) and precancer (n=247) cervical tissue. The 
mean in vivo spectrum of precancer cervical tissue is shifted vertically for better visualization. The 




Figure 4.3 (a) The mean in vivo NIR Raman spectra ± 1 standard errors (SE) and (b) the mean 
difference spectrum ± 1 SE from normal (n=993) and precancer (n=247) cervical tissue. The mean 
in vivo spectrum of precancer cervical tissue is shifted vertically for better visualization. The 
shaded area represents the respective SE. Note that the SE of precancer and normal Raman signals 
in Figure 4.3(a) have been magnified 20-fold for better visualization. 
 
The comprehensive biomolecular basis of NIR AF and Raman spectroscopic 
diagnosis of cervical dysplasia has been described in detail elsewhere.24, 115, 160 The 
AF spectra showed a slightly higher intensity for dysplasia; however, the change in 
AF intensity associated with dysplastic progression was not significant (p = 0.924), 
indicating that the confocal-based NIR AF spectroscopy is inefficient for precancer 
identification. Conversely, the intensity of Raman-active tissue biochemical 
constituents changed significantly (p < 0.05) with precancer transformation. For 
instance, the dysplastic tissue showed increased Raman signals at 1001, 1095 and 
1313 cm-1, but exhibited much lower signal at 854, 937, 1253, 1445 and 1654 cm-1 as 
compared to the normal tissue.15, 24, 118, 119, 160, 163 These striking differences in the 
Raman-active components between different tissue pathologies indicate the diagnostic 
potential of confocal Raman spectroscopy for rapid in vivo diagnosis of precancer and 
early cancer in the cervix.  
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PCA-LDA-based multivariate diagnostic algorithms were subsequently 
incorporated on the measured composite NIR AF/Raman spectra to extract the 
diagnostic information associated with underlying spectroscopy modalities to improve 
the discrimination between dysplasia and normal cervical tissues. The composite NIR 
AF/Raman spectra were mean centered to eliminate the common variance. Hotelling 
T2 and Q-residuals were employed to remove the spectra with unusual line shape 
variations due to non-contact measurements and probe handling variations. Figure 4.4 
shows the first three diagnostically significant PC loadings (PC4, 0.0023%; PC5, 
0.00095%; PC8, 0.00022%, (p < 0.05)), representing the variations in the major tissue 
Raman peaks (e.g., 854, 937, 1095, 1253, 1311, 1445 and 1654 cm-1) together with 
PC1 (99.93%, p = 0.924), typically exhibiting the broad tissue NIR AF features. LDA 
classifier was further employed on the diagnostically significant PCs and the cross-
validated classification results for each spectrum belonging to normal and precancer 
tissue categories were obtained (Figure 4.5).  
 
Figure 4.4 Principal components (PCs) loadings calculated from the in vivo composite NIR 
AF / Raman spectra of cervical tissue, revealing the diagnostically significant spectral features for 
tissue classification. The three diagnostically significant PCs (PC4, 0.0023%; PC5, 0.00095%; 
PC8, 0.00022%) accounting for about 0.00347% of total variance represented the major tissue 
Raman peaks; while the PC1 accounting for 99.93% of total variance, represented the tissue AF 
features. The loadings on PC2, PC3 and PC4 are vertically shifted for better visualization. The 
loading on PC1 has been magnified by 200-fold for better visualization. 
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The PC1 constituting the tissue AF features rendered a diagnostic accuracy of 59.6% 
(sensitivity of 49.8% (123/247) and specificity of 69.4% (689/993)). A diagnostic 
accuracy of 84.1% (sensitivity of 81.0% (200/247) and specificity of 87.1% 
(865/993)) could be achieved using PC4, PC5 and PC8, primarily describing the 
significant tissue Raman spectral features (e.g., 854, 937, 1095, 1253, 1311, 1445 and 
1654 cm-1). The PCs representing tissue AF (PC 1) as well as Raman features (PC4, 
PC5 and PC8) were combined together to assess the diagnostic ability of composite 
NIR AF/Raman spectroscopy modality, and achieved a diagnostic accuracy of 82.3% 
(sensitivity of 76.9% (190/247) and specificity of 87.7% (871/993)) (Table 4.1).  
 
 Figure 4.5 Scatter plots of the posterior probability of belonging to normal and precancer 
categories calculated from the three spectroscopic modalities: (a): composite NIR AF/Raman 
(PC1, PC4, PC5, PC8); (b): NIR AF (PC1); (c): confocal Raman spectra (PC4, PC5, PC8); 
(●)Precancer (n=247), (○)Normal (n=993). 
 
In addition, the diagnostic performance of the three spectroscopic modalities was 
further evaluated by splitting the total dataset multiple times (n=10) into a training set 
(70% of the total dataset) and a testing set (30% of the total dataset). The redeveloped 
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PCA-LDA models using the PCs representing tissue Raman, the composite NIR 
AF/Raman and NIR AF features provided predictive accuracies of 86.1% (95% CI): 
83.6% to 88.7%), 85.7% (95% CI: 80.5% to 90.8%) and 59.8% (95% CI: 52.6% to 
66.9%) for cervical precancer classification, respectively. 
Table 4.1 Comparison of diagnostic performance of different spectroscopic 
techniques (NIR AF, NIR confocal Raman, and the composite NIR AF/Raman) for 
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Figure 4.6 Receiver operating characteristic (ROC) curves of discrimination results for cervical 
precancer classification using in vivo confocal Raman, NIR AF and the composite NIR AF/Raman 
spectroscopy, respectively, based on PCA-LDA modeling together with leave-one patient-out, CV 
method. The areas under the ROC curves (AUC) are 0.88, 0.86 and 0.56 for the confocal Raman, 
the composite NIR AF/Raman, and NIR AF spectroscopy modalities, respectively. 
 
ROC curves were also generated to further compare the performance of PCA-LDA-
based diagnostic algorithms developed from the three spectroscopic modalities 
(confocal Raman, the composite NIR AF/Raman, and NIR AF) for in vivo tissue 
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classification (Figure 4.6). The AUC were 0.88, 0.56 and 0.86 for the PCA-LDA 
models developed from the confocal Raman, NIR AF and the composite NIR 
AF/Raman spectroscopy, respectively, demonstrating that the diagnosis achieved 
using the confocal Raman diagnostic modality was superior than NIR AF 
spectroscopy, but marginally higher than the composite NIR AF/Raman spectroscopy. 
4.4 Discussion 
In the past decade, substantial research efforts have been made to develop 
advanced optical spectroscopy modalities for non-invasive in vivo detection of 
cervical precancer and cancer. In particular, Raman spectroscopy is a unique 
molecular vibrational technology which has found its remarkable way into routine 
clinical oncology applications because of its excellent capability of non-destructively 
probing the changes of biochemical vibrational markers associated with dysplastic 
transformation. The dysplastic cells initially develop in the epithelium, such that 
targeted confocal illumination and collection of signals originating from the epithelial 
layer of cervix is essential to improving Raman spectroscopic diagnosis of precancer. 
Hence, in this study, we utilize a ball-lens confocal Raman probe to selectively 
measure the in vivo composite NIR AF/Raman spectra, which exhibit the spectral 
contributions primarily from the epithelial layer of cervix. Consequently, it can reveal 
the alterations in the Raman-active molecules related to metabolic changes in the 
cervical epithelium, while minimizing AF contributions from deeper stromal tissue 
layer.41, 42, 117  
 The PCA-LDA modeling was performed on the composite NIR AF/Raman 
spectra measured to extract the PC loadings related to tissue NIR AF (an intense 
decreasing broad band curve) and Raman features (highly specific tissue biochemical 
fingerprints), resolving the diagnostic features associated with distinctive 
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spectroscopy modalities. The NIR AF spectra of dysplasia tissue exhibited higher 
intensity than normal cervical tissue, which was in agreement with the literatures 
reported.157, 188 However, the origin of NIR AF is not yet well documented. Porphyrin 
is assumed to be one of the major fluorophores in the NIR region.188 The increase of 
tissue NIR AF with precancer progression could be correlated to the elevated level of 
porphyrins in cancer or precancer tissue, which has also been observed in human 
breast tissue,188 bladder tissue,189 hamster cheek pouch model of carcinogenesis190 as 
well as animal tumor model157, 190. The increase of porphyrins in the tumor tissue is 
probably due to necrosis, microbial contamination of tumor tissue or ability of 
concentrating porphyrins by some types of cells of epithelial origin.189, 191 The 
hypervascularization in the precancer tissue could also contribute to the increased 
level of porphyrins.157 The increase of epithelial fluorescence in dysplasia tissue could 
also be related to changes of other endogenous fluorophores (e.g., reduced 
nicotinamide adenine dinucleotide and flavin adenine dinucleotide) with the 
development of dysplasia in cervical tissue.192-194 The change in NIR AF spectral line 
shape was captured by PC1, accounting for the largest percentage of total variance 
(99.93%). The PC1 suggested that the increased NIR AF emission associated with 
precancer progression was insignificant (p = 0.924), indicating that the change in the 
concentration of NIR endogenous fluorophores probed from the epithelial tissue using 
the confocal Raman probe was inefficient for discriminating the dysplastic lesions 
from the normal cervical tissue. This resulted in very poor diagnostic accuracy of 
59.6% (sensitivity of 49.8% (123/247) and specificity of 69.4% (689/993)) using the 
confocal NIR AF spectroscopy (PC1 associated with tissue AF changes) (Figure 4.5). 
The PCA-LDA model developed using the PCs (PC4, 0.0023%; PC5, 0.00095%; 
PC8, 0.00022%), (p < 0.05)), representing the highly specific tissue Raman signatures 
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was able to extract the diagnostic information related to molecular changes in 
dysplastic cervix. These distinctive and significant variations (p < 0.05) in the relative 
intensities of Raman bands accompanying dysplastic transformation can be instantly 
correlated to the changes of tissue biochemical compositions. For instance, the spectra 
showed decreased glycogen and structural proteins (854 cm-1), primarily representing 
the loss of epithelial cell differentiation during neoplastic progression.2, 160 The 
increased nuclear content (1095 cm-1) indicated the elevated number of epithelial cells 
in the dysplastic cervix.2, 92, 160 The amide I (1654 cm-1) and amide III (1253 cm-1) 
bands were also noticeably decreased with dysplastic transformation.92 Hence, the 
diagnostic model developed using these changes in the concentration of Raman-active 
biomolecules associated with dysplastic progression yielded the diagnostic accuracy 
of 84.1% (sensitivity of 81.0% (200/247) and specificity of 87.1% (865/993)) 
(Figure 4.5), illustrating the diagnostic utility of confocal Raman spectroscopy for in 
vivo cervical precancer diagnosis at the molecular level.  
We also examined if the co-contributions of the composite NIR AF and 
confocal Raman spectroscopy could improve the precancer detection compared to 
confocal Raman spectroscopy alone. The PCA-LDA model was redeveloped by 
combining the PCs constituting the features of both NIR AF and Raman spectroscopy 
modalities (PC1, PC4, PC5, and PC8). The combined NIR AF/Raman diagnostic 
model achieved the accuracy of 82.3% with a sensitivity of 76.9% (190/247) and a 
specificity of 87.7% (871/993) (Figure 4.5), which was marginally reduced compared 
to the diagnostic ability of confocal Raman spectroscopy. This indicates that confocal 
Raman spectroscopy can be used as a standalone diagnostic modality for identifying 
the dysplastic cervix in clinical colposcopy. On the other hand, to better understand 
the ability of confocal Raman spectroscopy for improving cervical precancer 
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diagnosis, we have compared the tissue NIR AF/Raman spectra acquired from a two-
layer tissue model42 using both the ball-lens confocal Raman probe and a volume 
Raman probe under the 785 nm excitation light. The result42 shows that the volume 
Raman probe measures ~74% NIR AF/Raman signals emanating from deeper tissue 
layer. In contrast, the ball-lens confocal Raman probe detects ~80% of NIR 
AF/Raman signals originating from the superficial layer of the two-layer tissue model, 
confirming that confocal Raman spectroscopy technique is highly favorable for early 
detection of epithelial precancer in vivo. Unlike our previous gastric Raman study that 
used a volume Raman probe for improving gastric cancer diagnosis,105 the combined 
NIR AF and Raman spectroscopy using confocal probe in this study does not much 
improve the in vivo diagnosis of cervical precancer (Figures 4.5 and 4.6). The 
diagnostic differences could be due to the following reasons: (1) in gastric Raman 
study,105 we applied a volume Raman probe to investigate gastric cancer tissue 
whereby the proliferating cancer cells invaded the underlying basement membrane 
and stromal layer. The reduction in stromal collagen and AF reabsorption due to 
excessive angiogenesis in cancer tissue can result in a decrease of NIR AF associated 
with gastric cancer. Thus the volume Raman probe, particularly in favor of probing 
the deeper tissue changes, can be used to improve the detection of AF changes of 
deeper layer tissue (e.g., collagen in stromal tissue, vascular information) associated 
with gastric cancer. (2) In the current study, we targeted detecting cervical dysplasia 
largely confined to the epithelium (i.e., within the basement membrane) of cervix. A 
confocal Raman probe is specially designed in favor of probing the biochemical 
changes of superficial epithelial layer (rather than the deeper tissue layer). However, 
the change of AF spectra of dysplastic tissue is mostly occurring in the deeper 
connective tissue adjacent to epithelium,194, 195 which results in an inefficiency when 
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using confocal Raman probe for probing the AF changes of deeper cervical tissue 
associated with precancer transformation. One notes that the balanced accuracy 
((sensitivity + specificity)/2) is computed in this study due to the unbalanced dataset 
(a large number of true negatives).196 The ROC curves (Figure 4.6) further confirm 
the best diagnostic performance of confocal Raman spectroscopy (AUC, 0.88) 
compared to NIR AF (AUC, 0.56) or composite NIR AF/Raman spectroscopy (AUC, 
0.86) for cervical precancer identification. Overall, the results show that confocal 
Raman spectroscopy in conjunction with PCA-LDA modeling holds a great promise 
as a diagnostic tool for improving the detection of subtle biomolecular changes in 
dysplastic lesions leading to early cervical cancer. Currently, further clinical trials on a 
larger number of cervical patients with different pathological groups (e.g., low-
grade/high-grade dysplasia, squamous metaplasia) are in progress at NUH for 
evaluating the true clinical merits of confocal Raman technique for improving the 
early diagnosis of cervical precancer and cancer in obstetrics & gynecology clinic. 
4.5 Conclusion 
In summary, this study demonstrates that the NIR-excited confocal Raman 
spectroscopy can be used for improving precancer diagnosis by selectively probing 
dysplasia-associated molecular changes primarily from the epithelial tissue. Hence, 
confocal Raman spectroscopy technique has the potential to become a powerful 
diagnostic tool in adjunct to colposcopy for cervical precancer and early cancer 
detection in vivo.   
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Chapter 5.  In vivo detection of cervical precancer using 
Raman spectroscopy and genetic analysis techniques 
This study aimed to evaluate the clinical utility of NIR Raman spectroscopy 
and GA-PLS-DA to identify biomolecular changes of cervical tissue associated with 
dysplastic transformation during clinical colposcopic examinations. A total of 105 in 
vivo Raman spectra were acquired from 57 cervical tissue sites (35 normal and 22 
precancer sites) of 29 patients recruited, in which 65 spectra were from normal sites, 
while 40 spectra were from cervical precancerous lesions (7 low-grade and 33 high-
grade CIN). The GA feature selection technique incorporated with PLS was utilized to 
study the significant biochemical Raman bands for differentiation between normal 
and precancer cervical tissues. The GA-PLS-DA algorithm with dCV identified seven 
diagnostically significant Raman bands in the ranges of 925-935, 979-999, 1080-
1090, 1240-1260, 1320-1340, 1400-1420, and 1625-1645 cm-1 related to proteins, 
nucleic acids and lipids in tissue, and yielded a diagnostic accuracy of 82.9% 
(sensitivity of 72.5% (29/40) and specificity of 89.2% (58/65)) for precancer 
detection. The results of this exploratory study suggest that Raman spectroscopy in 
conjunction with GA-PLS-DA and dCV methods has the great potential to provide 
clinically significant discrimination between normal and precancer cervical tissue at 
the molecular level. 
5.1 Introduction 
In the past decade, Raman spectroscopy has been comprehensively 
investigated to non-invasively detect precancer and cancerous lesions in different 
tissues.24, 71, 72, 74, 92, 96, 116, 157 NIR Raman spectroscopy is a non-invasive technique 
based on the inelastic scattering process of photons by the vibration of bonds in the 
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molecules. By using NIR excitation light, Raman spectroscopy can analyze a deeper 
layer of the tissue due to less water absorption and far less tissue AF as compared to 
visible excitation light. Thus, NIR Raman spectroscopy has received great interest for 
in vivo optical diagnosis of cervical precancer by probing biochemical changes in the 
tissue associated with neoplastic transformation.2, 24, 114, 116, 118 Since Raman spectral 
patterns among different tissue types are usually very similar, different sophisticated 
multivariate algorithms such as PCA-LDA and PLS-DA have been deployed to 
translate these subtle molecular alterations reflected in the Raman spectra associated 
with precancer into clinically valuable information. Such statistical methods improved 
the precision of quantitative spectral analysis enormously by including multiple 
spectral intensities simultaneously.158, 197 However, these methods are still considered 
as full spectrum analysis. For example, both PCA-LDA and PLS-DA have to utilize 
the entire Raman spectrum (all the spectral data points ranging from 800 to 1800cm-1) 
for data analysis. Generally, spectroscopic measurements contain a large number of 
variables (features) that often include redundant and noisy variables.159 Most of the 
multivariate techniques were not designed to cope with these irrelevant spectral 
variables.198 For example, PCA-LDA is an excellent data dimension reduction 
technique, but it cannot interpret the physical meaning of the component spectra.198, 
199 In PLS-DA, the calculated LVs or PLS components may also be affected by these 
irrelevant variables.159 It has recently been recognized that the feature selection 
technique provides a simplified model with improved predictive ability by eliminating 
irrelevant or non-informative variables from the spectral dataset. Several feature 
selection techniques such as IVS, UVE, IPW and eClass can be used to increase the 
predictive ability and reduce the complexity of handling a large dataset.140, 200 
However, the features selected by most of the aforementioned methods are dispersed 
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throughout the entire spectrum.200 To tackle the problems, the GA was introduced in 
this study to ensure that the final model was composed of contiguous wavelength with 
less dispersed spectral features.140 The main advantages of adding a feature selection 
technique are to improve the model performance, to gain new insights into variable 
importance as well as to further reduce the model complexity by eliminating 
irrelevant features from the dataset.140, 158, 201 The GA feature selection method can be 
combined with multivariate statistics to eliminate the irrelevant variables that do not 
correspond to significant diagnostic features. The GA with PLS regression and 
contiguous block CV was utilized to search for the significant Raman spectral 
features. It was further integrated with PLS-DA and validated with dCV to classify 
normal and precancer spectra using GA selected features. Subsequently, the ROC was 
generated to further evaluate the performance of the GA-PLS-DA algorithm for in 
vivo diagnosis of cervical cancer and precancer. In this chapter, we aimed to explore 
the feasibility of applying Raman spectroscopy associated with GA-PLS-DA and dCV 
for effective diagnosis and detection of cervical precancer in vivo during clinical 
colposcopy.     
5.2 Materials and methods 
5.2.1 Raman instrumentation 
The Raman spectroscopy system used for in vivo tissue Raman measurements 
has been described in Confocal Raman instrumentation section in chapter 3.  
5.2.2 Patients 
The information about the patient recruitment, ethical protocol and spectral 
acquisition has been described in Patients section in chapter 4. A total of 105 in vivo 
Raman spectra (2 spectra per site) were measured from 29 patients with cervical 
abnormalities, in which 65 spectra were from 35 normal sites, while 40 spectra 
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(i.e., 7 low-grade CIN and 33 high-grade CIN) from 22 cervical precancerous lesions 
and 7 patients were benign, as confirmed by pathological examinations. 
5.2.3 Data preprocessing  
The data preprocessing technique is already explained in detail in On-line 
preprocessing and outlier detection section in chapter 3.  
5.2.4 GA-PLS  
GA is based on Darwinian theory of evolution (survival of the fittest): the best 
individuals, or the generation produced by mating of the best individuals, have a 
higher chance to survive in the living environment.202 The first step to generate GA is 
the creation of population of strings (chromosomes) for an initial population. One pair 
of chromosomes is randomly selected from existing population. Two offsprings 
obtained by cross-over and mutation enter the final population only if they are better 
than the worst chromosome. Eventually the final population contains the best 
chromosomes alone.136, 140, 201 Each string in the initial population has the same 
number of variables as those present in the dataset and it is coded with 1’s (variable 
present) and 0’s (variable absent). The probability of each variable to be present in 
each chromosome of the initial population is  
 /np       (5.1) 
 
where  is the total number of variables, and n is the number of variables present (1’s) 
in a chromosome. The vector p  can be modified by the frequency of selection of 
variables in previous runs. Eventually the values of elements corresponding to the 
most frequently selected variables are higher than the values of the least frequently 
















where selj is the number of selections of variable j in the previous runs.
140
  The value 
of
ip is proportional to the probability that the variable i is present in the chromosome. 
The parameters given for GA are the number of runs (100), regression method (PLS), 
double cross-over,  population size (32 chromosomes), and the probability of mutation 
(1%), using trial and error method. Each run in this feature selection technique 
maintains a slight dependency on the previous runs.  The information with regards to 
variables selection obtained from the previous runs is adopted to make the upcoming 
run concentrated solely on the most interesting regions. Therefore, the probability 
associated with the selection of each variable is negligible at the beginning but 
increases with the number of executed runs.140  
5.2.5 PLS-DA with dCV 
In this study, PLS-DA was integrated with GA to classify the normal and 
precancer tissue spectra using the GA selected spectral variables. The PLS-DA 
method has been described in detail in Multivariate statistical analysis section in 
chapter 1. PLS-DA employs the fundamental principle of PCA, but further rotates the 
components by maximizing the covariance between spectral variation and group 
affinity.107 Hence, the PLS components could explain the diagnostically relevant 
variation. However, the complexity of the PLS-DA model depends on the number of 
components used to build the model. CV methods such as single CV and dCV can be 
used to determine the optimum number of components. In single CV, single random 
splitting of dataset into calibration set and test set may yield inconsistent results, 
because the standard error of prediction (standard deviation of prediction errors or 
SEP) heavily depends on the test set.203, 204 When single CV was utilized to 
concurrently determine the optimum number of PLS components and for validation, 
the CV error was optimistically biased.205 In contrast to single CV, the prediction of 
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spectra using dCV is independent of model parameters, leading to a more accurate 
SEP.138 Hence, we employed the dCV method in this study to determine the optimum 
number of components, avoiding both overfitting and underfitting of the developed 
PLS-DA model.203 The dCV method was used to optimize the complexity of PLS-DA 
model and to estimate the prediction errors when the model is applied to new cases.203 
The dCV method consists of two nested CVs: the inner loop CV and the outer loop 
CV. The inner loop CV was used to determine the optimum number of components. 
The outer loop CV was used to estimate the prediction error and to determine the 
classification of each spectrum.203, 206 Initially, the entire dataset was randomly split 
into four segments in the outer loop. One of the four segments in the outer loop was 
withheld as a test set while the remaining segments were considered as the calibration 
set. This calibration set was again randomly split into seven segments inside the inner 
loop. One segment was left out for validation and the remaining six were taken as 
training set. The PLS-DA models were redeveloped for the training set and the 
predicted values were calculated for the withheld validation set. This process was 
repeated until all the withheld validation segments were predicted. The mean squared 
error (MSE) was calculated for the validation sets and was found to decrease with the 
increasing number of components. However, after reaching a minimum, the MSE 
started to increase again due to overfitting. The optimum number of components was 
estimated using a standard error method203 and the model was rebuilt for the whole 
calibration set. This model was applied to the respective test set and the response was 
predicted. This procedure was iterated until the predicted values were calculated for 
all the withheld test segments. After finishing the outer loop once, one predicted value 
for each sample/spectrum was obtained. This entire dCV process was repeated 
(repeated double cross validation, rdCV) 100 times to estimate the variability in the 
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model performance and to optimize the complexity of the PLS-DA model. The dataset 
was split randomly in each repetition to avoid the possibility of specific order of left-
out spectra influencing the results.206 SEP was calculated for each repetition to 
describe the variations in the model performance.203 
5.3 Results  
Figure 5.1a shows the comparison of in vivo mean Raman spectra ± 1 SD of 
normal (n=65) and precancer (n=40) cervical tissue. The prominent Raman peaks are 
located around 890, 1077, 1270, 1330, 1443 and 1657 cm-1. These peaks are 
tentatively assigned to proteins, phospholipids and nucleic acids, amide III (C-N 
stretching), CH3CH2 wagging in proteins and nucleic acids, CH2 bending mode of 
proteins and lipids, and amide I band (C=O stretching mode of proteins), 
respectively.71, 74, 96, 207 The spectral differences between normal and dysplastic 
cervical tissue can be observed clearly from the difference spectrum (Figure 5.1b), 
suggesting the feasibility of Raman spectroscopy for in vivo diagnosis of cervical 
precancer in the clinical environment.  
 
Figure 5.1 (a) Comparison of mean in vivo Raman spectra ± 1 standard deviation (SD) of 
precancer (n=40) and normal (n=65) cervical tissue spectra. The mean in vivo Raman spectrum 
corresponding to the normal cervical tissue is shifted vertically for better visualization. 
(b) Difference mean spectrum ± 1 SD between precancer (n=40) and normal (n=65) cervical tissue 
spectra. The shaded area represents the respective SD. 
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The GA-PLS algorithm was utilized to search for significant Raman spectral 
features that were directly correlated with different cervical tissue pathologies. The 
algorithm parameters were assigned to develop models that select identical variables 
subsets with the lowest root mean square error of cross-validation (RMSECV). The 
frequencies of selection for each feature in various models are concatenated together 
as the cumulative frequency of selection as shown in Figure 5.2. Thirteen significant 
spectral variables were selected from the Raman shift regions that showed highest 
cumulative frequency of selection according to the variables of importance associated 
with tissue malignancy. 
 
Figure 5.2 The cumulative selection frequencies of tissue Raman bands using GA-PLS with 100 
runs. ‘x’ indicates GA selected Raman features. GA-PLS, genetic algorithm – partial least squares. 
 
The selected thirteen variables corresponded to seven significant Raman band regions 
at around 925-935 cm-1 (δd(CCH) of glycogen, ν(C-C) of protein and collagen), 979-
999 cm-1 (phospholipids, glucose-I’-phosphate), 1080-1090 cm-1 (ν(PO2
-) nucleic 
acids and ν(C-C) phospholipids), 1240-1260 cm-1 (ν (C-N), δ(N-H) - amide III), 
1320-1340 cm-1 (CH3CH2 wagging of nucleic acids and CH3CH2 wagging of 




(ν(C=O) - amide I (α-helix)).2, 24, 118, 123, 160, 207-209 The tentative vibrational 
assignments of biochemicals in cervical tissue are listed in Table 5.1. The intensity 
differences between normal and precancerous tissues among these selected Raman 
spectral features were also verified to be significant (p<0.005, unpaired Student’s t-
test, 2-sided, equal variances) (Table 5.1). These selected regions were related to 
important diagnostic Raman features that correspond to the major biochemical 
changes associated with tissue dysplastic transformation. These Raman shift regions 
were arranged according to decreasing order of cumulative frequency of selection for 
further classification. 
Table 5.1 Tentative assignments of significant Raman bands in the cervical tissue identified for 




















_ 8.88E -09 
979-999 
 
Phospholipids, glucose-I’-phosphate + 2.25 E-05 
1080-1090 
 
ν(PO2-) nucleic acids 
ν(C-C) phospholipids 
+ 4.19 E-08 
1240-1260 
 
ν (C-N), δ(N-H) amide III _ 2.52 E-04 
1320-1340 
 
CH3CH2 wagging of nucleic acids 
CH3CH2 wagging of proteins 
+ 1.7 E-03 
1400-1420 
 
δ(CH3) proteins _ 3.7 E-06 
1625-1645 
 
ν(C=O) amide I (α-helix) _ 4.34 E-05 
ν – stretching mode, δd – deformation, δ – bending mode 
 
The mean intensity changes (increase: +; decrease: -) with precancer progression, and the p-
values of unpaired two-sided Student’s t-test on the Raman band intensities of normal and 
precancer cervical tissues.  
  
The PLS-DA model was then developed for the GA selected Raman shift regions 
together with dCV for validation. The permutation test (shuffling of class labels) 
confirmed that the model developed from the GA selected features did not overfit the 
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dataset.205, 206 The optimum number of LVs was determined by the inner loop CV 
using the standard error method.203 The PLS-DA model was developed for the 
calibration set using this selected one component. Subsequently, the predicted 
response for each spectrum/sample in the test set and SEP were calculated. Figure 5.3 
represents SEP as a function of number of LVs. SEP shows minimum value for the 
optimum number of components (first component) and it increases with increasing 
number of components due to overfitting.  
 
Figure 5.3 Standard error of prediction (SEP) as a function of number of latent variables.  
 
Posterior probability values were calculated from the predicted response as shown in 
Figure 5.4. The threshold line in the posterior probability scatter plot yielded a 
diagnostic accuracy of 82.9% (sensitivity of 72.5% (29/40) and specificity of 89.2% 
(58/65)) for separating dysplasia from normal cervical tissues. Hence, the GA-PLS-
DA algorithm renders a novel way to identify dysplasia from normal cervical tissues 
by developing a classification model from diagnostically significant Raman features. 
To further asses the predictive accuracy of GA-PLS-DA-based diagnostic algorithms 
together with dCV, the ROC curve (Figure 5.5) was also generated. The ROC curve 
for GA-PLS-DA was generated by choosing different threshold levels in the scatter 
plot of posterior probability (Figure 5.4). For each threshold, the discrimination 
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results (sensitivity and specificity) were computed to plot the ROC curve. The AUC is 
0.853, indicating the efficacy of the developed GA-PLS-DA diagnostic algorithm 
validated with dCV. This algorithm utilized the thirteen selected significant Raman 
features from the entire tissue Raman spectra for differentiating dysplasia from 
normal cervical tissues.  
 
Figure 5.4 Scatter plot of the posterior probability values for normal and precancer cervical 
tissues using the GA-PLS-DA together with dCV. The separate line provides a diagnostic 
sensitivity of 72.5% (29/40) and a specificity of 89.2% (58/65) for discriminating dysplasia from 
normal cervical tissue in vivo.  
 
Figure 5.5 Receiver operating characteristic (ROC) curves of discrimination results for in vivo 
cervical tissue precancer classification through the use of Raman spectroscopy and GA-PLS-DA 
together with dCV validation and PCA-LDA with leave-one tissue spectrum-out, cross-validation 
algorithms. The integrated areas under the ROC curves (AUC) for GA-PLS-DA and PCA-LDA 
are 0.853 and 0.813, illustrating the efficacy of GA-PLS-DA for in vivo Raman spectroscopic 
diagnosis of cervical precancer during clinical colposcopy.  
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However, to measure the variability in the performance of the model, dCV was 
repeated 100 times. This method was used to estimate the SEP values for new dataset 
by developing multiple models with random splitting of dataset in each repetition. 
Figure 5.6 shows the box plot of the distribution of SEP values versus the number of 
PLS components for 100 repetitions of dCV.  The variation in SEP values for each 
repetition depends on the selected test set. For example, a spectral test set composed 
of samples with large prediction errors will produce large SEP values.  Conversely, a 
spectral test set composed of samples with small prediction errors will produce small 
SEP values.203  















Figure 5.6 Box chart of the distribution of SEP values for varying number of PLS components. 
Each box represents the distribution of 100 SEP values calculated from the developed GA-PLS-
DA models for each PLS component. The selected final optimum number of components is one 
(aFINAL = 1) and the corresponding SEP value is 0.39 (SEPFINAL = 0.39). The line within each box 
represents the median, but the lower and upper boundaries of the box indicate the first (25
th
 
percentile) and third (75
th
 percentile) quartiles, respectively. Whiskers (error bars) represent 1.5-
fold inter-quartile range. The lower and upper circles represent the minimum and maximum SEP 
values, respectively.  
 
From Figure 5.6, it can be inferred that the final number of optimal components 
(aFINAL = 1) has the smallest SEP (SEPFINAL = 0.39). When the number of components 
98 
 
for developing the model increases, the SEP values also increase due to overfitting. 
This reconfirms that the model developed using one component in this study was 
simpler, providing good prediction without overfitting the dataset. Therefore, the 
aforementioned results suggest that we can ameliorate the model prediction 
performance by integrating GA with PLS-DA and dCV for in vivo Raman 
spectroscopic diagnosis of normal and precancer cervical tissues during the 
colposcopy procedure. 
5.4 Discussion  
Raman spectroscopy is a unique vibrational spectroscopic technique that is 
capable of probing biochemical information of native cervical tissue and its 
alterations with disease progression non-intrusively. But Raman signal emanating 
from the tissue is inherently weak, making the clinical application of real-time, in vivo 
Raman spectroscopy challenging. To maximize the tissue Raman signal collection, a 
rapid and portable Raman spectroscopy system was built in-house with a custom 
designed fiber optic Raman probe coupled with an NIR-coated sapphire ball lens at 
the tip. The significant differences in the intensity of normal and precancer cervical 
Raman spectra can be observed from the difference spectrum (Figure 5.1b), indicating 
the potential of Raman spectroscopy for differentiating dysplasia from normal 
cervical tissues. The main intensity differences can be found at around 935 cm-1 
(glycogen), 978 cm-1 (phospholipids, glucose-I’-phosphate), 1077 cm-1 (phospholipids 
and nucleic acid), around 1270 cm-1 (collagen-amide III), 1338 cm-1 (collagen and 
nucleic acids), 1443 cm-1 (CH2 and CH3 bending mode of lipids) and 1659 cm
-1 
(collagen – amide I). The above obvious biochemical alterations related to precancer 
were consistent with the report in the literature.24, 118 However, the observed Raman 
spectral patterns are very similar for normal and precancerous cervical tissues. Hence, 
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it is highly desirable to develop sophisticated multivariate diagnostic algorithms to 
interpret these subtle spectral changes.  
In this work, we utilized for the first time the robust GA-PLS-DA algorithms 
to translate the in vivo Raman spectral properties of normal and precancer cervical 
tissues into clinically useful information. GA-PLS identifies the diagnostically 
important variables that mainly correlate with dysplasia progression. These significant 
variables are confined within a reduced number of Raman bands that are mainly 
related to proteins, nucleic acids and lipids. The important seven significant Raman 
bands (Figure 5.2) are identified in the spectral regions around 925-935 cm-1 
(δd(CCH) of glycogen, ν(C-C) of protein and collagen), 979-999 cm
-1 (phospholipids, 
glucose-I’-phosphate), 1080-1090 cm-1 (ν(PO2
-) nucleic acids and ν(C-C) 
phospholipids), 1240-1260 cm-1 (ν(C-N), δ(N-H) of amide III), 1320-1340 cm-1 
(CH3CH2 wagging of nucleic acids and proteins), 1400-1420 cm
-1 (CH3 bending 
vibration of proteins), and 1625-1645 cm-1 (ν(C=O) - amide I (α-helix)) (assignments 
of biochemicals are listed in Table 5.1).2, 198, 207-209 For instance, the Raman peak 
intensity at 925-935 cm-1 (CCH deformation in glycogen and C-C stretching in protein 
and collagen) was found to decrease with the progression of precancer. The reduction 
in glycogen was due to the loss of differentiation in cervical epithelial cells with 
precancer transformation.2, 160 Some researchers also assigned this peak to C-C 
skeletal stretch in protein and collagen, indicating the presence of structural proteins 
in normal cervical tissue.36 But the dysplastic tissue exhibits increase of phospholipids 
(979-999, 1080-1090 cm-1), nucleic acids (1080-1090, 1320-1340 cm-1) and glucose-
I’-phosphate (979-999 cm-1), attributed to an increase in the number of epithelial cells 
with dysplastic progression.24 The Raman peaks at 1240-1260 cm-1 (amide III: β - 
sheet) and 1625-1645 cm-1 (amide I: α - helix) showed lower percentage of signals for 
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dysplasia tissue as compared to normal tissue due to reduction in the intensity of 
amide III and amide I, respectively.92 The above selected important Raman bands 
were used to further classify the spectra by integrating the GA with PLS-DA together 
with dCV. The PLS-DA model was developed for the calibration sets using one 
component (an optimum number of components). Subsequently, the prediction 
performance and SEP were computed for the corresponding test set. The permutation 
test confirmed that the model developed from the GA selected features did not overfit 
the dataset.203, 205, 206 As shown in Figure 5.3, SEP has a minimum value for the first 
component and it increases when more number of components included for the model 
development due to overfitting. This indicates that the generated model with one 
component provides the lowest SEP value and yields a diagnostic accuracy of 82.9% 
(sensitivity and specificity of 72.5% (29/40) and 89.2% (58/65), respectively) to 
classify dysplasia from normal cervical tissue (Figure 5.4). It also provides AUC of 
0.853 (Figure 5.5), confirming the efficacy of Raman spectroscopy associated with 
GA-PLS-DA algorithm for in vivo detection of cervical precancer during the 
colposcopic procedure.  
The dCV method was further repeated to check the variability in the model 
performance. By repeating the dCV 100 times, we obtained a total of 400 PLS 
components (the number of segments in the outer loop X the number of repetitions, 
i.e., 4X100). The frequency distribution of the obtained 400 values for the optimum 
number of components shows a maximum at the first component. The final optimum 
number of components was one (i.e., aFINAL = 1), which has the highest frequency. 
After finishing all the repetitions, multiple predicted values (100 values) were 
obtained for each spectrum. The total number of predicted test set values was 
increased to 10,500 values (105 tissue spectra X 100 repetitions=10,500 values). For 
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each repetition, a separate SEP value was also calculated from the 105 (the number of 
spectra) residuals. The distribution of 100 SEP values (obtained from 100 repetitions) 
for each component is shown in Figure 5.6, explaining the variations in the model 
performance. From Figure 5.6, we can find that the final optimum number of 
components (aFINAL = 1) has the smallest SEP (SEPFINAL = 0.39) with a narrow 
distribution, reconfirming that a good prediction is achieved with the developed 
simple PLS model using one component. But when the number of components 
increases, SEP also increases and has a broader distribution due to overfitting in the 
developed models. The rdCV method was also applied for all the 98 spectroscopic 
variables and the obtained SEPFINAL was 0.414. This demonstrated that the final 
performance of the model was improved with decreasing SEP from 0.414 to 0.39 by 
the inclusion of GA feature selection method. In our study, the accuracy of the model 
was increased from 79% (without GA) to 83% by adding the GA feature selection 
method with PLS-DA and rdCV, reconfirming that the reduction in SEP values 
improved the model performance. 
A reliable discrimination between different grades of precancer is challenging 
based on the current colposcopic examination because this technique can over-
diagnose the low-grade precancer as high-grade precancer.116 Distinguishing low-
grade precancer from normal/benign cervical tissue is also difficult even in the hands 
of expert colposcopists’ because the benign changes in the cervix tissues may also 
express similar features of low-grade precancer.116 In this work, we also explored the 
feasibility of in vivo Raman spectroscopy for differentiation among normal, low-grade 
and high-grade precancer cervical tissues. Within the limited Raman spectra numbers 
from low-grade and high-grade cervical precancer acquired, we utilized the empirical 
approach based on the intensity ratios of prominent Raman bands for cervical tissue 
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classification. For instance, the intensity ratio (I935/I1077) of Raman bands can provide 
the diagnostic accuracies of 79.2% (sensitivity of 71.4% (5/7) and specificity of 80% 
(52/65)) and 77.6% (sensitivity of 72.7% (24/33) and specificity of 80% (52/65)) for 
differentiating the low-grade and high-grade precancer from normal, respectively. 
This algorithm also rendered a diagnostic accuracy of 77.5% (sensitivity of 57% (4/7) 
and specificity of 73% (24/33)) for differentiation between low-grade and high-grade 
precancer lesions. The diagnostic accuracy is limited using the empirical method 
because most of the important Raman peaks are not fully utilized for tissue 
classification. Hence, multivariate analysis was also implemented in this study to 
improve the diagnostic accuracy by utilizing the entire Raman spectral region. We 
have applied the widely adopted PCA-LDA together with the leave-one tissue 
spectrum-out, CV on the same in vivo cervical Raman dataset for precancer diagnosis. 
The PCA-LDA algorithms utilizing the two most significant PCs (p<0.05, unpaired 
Student’s t-test, 2-sided) provided a sensitivity of 70% (28/40) and a specificity of 
83% (54/65) for cervical precancer diagnosis. It also rendered AUC of 0.813 
(Figure 5.5) for in vivo diagnosis of cervical precancer. Although the PCA-LDA 
method can give a good classification, it makes the interpretation of classification 
result arduous due to the transformation of high-dimensional original variables.39 
Specifically, the PCA cannot discriminate biochemical information from 
uninformative variation in the dataset.40 Therefore, we employed GA feature selection 
technique which can provide an improved diagnostic accuracy with improved 
predictive ability and simplified model by selecting the relevant important spectral 
regions alone.201 The GA-PLS-DA algorithm employed in this study utilizes 
significant Raman bands selected in the vicinities of 925-935, 979-999, 1080-1090, 
1240-1260, 1320-1340, 1400-1420, and 1625-1645 cm-1 with direct physical 
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meanings of diagnostic information associated with tissue malignancy, yielding an 
improved accuracy compared to the PCA-LDA technique (Figure 5.5). The betterment 
in the diagnostic performance by using the GA-PLS-DA may be due to the fact that 
the GA is a heuristic optimization technique that mainly selects the features with a 
high individual discriminating power. It can also find optimal values for various 
distinct variables associated with the calibration model.159, 210 Within the small tissue 
Raman dataset acquired, we have also used an independent test set prediction with 
random splitting of the dataset (75% for training and 25% for testing) to obtain the 
realistic estimation of true performance without bias using the developed GA-PLS-
DA-dCV model. The GA-PLS-DA feature selection technique validated with dCV 
significantly reduces spectral dimensions, paving a novel way for realizing real-time, 
in vivo diagnosis of cervical precancer in the clinical environment.  
5.5 Conclusion 
In conclusion, we have acquired in vivo Raman spectra from cervical tissue 
using a rapid and portable Raman spectroscopy system together with a ball lens 
Raman probe developed. We observed significant differences between normal and 
precancer cervical tissue spectra, suggesting the feasibility of in vivo Raman 
spectroscopy for dysplastic tissue classification. The GA feature selection technique 
was coupled with tissue Raman spectroscopy to identify the diagnostically important 
Raman features, and the integration of GA with PLS-DA rendered a good tissue 
classification. In addition, dCV was used to further improve the performance accuracy 
by developing the PLS-DA model with optimum complexity. Currently, further in 
vivo Raman measurements on a larger series of patients (approximately 50 patients or 
tissue sites for each tissue type according to power analysis)211 are in progress to 
provide a larger Raman spectral dataset with building a stable GA-PLS-DA-dCV 
104 
 
model for facilitating effective prediction and classification of cervical precancer and 
cancer. After the collection of large spectral datasets, the spectral variations due to the 
confounding factors (e.g., age, race, smoking/nonsmoking, menopausal status, HPV 
infection, etc.) in cervical Raman spectra will also be incorporated into the GA-PLS-
DA-dCV model for further improving the Raman diagnostic accuracy of cervical 
precancer.212, 213 We anticipate that in vivo Raman spectroscopy associated with robust 
GA-PLS-DA and dCV modeling can become a clinically useful tool for rapid, non-
invasive detection of cervical precancer at the molecular level during clinical 
colposcopic examination.   
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Chapter 6. Non-invasive analysis of hormonal variations and 
effect of postmenopausal Vagifem treatment on women using 
high wavenumber confocal Raman spectroscopy 
This study aims to evaluate the feasibility of applying HW confocal Raman 
spectroscopy for non-invasive assessment of menopause-related hormonal changes in 
the cervix as well as for determining the effect of Vagifem treatment on 
postmenopausal women with atrophic cervix. A rapid HW confocal Raman 
spectroscopy system coupled with a ball lens fiber-optic Raman probe was utilized for 
in vivo cervical tissue Raman measurements at 785 nm excitation. A total of 164 in 
vivo HW Raman spectra (premenopausal (n=104), postmenopausal-prevagifem 
(n=34), postmenopausal-postvagifem (n=26)) were measured from the normal cervix 
of 26 patients undergoing colposcopy. We established the biochemical basis of 
premenopausal, postmenopausal-prevagifem and postmenopausal-postvagifem cervix 
using semiquantitative biomolecular modeling derived from Raman-active 
biochemicals (i.e., lipids, proteins and water) that play critical role in HW Raman 
spectral changes associated with the menopausal process. The diagnostic algorithms 
developed based on PLS-DA together with leave-one patient-out, CV yielded the 
diagnostic sensitivities of 88.5%, 91.2% and 88.5% and specificities of 91.7%, 90.8% 
and 99.3%, respectively, for non-invasive in vivo discrimination among 
premenopausal, postmenopausal-prevagifem and postmenopausal-postvagifem cervix. 
This work demonstrates for the first time that the HW confocal Raman spectroscopy 
in conjunction with biomolecular modeling can be a powerful diagnostic tool for 
identifying hormonal/menopausal related variations in native squamous epithelium of 
normal cervix, as well as for assessing the effect of Vagifem treatment on 
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postmenopausal atrophic cervix in vivo during clinical colposcopic inspections.  
6.1 Introduction  
Atrophic vaginitis/cervicitis is a silent epidemic that may adversely affect the 
quality of life in postmenopausal women.
214
 This chronic and progressive medical 
condition occurs due to declined endogenous estrogen production and is frequently 
accompanied by symptoms including vaginal dryness, burning, itching, 
postmenopausal bleeding and dyspareunia.
215
 The vaginal and cervical epithelium 
becomes thin, dry, less elastic, visibly pale, and often leads to an abnormal Pap smear. 
The atrophic change is usually caused by lack of estrogen during menopausal or 
postmenopausal stage, but most of the time is misinterpreted as high-grade precancer 
related to HPV in the Pap smear.
215, 216
 The differential diagnosis of atrophy and 
precancer in postmenopausal women remains challenging by using the conventional 
Pap smear and colposcopy. Local estrogen treatment should be given to patients for 
definitive diagnosis to alleviate the menopausal symptoms by minimizing or reversing 
these physiological changes.
217
 The atrophic cervix is friable (i.e., bleeds upon touch); 
however, the patients have to be monitored by repeating Pap smears after a course of 
estrogen treatment. These conventional methods are subjective and inconclusive for 
making definite diagnosis of normal atrophic changes in the cervix or monitoring the 
effect of hormonal treatment on postmenopausal women with atrophic cervix. Hence, 
the development of an advanced diagnostic technique is essential for supporting 
clinicians in the management of menopause-related symptoms.  
      Raman spectroscopy is a unique analytical probe for measuring the changes in 
biomolecular vibrations of cells and tissues. Raman spectroscopy has shown great 
promise for early cancer detection due to its ability to provide specific biochemical 
information about tissue changes associated with neoplastic transformation.
24, 28, 34, 69, 
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74, 107, 119, 122, 162
 To date, most of the tissue spectroscopic studies were centered on the 
so-called “FP” region which contains information-rich spectral bands attributed to 
various vital tissue biochemical constitutions (i.e., proteins, lipids, nucleic acids, 
etc.).
15, 24, 28, 34, 40, 72, 104, 107, 108, 114, 117, 119
 The diagnostic capability of FP Raman 
spectroscopy for differentiating dysplastic cervix has already been well 
documented.
24, 34, 117, 119
 However, it is necessary to understand the sources of normal 
spectral variability (i.e., inter-/intra-patient variations) to further improve the 
diagnostic efficacy of Raman spectroscopy. Hence, subsequent studies in this area 
have uncovered the potential of FP Raman spectroscopy to identify the variations in 
normal cervical tissue spectra due to menopausal/hormonal stages,
218
 physiological 
variations such as race/ethnicity, body mass index (BMI), parity, socioeconomic 
status,
219
 and changes during pregnancy.
220
 However, tissue Raman signal in the FP 
region is extremely weak and usually encounters interference by the strong tissue AF 
background and silica Raman signals generated from the optical fiber itself. This 
requires integration of filtering modules making the Raman probe bulky and 
undesirable for in vivo biomedical applications.
79, 179
 In contrast, HW Raman 
spectroscopy generates intense tissue Raman signals with much less tissue/fiber 
background interference that leads to an effective miniaturized ﬁber Raman probe 
designs,
79, 179
 facilitating the adaptation of this technique for in vivo clinical 
practice.
103, 116, 117
 The diagnostic ability of HW Raman spectroscopy for the 
classification of laryngeal cancer
103
 and cervical precancer
116, 117
 have already been 
demonstrated in our previous studies. However, the applicability of HW confocal 
Raman spectroscopy to determine hormone/menopause-related (premenopause and 
postmenopause) biochemical changes in normal cervix as well as to evaluate the 
effect of Vagifem (vaginal estradiol tablets) treatment on postmenopausal atrophic 
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cervix have not yet been investigated. Vagifem is a modified release pessary used to 
treat certain menopausal symptoms by replacing the estrogen that can no longer be 
produced by menopausal ovaries. The vaginal menopausal symptoms are mainly 
related to thinning of the epithelium (atrophy) due to the loss of estrogen-dependent 
cellular maturation in menopausal women, which can dramatically reduce their 
quality of life.
221
 The atrophic cervical epithelium includes predominantly 
basal/parabasal cells without evidence of cellular differentiation.
222
 As such, targeted 
confocal illumination and collection of signals from the epithelial layer is crucial for 
biochemical characterization of normal hormonal variations in the cervix. Therefore, 
in this study, we characterized the spectral variations in the normal cervical 
epithelium associated with hormonal/menopausal status of women (premenopausal 
and postmenopausal) using in vivo HW confocal Raman spectroscopy. We further 
evaluated the effect of Vagifem treatment on the atrophic cervical epithelium of 
postmenopausal women (postmenopausal-prevagifem and postmenopausal-
postvagifem). We have also utilized multivariate algorithms based on PLS-DA 
together with leave-one patient-out, CV for differentiating the HW Raman spectra 
acquired from different menopausal cervices in vivo.  
6.2 Materials and methods 
6.2.1 Confocal Raman instrumentation 
The confocal Raman spectroscopy system used for in vivo tissue HW Raman 
measurements has been reported in detail in Confocal Raman instrumentation 
section in chapter 3.  
6.2.2 Patients  
The more information about the patient recruitment, ethical protocol and 
spectral acquisition has been described in Patients section in chapter 4. A total of 26 
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non-pregnant female patients between 18 to 70 years of age who underwent a 
colposcopy procedure follow-up for an abnormal Pap smear were enrolled in the 
colposcopy clinic at the NUH, Singapore. During colposcopy, 5% acetic acid solution 
was applied topically on the cervix for a couple of minutes by an experienced 
colposcopist to evaluate the color and density of acetowhite tissue. According to the 
accepted standard of clinical practice in obstetrics & gynecology,5, 186, 223 the normal 
mature squamous epithelium is identified if the colposcopic appearance shows the 
following features: (i) before applying acetic-acid: the saline washed cervix tissue 
shows smooth translucent surface with a pinkish tinge; the vascular pattern is rarely 
seen, but reticular or hairpin-shaped capillaries are apparent; (ii) after applying acetic-
acid: the tissue surface becomes dull and pale without showing acetic acid whitening 
changes (i.e., normal tissue does not stain acetowhite which only accompanies 
dysplastic epithelium). Upon visual colposcopic examination, the atrophic cervical 
epithelium appears pale, thin and fragile with minimal rugae. Its inconspicuous 
vascular patterns can be seen as looped capillaries or a fine network with subepithelial 
petechial haemorrhagic spots, as it is easily prone to trauma.5 The cardinal cytological 
features of atrophic squamous epithelium include preponderance of basal and 
parabasal squamous cells, uniform distribution of chromatic texture, perinuclear halos 
and multinucleation.224 Hence, the postmenopausal patients with atrophy are 
commonly treated with Vagifem tablets (film-coated estradiol vaginal tablets 
containing 25 µg of estradiol) twice a week for 3 months.217 Vagifem induces the 
maturation of epithelium and decreases the vaginal pH to acidic to improve the body’s 
natural defense mechanism against pathogens.221 The maturation of epithelium is 
evidenced by a decrease in parabasal cells and an increase in the proliferation of 
superficial cells. Hence, the in vivo HW Raman spectral measurements were taken 
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from normal ectocervical squamous epithelial sites of premenopausal patients, and for 
postmenopausal patients before (prevagifem) and after (postvagifem) the Vagifem 
treatment to determine the cervical tissue composition changes related to hormonal 
variations associated with menopausal status and Vagifem treatment. Note that the 
spectra were taken from colposcopically proven normal and atrophic cervices. 
Multiple Raman spectral measurements (~3 to 4) were taken from each site of the 
patient (~2 to 3 sites per patient) to include inter- and/or intra-tissue variability for 
data analysis. As a result, a total of 164 in vivo HW cervical tissue Raman spectra 
were measured from 26 patients recruited (10 premenopausal, 8 postmenopausal-
prevagifem, and 8 postmenopausal- postvagifem), in which 104 spectra were 
collected from normal premenopausal cervix, whereas 60 spectra were from normal 
postmenopausal cervix. Within 60 spectra, 34 spectra were measured from 
postmenopausal-prevagifem cervices and 26 spectra were from postmenopausal-
postvagifem cervices. The menopausal status and age of the patients measured were 
also recorded. 
6.2.3 Data preprocessing  
The data preprocessing techniques has been described in detail in On-line 
preprocessing and outlier detection section in chapter 3. 
6.2.4 Spectral modeling 
The biomolecular characterization of variations in normal cervix due to 
different hormonal/menopausal status that all women undergo in their lifetime is 
essential for better understanding of age-related problems and predictors of risks to 
provide better care for them. In this work, we developed a semiquantitative model 
based on a linear combination (NNCLSM fitting)99, 104, 109 of basis Raman spectra 
from the most prominent biochemicals in cervical tissues (e.g., proteins (collagen 
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type I), lipids (cholesterol), and water) to approximate the in vivo cervical tissue HW 
Raman spectra measured. The basis set component spectra excellently represented the 
major tissue HW Raman spectral features and provided the best fit to estimate the 
changes in the relative amounts of lipids, proteins and water content in the cervix in 
conjunction with the menopausal status. For instance, collagen type I, the most 
abundant protein in the extra cellular matrix can typically be used as a representative 
for protein Raman signals (2946 cm-1), and cholesterol for lipid Raman signals 
(2880 cm-1); The major contributor, water (double-distilled water, ddH2O) represents 
the tissue water content (3100 - 3700 cm-1 peaked at 3400 cm-1). These biochemicals 
could effectively characterize the hormone/menopause-related variations in normal 
cervices with very small ﬁt-residuals. The obtained fitting coefﬁcients for each 
menopausal category were further constrained to a coefficients sum of 100% to 
estimate the relative contribution of each basis spectrum to the in vivo cervix tissue 
HW Raman measurements. The more detail about NNCLSM semiquantitative model 
has been described in Biomolecular modeling section in chapter 1.   
6.2.5  Multivariate statistical analysis  
The PLS-DA multivariate method utilized in this chapter has been detailed in 
Multivariate statistical analysis section in chapter 1. The performance of the 
diagnostic algorithm rendered by the developed probabilistic PLS-DA models for 
differentiating different menopausal status of cervices (e.g., premenopausal, 
postmenopausal-prevagifem, postmenopausal-postvagifem) was validated in an 
unbiased manner using leave-one patient-out, CV method. 
6.3 Results 
Figure 6.1a shows the comparison of in vivo mean HW Raman spectra ± 1 SD 
acquired from the normal cervical tissues of postmenopausal women before (n=34)  
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and after (n=26) Vagifem treatment and premenopausal (n=104) women. The 
measured cervical tissue spectra showed salient Raman spectral peaks found at the 
following peak positions with tentative biomolecular assignments: 2880 cm-1 (CH2 
stretching of lipids), 2946 cm-1 (CH3 stretching of proteins) and the broad band of 
water from 3100 - 3700 cm-1 centering at 3400 cm-1 (OH stretching of water).116, 117  
 
Figure 6.1 (a) comparison of mean in vivo HW Raman spectra ±1 standard deviations (SD) 
acquired from the cervix tissue of women of different menopausal status (premenopausal (n=104), 
postmenopausal-prevagifem (n=34) and postmenopausal-postvagifem (n=26)). Note that the mean 
in vivo HW Raman spectra are shifted vertically for better visualization. The shaded area 
represents the respective SD. The SD conﬁdence intervals have been magnified by 3-fold for 
better visualization. (b) The mean difference spectra comparing different menopausal status of 
women including before and after Vagifem treatment in postmenopausal women. (PreM, 
premenopausal; PostM “PreV”, postmenopausal-prevagifem; PostM “PostV”, postmenopausal-
postvagifem). 
 
The difference spectra (Figure 6.1b) clearly reflect the specific biomolecular changes 
in the cervical tissue HW Raman spectra associated with the menopausal status of 
women. For instance, the spectra measured from the cervix of postmenopausal-
prevagifem women (atrophy) increased significantly at 2880 and 2946 cm-1,213, 225-228 
whereas the converse was true for water Raman signal (3400 cm-1),213, 225, 229 
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compared to premenopausal women (unpaired Student’s t-test (p < 0.05)). However, 
after the Vagifem treatment, postmenopausal women with severe atrophy 
(postmenopausal-prevagifem) move towards premenopausal women due to elevated 
levels of female reproductive hormone estrogen in the cervix. The significant 
differences observed between premenopausal and postmenopausal cervical tissue 
spectra confirm the capability of HW confocal Raman spectroscopy for in vivo 
identification of menopause/hormone-related changes in the cervix. The biochemical 
origins responsible for the menopausal transition are reflected in the measured 
cervical tissue Raman spectra.  
 
Figure 6.2 The basis reference HW Raman spectra (i.e., lipids (e.g., cholesterol), proteins 
(e.g., collagen type I) and water (ddH2O)) used for biochemical modeling of cervix tissue of 
women of different menopausal status. 
 
A semiquantitative model based on NNCLSM fitting utilizing three reference 
spectra (i.e., proteins, lipids, and water (Figure 6.2)) was developed to reconstruct the 
measured tissue spectra, and the relative spectral contribution of these biochemicals 
underpinning different menopausal statuses of the cervices can be estimated. 
Figure 6.3 shows the comparisons of mean measured HW Raman spectra acquired 
from premenopausal, postmenopausal-prevagifem and postmenopausal-postvagifem 
114 
 
cervices together with their corresponding reconstructed Raman and residual 
(measured – reconstructed) spectra. The relative contribution of different reference 
biochemicals were estimated to provide the best fit for each measured spectrum with 
minimum residual (of <10%)109 (residual variations for 6.3(a) - 6.3(c): ± 2E−4). This 
suggests that the linear combination of selected three biochemicals (i.e., cholesterol, 
collagen type I, and water) can be used to effectively characterize the major HW 
Raman spectroscopic variations associated with hormonal/menopausal status. 
Figure 6.4 displays the relative Raman spectral contribution (mean fit coefficients) of 
the three biochemicals for different menopausal categories of women with 
corresponding p-values, demonstrating that the spectral variations between 
premenopausal and postmenopausal-postvagifem women are subtle compared to the 
signiﬁcant differences observed between premenopausal and postmenopausal-
prevagifem women. The above results illustrate that HW confocal Raman 
spectroscopy is able to directly assess the biomolecular changes in cervices associated 
with menopausal stages of women.  
 
Figure 6.3 Comparison of in vivo HW Raman spectra measured from different menopausal status 
of cervices with the corresponding reconstructed Raman spectra using a linear combination of 
basis reference Raman spectra: (a) premenopausal, (b) postmenopausal-prevagifem, and 
(c) postmenopausal-postvagifem. Residuals (measured spectrum minus ﬁt spectrum) are also 
shown in each plot. (PreM, premenopausal; PostM “PreV”, postmenopausal-prevagifem; 




Figure 6.4 Histograms displaying the average biochemical composition of cervix tissues of 
women of different menopausal status (premenopausal, postmenopausal-prevagifem, and 
postmenopausal-postvagifem). The one standard error (SE) conﬁdence intervals are shown for 
each model component. The relative contribution of cholesterol in the tissue has been increased by 
5 times for all menopausal categories. The SE conﬁdence intervals have been magnified 10-fold 
for better visualization. Note: (*) indicates a signiﬁcant difference (p < 0.05); whereas (**) 
indicates a signiﬁcant difference (p < 1.0 × 10
−4
) for discriminating the cervix tissues of women of 
different menopausal status. (PreM, premenopausal; PostM “PreV”, postmenopausal-prevagifem; 
PostM “PostV”, postmenopausal-postvagifem). 
 
To further improve the tissue diagnosis, these chemical differences observed in 
the spectra of different menopausal status cervices were explored in detail using the 
PLS-DA multivariate algorithm. Prior to multivariate analysis, the measured in vivo 
HW Raman spectra were arranged into a dataset (X block) with each wavenumber 
being in columns and individual case rows. Y block were coded with a class 
membership of zeros and ones, representing group affinities. The arranged dataset was 
mean-centered to eliminate the common variance.107 Raman spectra were further fed 
to the model-specific outlier analysis using PCA coupled with Hotelling’s T2 and Q-
residual statistics to remove outliers (i.e., the spectra with unusual line shape 
variations due to non-contact measurements and probe handling variations).108 The 
multiclass PLS-DA diagnostic algorithm together with leave-one patient-out, CV was 
subsequently employed on the HW Raman spectral datasets using 1LV (Figure 6.5), 
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accounting for 15.04% and 47.96% of total Raman spectral variations in the X and Y 
directions, respectively. 1LV was found to be optimum based on the local minimum of 
CV classification error values.117 The selected diagnostically significant LV (p < 0.05) 
typically represented the spectral variations around the major Raman peak positions 
(2880, 2946, and 3400 cm-1). 
 
Figure 6.5 The ﬁrst diagnostically signiﬁcant latent variable (LV) accounting for 15.04% and 
47.96% of the total variation in the Raman spectral dataset in the X and Y directions, revealing the 
diagnostically signiﬁcant (p < 0.05) HW Raman spectral features for tissue classiﬁcation. 
 
Posterior probability values were further calculated using the developed multiclass 
PLS-DA model, and a two-dimensional ternary scatter plot107 was generated 
(Figure 6.6). The final diagnostic outcome (premenopausal, postmenopausal-
prevagifem and postmenopausal-postvagifem cervix) is determined by the nearest 
proximity of data-point to the diagnostic category related to the vertex of ternary plot 
(maximum of the obtained three probability values for each spectrum). The vertices of 
the triangle represent 100% posterior probability and opposite baselines represent 0%, 
belonging to premenopausal, postmenopausal-prevagifem and postmenopausal-
postvagifem cervices. The ﬁnal diagnostic outcome (% belong to a specific category) 





Figure 6.6 Two-dimensional ternary plot of the posterior probability belonging to cervix tissue of 
normal women of different menopausal status achieved by partial least squares-discriminant 
analysis (PLS-DA), together with the leave-one patient-out, CV method. (PreM, premenopausal; 
PostM “PreV”, postmenopausal-prevagifem; PostM “PostV”, postmenopausal-postvagifem). 
 
Table 6.1 Classiﬁcation results of in vivo cervical tissue HW Raman spectra of normal women 
with different menopausal status using PLS-DA algorithms, together with leave-one patient-out, 
CV method. 
 
Tissue type PreM PostM “PreV” PostM “PostV” 
PreM 92 12 0 
PostM “PreV” 2 31 1 
PostM “PostV” 3 0 23 
Sensitivity (%) 88.5 91.2 88.5 
Specificity (%) 91.7 90.8 99.3 
PreM, premenopausal; PostM “PreV”, postmenopausal-prevagifem; 
PostM “PostV”, postmenopausal-postvagifem. 
 
Table 6.1 summarizes the diagnostic results for in vivo HW Raman spectra belong to 
different menopausal category cervices using PLS-DA together with leave-one 
patient-out, CV method. Diagnostic sensitivities of 88.5%, 91.2%, and 88.5%, and 
speciﬁcities of 91.7%, 90.8%, and 99.3%, respectively, can be achieved for 
discrimination among premenopausal, postmenopausal-prevagifem and 
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postmenopausal-postvagifem cervices (Figure 6.6). The above results demonstrate the 
utility of HW confocal Raman spectroscopy to noninvasively monitor the 
physiological changes during menopausal transitions (premenopausal to 
postmenopausal-prevagifem) as well as the effect of Vagifem administration 
(postmenopausal-prevagifem to postmenopausal-postvagifem) on menopausal 
changes making the atrophic patients closer to premenopausal women.   
6.4 Discussion 
The cyto-histopathologic diagnosis of cervical precancer relies on cytological 
and morphological alterations within the cells and tissues. The current recommended 
clinical diagnostic techniques (e.g., colposcopy and histology (colposcopy-directed 
biopsies)) are visual inspection methods and are prone to considerable intra- and inter-
observer disagreements. For instance, there is an acceptable level of agreements 
among pathologists for two major comparative group classifications (e.g. cancer, non-
cancer). However, the acceptable level of agreements is poor for multiclass prediction 
(e.g. cancer, non-cancer, low-grade precancer and high-grade precancer).15 Hence, the 
visual identification and interpretation of normal tissue variations due to physiological 
factors such as hormonal/menopausal status especially the time of onset and 
completion, location within the menstrual cycle, etc. will be even more challenging. 
The identification of postmenopausal atrophic lesions associated with basal/parabasal 
cells is especially difficult for cytologists and is often confused with clinically 
significant squamous dysplastic cells. Research studies have been carried out to 
develop advanced optical-diagnostics modalities for the noninvasive in vivo detection 
of changes in the composition of ectocervix related to menopausal variations.213, 218, 
219, 230-232 Raman spectroscopy is a unique molecular vibrational technology which 
provides a promising new approach for probing the changes in the intrinsic tissue 
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biochemical markers associated with normal physiological variations in the cervix.218, 
219 In this study, the utilization of HW confocal Raman spectroscopy for identifying 
molecular changes in the cervix in relation to different menopausal stages as well as 
for the evaluation of the effect of Vagifem treatment on the postmenopausal atrophic 
cervix have been investigated.  
Significant differences (p < 0.05) have been observed in the HW Raman 
spectra measured from the cervix of women of different menopausal status, especially 
around the prominent Raman peak positions (i.e., 2880, 2946 and 3400 cm-1) 
(Figure 6.1). Briefly, the postmenopausal HW Raman spectra showed increased lipids 
(2880 cm-1)226-228 and proteins (2946 cm-1)213, 225 content, whereas elevated tissue 
water content (3100 - 3700cm-1 broad water band peaked at 3400 cm-1) was noticed in 
premenopausal women.225 Within the postmenopausal women, the postmenopausal-
prevagifem patients showed the most increased lipids and proteins content while the 
least water content. However, after the Vagifem therapy (postmenopausal-
postvagifem), the lipids and proteins started to decrease and water began to increase 
towards premenopausal women.225-229, 233 The relative increase or decrease of 
biochemicals associated with menopausal status of women that are responsible for the 
differences in cervical HW Raman spectra were further investigated using NNCLSM 
technique. The NNCLSM models are developed with the presumption that the Raman 
intensity scales linearly with the concentration of biochemical components in the 
tissue. The measured and fitted Raman spectra for each menopausal category of 
women together with the residual spectra are shown in Figure 6.3. Note that the water 
signals in the reconstructed spectra are red shifted compared to the measured tissue 
spectra. This is probably due to the fact that the intracellular water signal in the tissue 
is drastically different from the bulk water signal and the tissue Raman signal is also 
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sensitive to the characteristic features of confined water molecules at the biological 
interface.234 Moreover, the confinement of water molecule in the restricted biological 
environment does not show the same vibrational Raman spectroscopic behavior. 
Rather, the structure and dynamics of the confined water differs for different 
biological interfaces such as interaction with proteins, lipids and DNA, etc. It has 
been already reported that the vibrational pattern of water in the confined biological 
environment is different from the outside water and has been confirmed by the red 
shift of the water (OH stretching) peak positions at biological environment.234 The 
change in the vibrational behavior pattern of the intracellular water molecule could 
also be attributed to different polarization properties of intracellular water (e.g., higher 
viscosity and smaller spread of intracellular water; local disruption of OH-bond 
network; decoupling of the vibrations of OH bonds in the water molecule or change of 
vibrational selection rules)234, 235 at biological interfaces. The intracellular water can 
self-structure differently in different tissue pathologies by forming clusters with 
nearby structures by their hydrogen-bonding capabilities.235 Therefore, the water used 
for NNCLSM modeling may not reflect its true in vivo tissue conditions, which could 
lead to the red shift of water Raman peak in the fitted Raman spectra.  
Nevertheless, the ﬁt coefﬁcients of the biochemicals (e.g., proteins, lipids and 
water) obtained by NNCLSM modeling (Figure 6.4) reveal significant spectral 
variations (p < 1×10−4) between the premenopausal and postmenopausal-prevagifem 
cervical tissues as compared to the spectral variations between premenopausal and 
postmenopausal- postvagifem cervices (p < 0.05), which are in agreement with the 
variations observed in the measured tissue spectra. The biological reasons responsible 
for the change of these biochemicals could be explained as follows: The significant 
increase of protein (collagen) Raman signal in postmenopausal women could be 
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originated from stromal tissue due to the thinning of epithelium and increased 
collagen cross-linking (stiffness) with menopausal transition.213, 225 The higher lipid 
content (e.g., cholesterol) in postmenopausal-prevagifem women may be associated 
with a lack of estrogen.227  The administration of estrogen improves the vaginal blood 
flow and also reduces the level of cholesterol (low-density lipoprotein (LDL)) through 
enhancing the LDL receptor activity level which in turn increases fractional catabolic 
rate for LDL apolipoprotein B.226 The reduced water content in the postmenopausal-
prevagifem cervix could also be correlated with the declined estrogen, because the 
circulating estrogen stimulates the attraction of water molecules into the cervical 
tissue.225, 229, 233 Hence, Vagifem therapy is usually given for postmenopausal atrophic 
patients to replace the estradiol that the ovaries can no longer produce.225 After 
Vagifem therapy, the water content in the postmenopausal-prevagifem women move 
towards that of premenopausal women, probably due to the restoration of the fluid-
retaining properties of ovarian steroids.225 Overall, the protein and lipid signals began 
to diminish and the water Raman signal started to improve for postmenopausal-
postvagifem women to restore the quality of the epithelium (i.e., the thickness and 
elasticity of the tissue).236 Figure 6.6 again reconfirms the substantial biochemical 
changes between premenopausal and postmenopausal-prevagifem cervices, thereby 
proving the utility of in vivo HW Raman spectroscopy for separation between 
premenopausal and postmenopausal-prevagifem cervix data. The PLS-DA diagnostic 
model developed using the changes of Raman-active biomolecules associated with the 
menopausal transition yielded the diagnostic sensitivities of 88.5%, 91.2% and 88.5%, 
and specificities of 91.7%, 90.8% and 99.3%, respectively, for in vivo discrimination 
among different menopausal statuses (Figure 6.6). Thus, the biomolecular changes 
across different hormonal statuses revealed by both biomolecular modeling and the 
122 
 
measured Raman spectra confirm the capability of HW confocal Raman spectroscopy 
technique for identifying the normal hormonal variations in women.  Currently, HW 
confocal Raman clinical trials on a larger number of patients in each menopausal 
category (i.e., premenopausal, perimenopausal and postmenopausal before and after 
Vagifem treatment) are in progress to further evaluate its true clinical merits for real-
time differentiation among different hormonal/menopausal statuses of women.  
6.5 Conclusion 
In conclusion, we have successfully applied in vivo HW confocal Raman 
spectroscopy to characterize the variations in normal cervical tissue related to 
hormonal/menopausal status and Vagifem treatment. Biomolecular modeling confirms 
that there are significant variations between premenopausal and postmenopausal-
prevagifem cervical tissue compared to premenopausal and postmenopausal-
postvagifem cervical tissue. This work demonstrates for the first time that HW 
confocal Raman spectroscopy provides a new tool for the noninvasive in vivo 
classification and characterization of compositional changes in normal cervices 
associated with menopausal status during clinical colposcopic examinations.  
123 
 
Chapter 7. Integrated fingerprint and high wavenumber 
confocal Raman spectroscopy for enhancing early detection 
of cervical precancer in vivo 
In this chapter, we investigate the diagnostic utility of an integrated FP and 
HW confocal Raman spectroscopy developed for improving in vivo diagnosis of 
cervical precancer (dysplasia). A total of 476 in vivo integrated FP/HW Raman spectra 
(356 normal and 120 precancer) are acquired from 44 patients within 1 sec during 
clinical colposcopy. The distinctive Raman spectral differences between normal and 
dysplastic cervical tissue are observed at ~854, 937, 1001, 1095, 1253, 1313, 1445, 
1654, 2946 and 3400 cm-1 mainly related to proteins, lipids, glycogen, nucleic acids 
and water content in the tissue. Multivariate diagnostic algorithms developed based on 
PLS-DA together with the leave-one-patient-out, CV yield the diagnostic sensitivities 
of 84.2%, 76.7% and 85.0%, respectively; specificities of 78.9%, 73.3% and 81.7%, 
respectively; and overall diagnostic accuracies of 80.3%, 74.2% and 82.6%, 
respectively, using FP, HW, and integrated FP/HW Raman spectroscopic techniques 
for in vivo diagnosis of cervical precancer. ROC analysis further confirms the best 
performance of the integrated FP/HW confocal Raman technique, compared to FP or 
HW Raman spectroscopy alone. This work demonstrates, for the first time, that the 
simultaneous FP/HW confocal Raman spectroscopy has the potential to be a clinically 
powerful tool for improving early diagnosis and detection of cervical precancer in 
vivo during clinical colposcopic examinations. 
7.1 Introduction 
NIR-excited Raman spectroscopy which measures the inelastic light scattering 
processes in the NIR range has excelled in early detection of precancer and cancer in 
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biomedical tissues.24, 34, 72, 74, 109, 119, 176 Currently, Raman research for precancer or 
cancer diagnosis has been reported either in FP region 34, 71, 72, 74, 75, 109, 119, 160 or HW 
region79, 116, 176-178. To date, the combination of the FP and HW Raman spectroscopic 
techniques for disease diagnosis in the cervix has not been reported in literature. We 
have already discussed the development of real-time simultaneous FP/HW confocal 
Raman spectroscopic system for in vivo tissue Raman measurements in the cervix in 
chapter 3. We have also described the diagnostic utility of FP as well as HW Raman 
spectroscopy for cervical precancer diagnosis in previous chapters. Encouraged by 
these results, in this chapter, we evaluated the diagnostic utility of the integrated 
FP/HW confocal Raman spectroscopy for improving in vivo cervical dysplasia 
detection. Multivariate statistical techniques, including PLS-DA, were employed to 
translate the FP/HW Raman spectral differences between the normal and dysplastic 
tissue into diagnostically useful information for effective tissue classification. 
7.2 Materials and methods 
7.2.1 Raman instrumentation 
The integrated confocal FP/HW Raman spectroscopy system that measures the 
in vivo FP and HW Raman signals simultaneously from the cervix tissue at 
colposcopy has been described in detail in Confocal Raman instrumentation section 
in chapter 3.  
7.2.2 Patients 
The more information about the patient recruitment, ethical protocol and 
spectral acquisition has been described in Patients section in chapter 4. To include the 
intra/inter-subject variations for data analysis, multiple Raman spectra (~5-8 spectra) 
were collected from each tissue site. As a result, a total of 476 in vivo Raman spectra 
(356 normal and 120 dysplasia) were collected from 44 patients recruited.  
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7.2.3 Data preprocessing 
The data preprocessing technique is already explained in detail in On-line 
preprocessing and outlier detection section in chapter 3. In short, The cervical tissue 
Raman spectra were acquired in the spectral range of 800 - 4000 cm-1, and analyzed in 
FP (800 - 1800 cm-1) and HW (2800 - 3700 cm-1) region, alone and in combination. 
The middle region (1800 - 2800 cm-1) was eliminated due to the absence of 
biochemical information associated with tissue dysplastic transformation. A fifth order 
and first order polynomial provided the best fit in FP and HW region, respectively.74, 
116, 133 This polynomial was then subtracted from the noise smoothed spectrum to 
yield tissue Raman signal alone. The background subtracted Raman spectra were 
further normalized to an integrated area under the curve belonged to their respective 
spectral range (FP or HW) for standardizing the absolute tissue Raman spectral 
intensities.72, 74, 116  
7.2.4 Multivariate analysis 
Multivariate PLS-DA diagnostic algorithm was utilized for FP, HW and 
integrated FP/HW spectroscopic tissue diagnostics and the performance of the PLS-
DA algorithm was validated in an unbiased manner using leave-one-patient-out, CV 
method. The more details about PLS-DA multivariate method have been described in 
Multivariate statistical analysis section in chapter 1. The ROC curves were 
generated to further compare the performance of the PLS-DA models developed using 
the three spectral datasets (FP, HW and integrated FP/HW) for improving in vivo 
diagnosis of cervical precancer and cancer.  
7.3 Results  
Figure 7.1a shows the comparison of in vivo mean FP/HW Raman spectra ± 
1 SD of normal (n=356) and precancerous (n=120) cervical tissues. The normal and 
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precancerous cervix tissue spectra showed prominent Raman vibrational bands at 854 
(glycogen ((CCH) deformation - aromatic) and (C-C) stretching of structural proteins 
and collagen), 937 ((C-C) peak of proline, valine, and glycogen), 1001 ((C–C) ring 
breathing of phenylalanine), 1095 (phospholipids and nucleic acids), 1253 (amide III), 
1313 (CH3CH2 twisting mode of lipid/protein (collagen)), 1445 (CH2 bending mode 
of proteins and lipids), 1654 (amide I band - (C=O) stretching mode of proteins), 2946 
(proteins - CH3 stretching), and 3400 cm
-1 (water - (OH) stretching), respectively.15, 24, 
71, 74, 116, 118, 160, 163, 176 The tentative assignments of biochemicals corresponding to 
major Raman bands observed in normal and precancer cervical tissues are listed in 
Table 7.1. The comprehensive biomolecular basis of in vivo FP and HW Raman 
spectroscopic diagnosis of cervical dysplasia has been described in detail elsewhere.24, 
34, 79, 116, 119  
 
Figure 7.1 (a) Mean in vivo FP/HW Raman spectra ±1 standard deviations (SD) of normal 
(n=356) and precancer (n=120) cervical tissue. The mean in vivo Raman spectrum of normal 
cervical tissue is shifted vertically for better visualization. (b) The corresponding mean difference 
spectra ± 1SD calculated from the mean precancer (n=120) and normal (n=356) cervical tissue 
spectra. The shaded areas represent the respective SD. The broken interval (-//-) indicates the 
region of 1800 - 2800cm
-1




Figure 7.1b shows the difference spectra, reflecting the molecular changes in the 
tissue associated with dysplastic progression. For instance, the dysplastic cervical 
tissue spectra increases significantly at 1001, 1095, 1313, and 3400 cm-1, but exhibit 
much lower signal at 854, 937, 1253, 1445, 1654, and 2946 cm-1 as compared to the 
normal tissue (unpaired 2-sided Student’s t-test (p<0.05)).15, 24, 74, 96, 116, 118, 160, 163, 176 
The significant increase or decrease of some specific biomolecules in cervical 
dysplastic tissue prove the diagnostic utility of the integrated FP/HW Raman 
spectroscopy for in vivo identification of premalignant cervical lesions at colposcopy. 
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To improve the tissue diagnosis, these elusive chemical differences observed 
in the spectra of different tissue types were explored in detail using PLS-DA 
algorithm. The in vivo FP, HW and integrated FP/HW Raman spectral datasets were 
mean centered to eliminate common variance. The leave-one-patient-out, cross-
validated PLS-DA diagnostic models were developed for FP, HW and integrated 
FP/HW Raman spectral datasets using optimum number of components (3 LVs, 1 LV 
and 3 LVs (Figure 7.2)), accounting for 43.43%, 27.99% and 38.77% of total Raman 
spectral variations, respectively,  for identifying dysplastic cervical tissue. The 
optimum number of components was estimated based on the local minimum of CV 
classification error values.237 For instance, the optimum number of components for an 
integrated FP/HW spectral dataset was determined to be 3LVs (Figure 7.2).  
 
Figure 7.2 The number of PLS components (LVs) versus CV error for correct classification of 
normal and cervical dysplasia using FP, HW, and integrated FP/HW Raman spectroscopy.  
 
Figure 7.3 shows the diagnostically significant LV loadings (p<0.005) for the 
integrated FP/HW spectral dataset, accounting for 38.77% (LV1, 24.03%; LV2, 
10.73%; and LV3, 4.01%) of the total Raman spectral variations, which typically 
represent the spectral variations around the major Raman peak positions (854, 1095, 
1253, 1313, 1445, 1654, 2946, and 3400 cm-1). Figure 7.4(a)-(c) shows the box charts 
of significant LV scores obtained from the integrated FP/HW spectral dataset to 
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visualize different degrees of diagnostic utility of significant LVs for dysplasia 
classification. For instance, LV2 shows the greatest efficacy in differentiating cervical 
dysplasia than other LVs. 
 
Figure 7.3 PLS component (LV) loadings in the developed PLS-DA model. The first three 
diagnostically significant LVs (LV1, 24.03%; LV2, 10.73%; and LV3, 4.01%) accounting for 
~38.77% of the total variance were calculated from the in vivo integrated FP/HW Raman spectra 
of cervical tissue, uncovering the diagnostically relevant spectral features for precancer 
classification. Each loading is shifted vertically for better visualization. The broken interval (-//-) 
indicates the region of ~1800 - 2800cm
-1




Figure 7.4 Box charts of the three significant PLS component (LV) scores calculated from the in 
vivo integrated FP/HW Raman dataset for normal and dysplastic cervical tissue types: (a) LV1 
score, (b) LV2 score, and (c) LV3 score. The line within each box represents median, while the 
lower and upper boundary of the box indicate the first (25th percentile) and the third (75th 
percentile) quartiles, respectively. Whiskers (error bars) represent 1.5-fold interquartile range. The 
p - values of unpaired two-sided Student’s t-test (p<0.005) on the LVs of normal and precancer 





Figure 7.5 Scatter plots of the posterior probability values belonging to normal and precancer 
cervical tissue categories calculated from (a) FP, (b) HW, and (c) integrated FP/HW Raman 
spectra, respectively, using the PLS-DA together with leave-one patient-out, CV method. The 
dotted line gives sensitivities of 84.2% (101/120), 76.7% (92/120), and 85.0% (102/120), 
respectively; specificities of 78.9% (281/356), 73.3% (261/356), and 81.7% (291/356), 
respectively, for separating dysplasia from normal cervical tissue using FP, HW, and integrated 
FP/HW Raman spectra. (▲) Precancer (n=120), (○) Normal (n=356). 
 
Table 7.2 Comparison of diagnostic performance of different Raman techniques (FP, HW, and the 
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 Figure 7.5 shows the cross-validated prediction results (posterior probabilities) 
belonging to normal and cervical precancer pathologies as calculated for (a) FP, (b) 
HW, and (c) integrated FP/HW datasets, respectively. The threshold lines in the 
posterior probability scatter plots yield diagnostic accuracies of 80.3% (382/476), 
74.2% (353/476), and 82.6% (393/476) (sensitivities of 84.2% (101/120), 76.7% 
(92/120), and 85.0% (102/120) and specificities of 78.9% (281/356), 73.3% 
(261/356), and 81.7% (291/356) (Table 7.2)), respectively, confirming that integrated 
FP/HW confocal Raman spectroscopy is the most robust for in vivo diagnosis of 
cervical dysplasia. The ROC curves (Figure 7.6) are also generated for the three 
spectral datasets (FP, HW, and the integrated FP/HW) to further evaluate the group 
separations. The AUC are 0.88, 0.78, and 0.92 for FP, HW and the integrated FP/HW 
Raman spectroscopy, respectively, substantiating the efficacy of the integrated FP/HW 
confocal Raman spectroscopy for improving dysplastic classification as compared to 
FP or HW spectroscopy alone. 
 
Figure 7.6 Receiver operating characteristic (ROC) curves of discrimination results for in vivo FP, 
HW and integrated FP/HW Raman spectra for cervical precancer tissue classification through the 
use of Raman spectroscopy and PLS-DA together with leave-one patient-out, CV method. The 
integrated area under the ROC curves are 0.88, 0.78, and 0.92 for FP, HW and integrated FP/HW 
Raman spectra, respectively, illustrating the best performance of integrated FP/HW Raman 
spectroscopy for in vivo cervical precancer diagnosis during clinical colposcopy. 
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7.4 Discussion  
Cyto-histopathologic correlation (colposcopic-guided biopsies due to 
cytological abnormality) for cervical precancer diagnosis relies on cytological and 
morphological alterations within the cells and tissues.96 These guided clinical 
diagnostic techniques are subjective and prone to considerable intra- and inter-
observer disagreements, leading to extensive research in optical-diagnostics 
(i.e., optical biopsy) of precancer and cancer. Recently, Raman spectral diagnostic 
techniques have been comprehensively investigated for molecular discrimination of 
precancer and cancer due to its ability to provide extensive information about the 
changes of biochemical/biomolecular structures and conformations in tissue 
associated with disease transformation.24, 72, 74, 109, 119 However, most of the studies 
have evaluated tissue Raman spectra either in FP24, 71, 72, 74, 109, 119 or HW79, 116, 176, 179 
region. In this study, we explore the diagnostic utility of the integrated FP/HW 
confocal Raman spectroscopy for improving in vivo cervical dysplasia detection.  
We employed PLS-DA methodology to explore the diagnostic utility of 
integrated FP/HW confocal Raman spectroscopy for improving in vivo diagnosis of 
cervical precancer. The PLS-DA modeling of FP Raman spectra was able to extract 
diagnostically significant Raman spectral features (LV1, 24.03%; LV2, 10.73%; and 
LV3, 4.01%), resolving highly specific biomolecular information in FP region (854, 
1095, 1253, 1313, 1445 and 1654 cm-1). Speciﬁcally, the tissue Raman spectra 
showed reduced glycogen and proteins (854 and 1654 cm-1), and increased nuclear 
content (1095 cm-1) with dysplastic progression in cervix. The decreased glycogen 
and structural proteins (elastin and collagen) were mainly related to the loss of 
diﬀerentiation in the cervical epithelial cells during neoplastic progression and the 
existence of structural proteins in normal cervix,2, 160 whereas the increased nuclear 
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content (1095cm−1) indicated the elevated number of epithelial cells associated with 
dysplastic progression in cervix. The amide I (1654 cm-1) and amide III (1253 cm-1) 
was also noticeably decreased with dysplastic transformation.92 Thus, FP Raman 
spectroscopy associated with PLS-DA modeling using 3 LVs provides highly specific 
signatures of various biomolecules, enabling in vivo identification of tissue pathology 
in cervix at the molecular level with a diagnostic accuracy of 80.3% (382/476) 
(sensitivity of 84.2% (101/120) and specificity of 78.9% (281/356)). 
On the other hand, the PLS-DA modeling of HW Raman spectra is able to 
determine the significant Raman diagnostic information (LV1, 27.99%) mainly 
associated with protein and water changes with dysplastic transformation. The 
biochemical basis of HW Raman spectra associated with cervical precancer 
progression has been discussed elsewhere.116 In short, the dysplastic Raman spectra 
showed signiﬁcantly reduced protein (2946 cm−1, CH3 stretching of proteins) and 
increased tissue water content (3100 - 3700 cm−1 broad OH band). The lower protein 
content (2946 cm-1) could be attributed to significant reduction in collagen Raman 
signals (i.e., from stroma) due to thickening of epithelium with dysplastic 
transformation; while the high tissue water content is likely related to an increase of 
certain types of aquaporins (AQP) in the dysplastic cervical cells.116, 176 The HW 
tissue Raman spectroscopy based on PLS-DA modeling (1 LV) rendered a diagnostic 
accuracy of 74.2% (353/476) (sensitivity of 76.7% (92/120) and specificity of 73.3% 
(261/356)) for in vivo cervical precancer detection. The PLS-DA modeling of the 
integrated FP/HW Raman spectra rendered intricate 3 LVs (LV1, 24.03%; LV2, 
10.73%; and LV3, 4.01%), revealing the diagnostic features in both FP and HW 
regions for in vivo tissue diagnosis and characterization (Figure 7.3). Hence, the 
integrated FP/HW Raman spectroscopy provides the best diagnostic accuracy of 
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82.6% (393/476) (sensitivity of 85.0% (102/120) and specificity of 81.7% (291/356)) 
for improving in vivo precancer diagnosis, compared to either FP or HW Raman 
spectroscopy alone (Figure 7.5).  
The complementary nature of both Raman spectral modalities for enhancing 
tissue diagnosis and characterization can be explained by backtracking the 
misclassiﬁed cases of each Raman spectral modality. The FP and HW Raman 
spectroscopy misclassiﬁed 94 and 123 spectra, respectively, from 21 patients of the 
total 44 patients recruited, in which 5 misclassiﬁed patients were identical in both the 
modalities. However, the integration of these two Raman modalities reduced the 
number of misclassiﬁed patients to 11 (83 spectra), whereby 4 patients were identical 
for both Raman regions. The result demonstrates that combining the FP and HW 
Raman spectral modality can largely reduce the misclassiﬁcation of non-identical 
patients, conﬁrming the addition of complementary spectral information required for 
enhancing precancer diagnosis. For instance, the change of water content of cervical 
tissue with dysplastic progression is reﬂected in the HW region, but not in the FP 
region. The ROC curves (Figure 7.6) further validate the best performance and 
robustness of the integrated FP/HW Raman spectroscopy for in vivo cervical 
precancer detection at colposcopy. This work suggests that by fully utilizing the 
complementary Raman spectral signatures in FP and HW regions, the integrated 
FP/HW Raman spectroscopy can be a novel and sensitive diagnostic means for 
improving the identiﬁcation of early pathologic changes (e.g., dysplasia) in cervix at 
the molecular level.  
7.5 Conclusion 
We report for the first time (to the best of our knowledge) the utilization of 
simultaneous FP/HW confocal Raman spectroscopy developed for improving in vivo 
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diagnosis of cervical precancer. This study discloses that FP and HW Raman 
spectroscopic techniques are complementary, and the integration of the two 
complementary Raman spectroscopic techniques further improves in vivo cervical 
precancer detection. It is expected that the simultaneous FP/HW confocal Raman 
spectroscopy could become a promising clinical diagnostic tool for enhancing real-




Chapter 8. Conclusions and future directions 
8.1 Conclusions 
In this dissertation, we first evidenced the promising potential of Raman 
micro-spectroscopy for differentiating cervical cancer cells. We also constructed 
Raman-based images to visualize carcinogenesis-related molecular changes in the 
cells. We further demonstrated the diagnostic efficacy of fiber-optic Raman 
spectroscopy for in vitro characterization of progressive precarcinogenesis in the 
cervix tissue in conjunction with biomolecular modeling. This study provides insights 
into the pathogenesis of different stages of cervical precancer by elucidating the 
underlying distinctive biochemical changes. We further reported for the first time the 
development of simultaneous FP/HW confocal Raman spectroscopy in favor of 
probing biochemical changes originating from the epithelial layer of cervix, integrated 
with the Raman spectroscopic diagnostic framework for real-time in vivo cervical 
precancer diagnosis in sub-seconds. The developed on-line biomedical Raman 
spectroscopic framework translates the cumbersome processing and multivariate 
analysis into an easy-to-use GUI interface for real-time in vivo diagnosis of 
premalignancies in cervix. We further evidenced the diagnostic potential of 
NIR-excited confocal Raman spectroscopy as a stand-alone diagnostic modality for 
identifying dysplastic cervix at clinical colposcopy. We also utilized different 
diagnostic algorithms, and warranted that the coupling of feature selection algorithms 
(e.g., GA) with confocal Raman spectroscopy can identify the diagnostically 
important Raman features and render a good classification. We also for the first time 
established a biochemical model using HW Raman spectroscopy for characterizing 
the compositional changes in normal cervix associated with hormonal/menopausal 
status and Vagifem treatment during clinical colposcopic examinations. The 
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biomolecular modeling confirms the significant variations between premenopausal 
and postmenopausal-prevagifem cervix compared to premenopausal and 
postmenopausal-postvagifem cervix. Finally, we combined both the FP and HW 
Raman spectroscopy and the study disclosed that by utilizing the complementary 
information obtained from FP (i.e., protein, DNA, and lipid content) and HW range 
(i.e., proteins, lipids, and water), Raman spectroscopy can further improve the tissue 
diagnosis and characterization in vivo. It is expected that the integrated FP/HW 
confocal Raman spectroscopy coupled with the on-line spectroscopic diagnostic 
framework has the potential to become a promising clinical diagnostic tool in adjunct 
to colposcopy for realizing real-time in vivo diagnosis and characterization of cervical 
precancer and cancer.  
8.2 Future directions 
This dissertation warrants the promising potential of integrated FP/HW Raman 
spectroscopy for real-time diagnosis of cancers and precancers in cervix at 
colposcopy. However, there are still challenges to be addressed to translate the current 
bench-top fiber-optic Raman technology to a routine biopsy-free clinical diagnostic 
tool in colposcopic settings:  
 
(i) Development of depth-resolved confocal Raman spectroscopy integrated with 
optical coherence tomography (OCT)  
Raman spectroscopy has been utilized for probing the changes in the tissue associated 
with disease transformation at the biomolecular level. However, in the current Raman 
spectroscopic studies, the acquired tissue Raman signals are typically a mixture of 
Raman signal originating from different tissue layers (e.g., epithelium, stroma), 
having different optical properties (e.g., absorption coefficient, scattering coefficient, 
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anisotropic factor, refractive index). It is highly desirable to develop a depth-sensitive 
Raman spectroscopy (e.g., confocal Raman) for complete characterization of 
biochemical state of a layered tissue. On the other hand, OCT performs micro-
structural imaging and provides morphological information across various depths 
(~mm depth). The co-registration of Raman spectroscopy and OCT238, 239 (i.e., by 
precisely guiding the Raman spectroscopy with OCT) can measure the depth-sensitive 
Raman signal from the tissue layers imaged by the OCT, enhancing the tissue 
characterization and diagnosis by compensating the lack of molecular specificity in 
OCT with the biochemical specificity of Raman spectroscopy. The design of 
combined OCT and Raman spectroscopy for careful characterization of epithelial 
layer can further enhance the diagnosis of cervical precancer. 
 
(ii) Instrument standardization for transferring tissue Raman spectral libraries across 
different Raman instruments for prospective multi-center clinical trials 
Most of the in vivo Raman spectroscopic studies for cervical precancer diagnosis were 
carried out through single-center retrospective validation. The fiber-optic Raman 
spectroscopy technique has mainly been limited to single system configurations and 
no attempts have been made to transfer into multi-centre clinical trials. Because 
Raman spectroscopy relies on extremely weak, well-resolved signals and the 
technique is very sensitive to instrumental changes such as interchanging of fiber-
optic probes and therefore significantly limit the practical use in clinical trials and 
routine diagnostics. This requires instrumentation standardization technique for 
clinical applications, which is currently falling far behind the pace of Raman 
technology advancement. The next phase of large single-center as well as multi-center 
prospective validation is also essential for clinical acceptance of new laboratory 
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technique (i.e., moving the Raman spectroscopic technique from laboratory bench-top 
to patient’s bedside).  
 
We anticipate that within the next five years, many of the above challenges can be 
resolved through close collaborations among the multidisciplinary team including 
bioengineers, biophysicists, biochemists, biospectroscopists, biostatisticians, 
pathologists, and clinicians. The development of fully automated, fast acquisition 
fiber-optic Raman spectroscopy will undoubtedly open up new horizons in the field of 
biomedicine that enables biopsy-free, real-time, in vivo cervical precancer and cancer 
diagnosis for targeted biopsies and tumor resection margins for the patients at high 
risk. Thereby modern Raman technique could confer benefit to the patients with early 
optical biopsy diagnosis and to the healthcare community with critical diagnostic 
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